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Streptomyces clavuligerus deacetoxycephalosporin C synthase (scDAOCS) is 
an important industrial enzyme for the production of 7-
aminodeacetoxycephalosporanic acid, a precursor for the production of semi-synthetic 
cephalosporins. However, the substrate affinity of scDAOCS, in the conversion of 
penicillins to corresponding expanded cephalosporins, has limitations. Thus, the main 
objective in this study was to manipulate scDAOCS via understanding the molecular 
basis of its functionality and to forge it to accommodate a wider spectrum of 
substrates for enhanced conversion into new antimicrobial products. To this end, a 
cohort of site-directed mutated scDAOCS proteins were made and investigated for 
changes to their prowess in transforming penicillins, including ampicillin, 
carbenicillin and phenethicillin, to cephalosporin moieties. Results of the study on the 
involvement of amino acid residues, Y184, L186, V275, C281, W297, I298, V303 
and the C-terminal residues between N304-R307, were found to be most prominent in 
affecting the entry of selected substrates, enhancing substrate binding affinities and 
improving catalytic activities up to 283% of the wild-type enzyme activity . As such, 
the possibility of transforming existing penicillins into new cephalosporins, as 
potential antibacterials, looks promising.  
To understand the effects of combining various beneficial mutations, selected 
mutations were also paired and analysed. The bioassay results showed that the C-
terminal mutations, i.e., N304A, N304L, N304M, N304K, N304R, I305M, R306L 
and R307L, in combination with C281Y or V275I substantially increased the catalytic 
activities further by up to 1,347% of the wild-type enzyme activity. Based on these 
v	  
	  
studies, it was clear that double mutants had enhanced substrate binding affinities 
compared to single mutants.  
The understanding of the substrate binding mechanism of scDAOCS was also 
exploited for the investigation of the substrate selectivity of another biosynthetic 
enzyme, deacetylcephalosporin C synthase (DACS), which catalyses a hydroxylation 
reaction. Genetic modifications of its C-terminal residues T308 and H310 conferred a 
ring-expansion activity to provide this additional function to DACS. This finding 
suggested that the C-terminal of DACS is likely to be involved in substrate selectivity 
leading to the type of enzymatic activity it catalyses. This study supports the 
implication of mobilizing the substrate binding properties of biosynthetic enzymes to 
tailor desired bioactive products.  
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Chapter 1: Introduction  
 
1.1. Antibiotics and emerging resistant pathogens  
Antibiotics are widely known as compounds produced by microorganisms to 
inhibit the growth of other organisms in their environment (Davies, 1990; Davies, 
2006; Waksman, 1947; Yim et al., 2006). The first and most well-known antibiotic is 
penicillin, which was serendipitously discovered and reported by Sir Alexander 
Fleming in 1928 (Mann, 2004; Demain and Elander, 1999). However, it was only 
successfully purified from the Penicillium culture by Sir Howard Florey and Sir Ernst 
Chain in 1942. These three scientists were awarded the Nobel Prize (Physiology or 
Medicine) in 1945 “for the discovery of penicillin and its curative effect in various 
infectious diseases” (Levinovitz and Ringertz, 2001). Due to the many epidemics like 
“Black Death” that took numerous lives in the pre-antibiotic era, the successful 
treatment of several infectious diseases, e.g., meningitis, tuberculosis, gonorrhoea and 
pneumonia, through the use of antibiotics resulted in them being labelled as “miracle 
drugs” in the late 1940s (Mann, 2004).  
From the discoveries of “pioneer” antibiotics, such as penicillin and 
streptomycin, to the current development of semi-synthetics, countless lives have 
been saved from infectious diseases. However, the use of these antibiotics to inhibit 
and kill the microorganisms has concomitantly selected for pathogens that become 
resistant to them. It was clear then that “acquired resistance to penicillins” was a new 
challenge to overcome (Chain, 1972; Kirby, 1944). However, this was ignored or 
overlooked probably due to the lack of understanding in the molecular biology of the 
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bacteria that produced the antibiotics and of the mechanisms negating the efficacies of 
antibiotics. 
 
1.1.1. Paradox of antibiotics  
Due to the prevalent use of antibiotics, many resistant pathogens have 
emerged and colonised various habitats (French, 2005; Jones and Pfaller, 1998). Of 
great concern are the nosocomial infections. Instead of receiving treatments for their 
illnesses in the hospital and recovering from them, many patients were infected by 
these resistant pathogens in hospitals, with cases resulting in mortality. These 
pathogens were collectively known as the ESKAPE pathogens, which refer to 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species (Boucher et al., 
2009). Incidences of infections by these bacteria are becoming increasingly common, 
with these bacteria also developing greater resistance to existing antibiotics (Boucher 
et al., 2009; Rice, 2008). For example, a study was conducted by the Asian Network 
for Surveillance of Resistant Pathogens to characterise the macrolide resistance 
mechanism of Streptococcus pneumoniae isolates collected from 10 Asian countries 
(Korea, China, Hong Kong, Thailand, Taiwan, India, Sri Lanka, Singapore, Malaysia 
and Vietnam) between 1998 and 2001, which reported that about 60% of the 555 
isolates studied were resistant to erythromycin. Vietnam, Taiwan, Korea, Hong Kong 
and China had very high incidences of erythromycin-resistant S. pneumonia, with 
more than 70% of the isolates from these countries being highly resistant to 
erythromycin (Song et al., 2004). Both Singapore and Malaysia were reported to have 
increased erythromycin resistance based on comparing the data collected from 1996 
to 2001 (Song et al., 2004). However, it was not clear whether the high prevalence of 
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erythromycin resistance in these Asian countries was due to drug selection through 
the use of erythromycin.  
Other than the selection of resistant bacteria through the use of antibiotics, 
globalisation also played an important part in disseminating these resistant pathogens 
around the world (So et al., 2010). Medical tourism is also likely to promote the 
dissemination of resistance. Recently, a Swedish patient was reported to be infected 
with a carbapenem-resistant Klebsiella pneumoniae, which harboured a new metallo-
β-lactamase gene blaNDM-1, after travelling to India for medical treatment (Yong et al., 
2009). This gene encodes a metallo-β-lactamase that degrades carbapenems, which 
are often regarded as the last line of defence against multi-drug resistant pathogens 
(Wilcox, 2009; Schwaber and Carmeli, 2008). Subsequent reports on the detection of 
this metallo-β-lactamase in other countries followed (Tijet et al., 2011; Poirel et al., 
2011; Mulvey et al., 2011; Pfeifer et al., 2011; Samuelsen et al., 2011; Moellering, 
2010). This has continued to raise concerns on the prevalent use of antibiotics and the 
selection of strains resistant to the antibiotics used (Bush, 2010). However, the 
correlation between the use of antibiotics and the selection of antibiotic resistance in 
different bacterial species is influenced by subjective factors and cannot be easily 
established. To this end, a study was conducted by the Network for Antimicrobial 
Resistance Surveillance (Singapore) to determine the correlation between antibiotic 
prescription and antibiotic resistance of Gram negative bacteria in Singapore 
hospitals. This study showed that there was a correlation between the prescription of 
several key antibiotics and the resistance of Gram negative bacteria but not for 




1.1.2. Efforts in generating “better” antibiotics  
Since the discovery of penicillins as “miracle drugs”, antagonism against these 
antibiotics was not unknown (Chain, 1972; Kirby, 1944). Failures in treatments were 
not uncommon. With the advancement in research and technology, the mechanism of 
antibiotic resistance becomes clearer and we are better equipped with the knowledge 
of countering antibiotic resistance. Global efforts of genome sequencing and 
proteome analysis of many bacterial pathogens have also revealed more targets for 
drug intervention (Moellering, 2011; Coates et al., 2002). Retrospectively, the 
completion of genome sequencing of various actinomycetes, a family of well-known 
antibiotic producers, is likely to aid in the production of existing and novel antibiotics 
(Katz and Khosla, 2007). For example, the completion of genomic sequencing of 
Streptomyces coelicolor (Bentley et al., 2002), S. avermitilis (Ikeda et al., 2003; 
Omura et al., 2001), S. clavuligerus (Song et al., 2010) and S. griseus (Ohnishi et al., 
2008) revealed a number of biosynthetic gene clusters of previously uncharacterised 
antibiotics. This has allowed genetic manipulation of various gene clusters to produce 
new antibiotics (Hranueli et al., 2005). By studying and understanding the 
biosynthetic enzymes of antibiotics, more opportunities will also be available for 
modifying the chemical structure of antibiotics to improve their efficacies.  
With the large number of different antibiotic classes already discovered, the 
challenge of finding new antibiotic classes becomes greater. By understanding the 
structure-activity relationship of an antibiotic, it will be easier to modify the important 
regions of the antibiotic that could improve its efficacy and reduce its toxicity to 
humans. This has been applied to many natural antibiotics to improve their 




Despite the finding that the prevalent use of antibiotics has resulted in the 
selection for resistant pathogens, some even harder to treat, antibiotics remain the 
most important “weapons” to fight against them (Demain and Sanchez, 2009). Hence, 
existing antibiotics need to be replaced by more efficacious ones. Historically, as soon 
as a new antibiotic became available for clinical use, resistant bacteria would 
subsequently emerge (Kirst, 2010). This has dampened the drive for many 
pharmaceutical companies to develop better antibiotics (Demain and Sanchez, 2009; 
Vicente et al., 2006; Projan, 2003). However, recent efforts in modifying 
cephalosporins have continued to shed some hope in the fight against β-lactam-
resistant bacteria (Figure 1.1). Two cephalosporins, namely ceftobiprole (Llarrull et 
al., 2009; Deresinski, 2008) and ceftaroline (Llarrull et al., 2009; Villegas-Estrada et 
al., 2008), were developed and shown to be efficacious against methicillin-resistant 
Staphylococcus aureus (MRSA). Ceftobiprole has also been demonstrated to have 
activity against many Gram-negative bacteria in vitro, including P. aeruginosa 
(Barbour et al., 2009; Zhanel et al., 2008). Other cephalosporin derivatives, with 
structurally different C3 side chains from ceftobiprole and ceftaroline, were also 
synthesised and demonstrated to be effective against MRSA and vancomycin-resistant 
S. aureus (Fuda et al., 2006). By modifying the C3 side chain of ceftazidime, a new 
cephalosporin CXA-101 has been demonstrated to resist the action of P. aeruginosa 
AmpC β-lactamase (Murano et al., 2008; Toda et al., 2008). More recently, it was 
also tested to be effective against various β-lactam-resistant strains of P. aeruginosa 






















































































































































Figure 1.1. Newly developed cephalosporins. Ceftobiprole medocaril, ceftaroline 
fosamil, ABRI-1175, ABRI-2901 and ABRI-1974 are anti-MRSA cephalosporins. 
FR259647 and CXA-101 are anti-pseudomonal cephalosporins.  
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1.2. β-Lactam antibiotics   
It has been estimated that the global antibiotics market generated sales of 
US$42 billion in 2009. The class of antibiotics that forms the largest proportion of 
total sales is the cephalosporins, followed by the penicillins, generating US$11.9 
billions and US$8.8 billions, respectively. They made up almost 50% of the 
antibiotics market, illustrating the usefulness and relevance of these related classes of 
β-lactam antibiotics (Hamad, 2010). 
 
1.2.1. Penicillin and cephalosporin 
Penicillin and cephalosporin antibiotics have been very successful as 
chemotherapeutics due to their high target specificity and low toxicity to humans 
(Demain and Elander, 1999). These are partly due to the attributes of their drug 
targets, penicillin binding proteins (PBPs). The PBPs, which are responsible for the 
synthesis of the bacterial cell wall, are not found in mammalian cells (Bugg et al., 
2011; Schneider and Sahl, 2010). Many early penicillin and cephalosporin derivatives 
were developed with wide antimicrobial spectrum for clinical applications (Silver, 
2007; Vicente et al., 2006). However, due to the prevalent use of these antibiotics, 
resistant bacteria have emerged, leading to the increase in nosocomial infections 
(French, 2005; Jones and Pfaller, 1998).  
Both penicillin and cephalosporin are important classes of antibiotics 
(Collignon et al., 2009). However, the structural relationship between penicillin and 
cephalosporin was only realised in the late 1950s, about a decade after the discovery 
of cephalosporin C in Cephalosporium acremonium (presently known as Acremonium 
chrysogenum) (Hamilton-Miller, 2000; Abraham and Newton, 1961). Penicillin and 
cephalosporin possess a four-membered β-lactam ring that binds covalently with 
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nucleophilic active site serine residues in bacterial cell wall biosynthetic enzymes, 
leading to their inactivation and indirectly, lysis of the bacterial cell walls (Zapun et 
al., 2008a; Essack, 2001; Ghuysen, 1991). The basic difference between the nuclei of 
penicillin and cephalosporin lies in the additional cyclic structure fused to the β-
lactam ring, i.e., penicillin has a five-membered thiazolidine ring and cephalosporin 
has a six-membered dihydrothiazine ring (Figure 1.2). This difference allows the 
latter to evade destruction by penicillinase, which is produced by penicillin-resistant 
bacterial strains. Thus, the cephalosporins are generally considered to have a broader 
antimicrobial spectrum than the penicillins (Marshall and Blair, 1999). In addition, the 
cephalosporin nucleus has two sites for modification, as compared to the penicillin 
nucleus which has only one, thus enabling the synthesis of a wider variety of 
cephalosporins. 
The production of cephalosporin derivatives stemmed from the feasibility to 
synthesise the penicillin nucleus, 6-aminopenicillanic acid (6-APA), and to add 
different side chains to this nucleus in order to create a variety of penicillin 
derivatives with medicinal value (Hamilton-Miller, 2008, 2000). Hence, it was clear 
that progressive development of various cephalosporin derivatives as useful 
therapeutics depended on the ability to obtain the cephalosporin nucleus. This was 
probably one of the factors that initiated interest in deciphering the biosynthetic 
pathway of cephalosporin. The availability of the cephalosporin nuclei, 7-
aminodeacetoxycephalosporanic acid (7-ADCA) and 7-aminocephalosporanic acid 
(7-ACA), led to the production of many semi-synthetic cephalosporins which differ 
widely in antimicrobial spectrum and pharmacokinetics (Barber et al., 2004; Elander, 
2003; Demain and Elander, 1999; Marshall and Blair, 1999). However, these semi-
synthetic cephalosporins are expensive due to high production cost. For example, 7-
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ADCA is synthesised by multi-step chemical ring-expansion of penicillin G, which is 
an expensive and polluting process (Velasco et al., 2000). This has led to serious 
considerations for synthesis of the cephalosporin nucleus by enzymatic processes, 



































Figure 1.2. Basic chemical structures of penicillin (6-APA) and cephalosporin (7-
ADCA) nuclei. 
 
1.2.2. Chemotherapeutic and non-medicinal applications of cephalosporins 
The initial interest on cephalosporin C was mainly due to its ability to inhibit 
some Gram negative bacteria and simultaneously resist the action of penicillinase. 
Furthermore, with the ability to modify the structure of cephalosporin to improve its 
efficacy, a plethora of cephalosporin derivatives was developed and marketed. It was 
estimated that at least 50 different cephalosporins were available in the market by 
2003 (Hamilton-Miller, 2008, 2000; Elander, 2003). They have been classified based 
on their antimicrobial properties and grouped into generations, which is considered 
more useful for clinical prescription. The first generation cephalosporins are made up 
of cephalosporins that have similar antimicrobial spectra as cephalexin. Cephalexin is 
one of the earlier semi-synthetic cephalosporin available and has the same side chain 
as ampicillin. Its antimicrobial spectrum encompasses that of ampicillin, except that 
its resistance to penicillinase bestowed upon itself a wider spectrum than ampicillin 
(Hansch et al., 1990). The next two generations of cephalosporins have a wider 
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spectrum against many Gram negative bacteria and are more resistant to the evolving 
β-lactamases, but with decreasing inhibitory activity against Gram positive bacteria. 
In contrast to the first three generations, fourth-generation cephalosporins have a 
broader antimicrobial spectrum, encompassing those of the first generation 
cephalosporins and many Gram negative bacteria, including pathogenic P. 
aeruginosa. They are also generally more resistant to the evolved β-lactamases active 
against earlier generations of cephalosporins (Marshall and Blair, 1999). 
Other than using cephalosporins as antibacterial drugs, a recent screening 
effort has also identified ceftriaxone and other β-lactams as activators for the 
expression of the excitatory amino acid transporter in humans, which is important for 
preventing glutamate neurotoxicity (Rothstein et al., 2005). This has invoked 
intensive discussion on the “re-discovery” of other possible applications of β-lactam 
antibiotics, with the obvious advantage that many of these β-lactam antibiotics have 
already been demonstrated to be non-toxic to humans (Secko, 2005; Beghi et al., 
2005; Eisenstein, 2005; Mao, 2005; Miller and Cleveland, 2005). Another 
chemotherapeutic application of cephalosporins was as inhibitors against serine 
proteases, which have been implicated in certain diseases, e.g. human elastase in 
pulmonary emphysema (Doherty et al., 1986). Since they are acylating inhibitors of 
bacterial serine proteases (PBPs), it is very likely that they could also inhibit 
mammalian serine proteases (Veinberg et al., 2003; Davies et al., 1991; Doherty et al., 
1986). In fact, various cephalosporin derivatives have been synthesised and 
demonstrated to inhibit human leukocyte elastase (Alpegiani et al., 1994; Knight et 
al., 1992; Doherty et al., 1986). 
A third application of cephalosporins is towards diagnostic and research 
purposes. Since they are substrates of β-lactamases, they are used for the detection of 
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β-lactamase-producing pathogens in hospitals and also β-lactamase reporter activity in 
protein complementation assay for protein-protein interaction studies. This can be 
achieved by attaching fluorogenic or chromogenic moieties to the C3 or C7 positions 
of the cephalosporin core structure (Remy et al., 2007).  
 
1.2.3. Industrial production of cephalosporins: a move towards “Green 
Chemistry” 
Due to the difficulties in synthesising cephalosporin from the three amino acid 
precursors in vitro, it is still relevant to obtain cephalosporins from the fermentation 
culture of producing organisms. Many existing semi-synthetic cephalosporins are 
produced using 7-ACA or 7-ADCA as a precursor. 7-ACA and 7-ADCA are derived 
from deacylation of cephalosporin C and G-7-ADCA, respectively (Elander, 2003; 
Demain and Elander, 1999). Industrial production of cephalosporin C involves the 
fermentation of Acremonium chrysogenum. However, the problem with cephalosporin 
C fermentation is the intrinsic chemical instability of cephalosporin C. It is readily 
degraded in long-cycle cephalosporin C fermentations, which can account up to 40% 
loss of the cephalosporin C produced (Elander, 2003; Usher et al. 1988). Hence, 
chemical ring-expansion of penicillin G was deemed as an alternative since penicillin 
G is cheap and easily available from the fermentation culture of Penicillium 
chrysogenum (Wegman et al., 2001). Silyl protection chemistry was used to 
chemically ring-expand penicillin G to produce G-7-ADCA. However, this method 
involves multiple steps, is expensive and polluting (Velasco et al., 2000). An 
alternative “greener” method to synthesise G-7-ADCA would be to exploit the 





1.3. Biosynthesis of cephalosporins  
1.3.1. Deacetoxycephalosporin C synthase: ring-expansion of penicillin to 
cephalosporin   
Deacetoxycephalosporin C synthase (DAOCS) (EC number 1.14.20.1) is the 
key enzyme in the β-lactam biosynthetic pathway. It is an iron-dependent and α-
ketoglutarate-requiring dioxygenase encoded by cefE gene. It catalyses the ring-
expansion of penicillin N to DAOC and hence, it is also known as expandase (Figure 
1.3). It was previously thought to have a very narrow substrate specificity, in that it 
can only convert its natural substrate penicillin N but not other penicillin analogues 
(Maeda et al., 1995; Dotzlaf and Yeh, 1987). However, Cho and co-workers (1998) 
derived a new reaction condition that allows the conversion of penicillin G and 14 
other penicillins into cephalosporins. Subsequently, Sim and Sim (2001) further 
refined the catalytic conditions by omitting superfluous reagents, resulting in higher 
enzymatic activity. Hence, this optimised reaction condition has provided the milieu 
for extensive studies on DAOCS and its possible application in the industry for 
producing “better” cephalosporins. 
Although studies have shown that DAOCS possesses wide substrate 
specificity (Chin et al., 2003; Cho et al., 1998), its catalytic efficiency in converting 
penicillin G is rudimentary (Table 1.1) (Wei et al., 2005; Hsu et al., 2004). So far, 
Streptomyces clavuligerus DAOCS (scDAOCS) is the most active enzyme in 
converting penicillin G, compared to orthologues from other organisms (Hsu et al., 
2004; Chin et al., 2003). Various studies have suggested that the C-terminal of 
scDAOCS is important in guiding and orientating the penicillin substrate into its 
catalytic pocket (Chin and Sim, 2002; Lee et al., 2002; Lee et al., 2001). However, the 
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molecular mechanism of this interaction is still not clear. Mutagenesis studies have 
indicated that mutations of C-terminal residues, e.g. N304L, I305M, R306L and 
R307L, improved the penicillin G conversion activity of the enzyme (Wei et al., 2003; 
Chin and Sim, 2002; Lee et al., 2001; Lloyd et al., 1999). The rationale behind these 
mutations could not be comprehended in the absence of a crystal structure complex 
with a penicillin substrate (Lee et al., 2001; Valegård et al., 1998). Fortunately, such a 
structure has been timely resolved (Valegård et al., 2004) for this study and has 
provided the opportunity to virtually view the catalytic properties of this enzyme and 
understand its substrate binding mechanism, for the prediction and improvement of its 
catalytic functions via protein engineering (Barends et al., 2004). To achieve this, site-
directed mutagenesis (SDM) was used to construct novel proteins with desired 
properties, such as enhanced activity and/or alteration in substrate specificity, for 
industrial applications. For example, Lee et al. (2001a) showed that a single 
replacement of R258 with glutamine in scDAOCS altered its co-substrate specificity. 
This technique has shaped the basis of protein engineering and has been applied 
widely. Thus, in this study, scDAOCS was targeted as a potential platform for 
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Table 1.1. Kinetic parameters of wild-type scDAOCS in penicillin N and penicillin G 
conversions (Wei et al., 2005). 
 
























2.58 0.0453 18 8.2x10-4 
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1.3.2. Deacetylcephalosporin C synthase: hydroxylation of cephalosporin  
Deacetylcephalosporin C synthase (DACS) (EC number 1.14.11.26) is the 
enzyme that catalyses the conversion of DAOC to DAC in the β-lactam biosynthetic 
pathway of cephalosporin producers (Figure 1.4). It is also known as 
deacetoxycephalosporin C hydroxylase or 3'-methylcephem hydroxylase (Coque et 
al., 1996; Baker et al., 1991). Its enzymatic reaction is essentially an oxidation 
reaction similar to the enzymatic reaction of DAOCS; it is also a 2-oxoglutarate 
dioxygenase enzyme, which has an absolute requirement for ferrous iron and 2-
oxoglutarate (also known as α-ketoglutarate) as co-factor and co-substrate, 
respectively, for catalysis.  
Based on primary sequence alignment, DACS has high resemblance to 
DAOCS. For example, S. clavuligerus DACS (scDACS) has been reported to possess 
59% and 71% identity with scDAOCS at the protein and nucleotide sequence level, 
respectively (Kovacevic and Miller, 1991). Hence, it has also been postulated to have 
arisen from a gene duplication event during the evolution of streptomycetes 
(Kovacevic and Miller, 1991). However, studies on this enzyme have been limited 
due to the difficulty in synthesising the native substrate DAOC. Nevertheless, 
biochemical studies have revealed its highly specific hydroxylation activity despite 
sharing high protein sequence identity, similar catalytic platform and reactants with 
DAOCS, which demonstrated dominant ring-expansion activity (Baker et al., 1991).  
Intriguingly, A. chrysogenum possesses an enzyme with both ring-expansion 
and hydroxylation activities. It is known as deacetoxy/deacetylcephalosporin C 
synthase (DAOC/DACS). Although studies on this bifunctional enzyme have revealed 
some important sites for either ring-expansion or hydroxylation activities (Lloyd et 
al., 2004), this is not well understood in the monofunctional enzymes. By elucidating 
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the determinants and mechanism behind these structure-function differences in 
conferring the enzyme with either or both activities, it will become easier to tailor-
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1.4. Objectives of this study 
Preceding studies on the characteristics of scDAOCS have exemplified the 
potential of modifying it to accept a range of industrially preferred penicillin G and 
other non-native penicillins as substrates. Understanding the mechanisms behind 
enzyme-substrate interaction and those mutations that led to improved ring-expansion 
activity of scDAOCS for hydrophobic penicillin conversions will provide a basis for 
improving scDAOCS, thus leading to a more efficient and cleaner process for the 
production of cephalosporin and possibly, the generation of novel cephalosporins. The 
objectives of this project will entail the following: 
1. Map the functional domains of scDAOCS involved in substrate binding via 
biocomputational tools and predict useful substitutions. 
2. Validate the predicted substitutions using SDM and activity studies, and 
elucidate the substrate binding mechanism of scDAOCS. 
3. Investigate the functionality of S. clavuligerus DACS via biocomputational 
analyses, SDM and enzymatic assays using scDAOCS as a model. 
4. Evaluate the antimicrobial activities and efficacies of the biotransformed 
cephalosporin products 
5. Investigate additional properties conferred on the biotransformed 
cephalosporin products, e.g., against elastase. 




Understanding	  the	  substrate	  binding	  mechanism	  of	  
Streptomyces	  clavuligerus	  deacetoxycephalosporin	  C	  
synthase	  for	  biosynthesis	  of	  novel	  cephalosporins
Mapping	  functional	  domains	  of	  scDAOCS

























Mutagenesis	  studies	  of	  
scDACS using	  scDAOCS
as	  a	  model:	  
SwissPdbViewer
LIGPLOT















Figure 1.5. Overall scheme of work for this project.  
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Chapter 2: Literature review  
 
2.1. Antibiotics: secondary metabolites of microorganisms  
Secondary metabolites are low molecular weight compounds that are non-
essential to the growth and proliferation of the host organisms. They are structurally 
and taxonomically diverse with ambiguous functions, and noticeably characteristic to 
specific types of organisms (Berdy, 2005).  
Although the definition of antibiotic in dictionaries and textbooks may differ 
slightly, antibiotic is generally considered a secondary metabolite produced by 
microorganisms that exhibit growth inhibition on other microorganisms. Examples of 
major classes of antibiotics are summarised in Table 2.1. However, the physiological 
role or evolutionary biology of these naturally occurring low molecular weight 
biomolecules remains poorly understood (Davies et al., 2006). On the basis that they 
exhibit antibiosis at certain concentration, they were deemed as “weapons” produced 
by the host organism against competitors in the harsh environment to enhance its own 
survival. However, under normal physiological or environmental conditions, 
inhibitory concentrations of these naturally occurring antibiotics are seldom achieved 
(Davies et al., 2006). Recently, antibiotics at sub-inhibitory concentrations were 
recognised to have physiological effects, leading to changes in 5-10% of the host’s 
transcriptome. This concentration-dependent effect has been described as hormesis 
(Calabrese and Blain, 2005; Davies et al., 2006). In turn, this has very important 
implications for the use of antibiotics as chemotherapeutics, particularly in the 
development and selection of antibiotic resistance (Davies et al., 2006). 
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Table 2.1. Major classes of antibiotics.  
Class of 
antibiotics Mode of action 
Example of natural 
antibiotic  Producer  References  
Aminoglycosides  Interfere with protein synthesis  
Kanamycin Streptomyces 
kanamyceticus  
(Okami et al., 1959)  
Gentamicin  Micromonospora sp. (Weinstein et al., 
1963)  
Ansamycins Inhibit Hsp90  Geldanamycin Streptomyces hygroscopicus 






Penicillin G  Penicillium chrysogenum  (Peterson and 
Tornqvist, 1956) 
Cephalosporin C Acremonium chrysogenum  (Smith et al., 1967) 
Cephamycin C Nocardia lactamdurans, 
Streptomyces clavuligerus  
(Nagarajan et al., 









Vancomycin  Amycolatopsis orientalis (Levine, 2006)  
Lincosamides  Interfere with protein synthesis Lincomycin  Streptomyces lincolnensis 
(Macleod et al., 
1964)  
Lipopeptides  
Bind to bacterial cell 
membrane and cause 
rapid depolarisation and 
loss of membrane 
potential leading to 
inhibition of protein, 
DNA and RNA synthesis 
Daptomycin Streptomyces roseosporus (McHenney et al., 1998)  










2.1.1. Industrial production of antibiotics: “Green Chemistry”  
Some natural antibiotics have limited clinical uses because of undesirable 
side-effects, poor pharmacokinetics or low antimicrobial activity, especially against 
resistant pathogens (Chin et al., 2006; Riva, 2001). Hence, modifications were often 
made to the core structure of the natural antibiotics to improve their antimicrobial or 
pharmacokinetic properties. These derivatives, including the active pharmaceutical 
ingredients, are often produced via chemical means using reagents and by-products 
that are mostly hazardous (Bruggink et al., 2003; Wohlgemuth, 2010).  
With increasing knowledge of antibiotic synthesis enzymes, many of these 
chemical processes could actually be replaced by environmentally friendly enzymatic 
methods, which are also more specific in their reactions. In turn, this can effectively 
reduce the number of production steps (Gotor, 2002). For example, in the industrial 
production of cephalexin, the original chemical procedure requiring ten steps was 
reduced to six by replacing some steps with enzymatic processes (Gotor, 2002).  
The remarkable feature of enzyme is its lately recognised plasticity and 
amenability to modification in order to alter its functionalities. Many enzymes have 
the ability to accept a wide range of substrate derivatives, while catalysing specific 
biochemical reactions. Hence, the use of enzymes in an industrial process has the 
advantage of avoiding the need for blocking or deblocking steps that are common in 
many chemical syntheses to prevent side-reactions (Singh et al., 2006). This will 
result in lower by-product formation and consequently, avoid the need for the 
purification of the desired products. Hence, enzymatic process is often deemed as a 




2.1.2. Microbial enzymes for secondary metabolite production and modification 
There are several advantages in using enzymes over chemical catalysts. 
Enzymes are derived from renewable resources and are biodegradable. These 
attributes make them an attractive substitute to chemical catalysts. They generally 
function under relatively mild conditions of pH and temperature, hence, the enzymatic 
process is generally less hazardous compared to a chemical reaction (Bruggink et al., 
2003; Riva, 2001; Schmidt, 2010; Wohlgemuth, 2010). Furthermore, the reactions 
they catalyse are often specific and yet, their structural plasticity allows selectivity in 
both reactant and product stereochemistry. In addition, improvement to substrate 
selectivity and/or reactivity can be achieved by protein engineering (Bottcher and 
Bornscheuer, 2010). With increasing awareness of the effects of industrial pollution to 
the environment, the need to find a “greener” alternative for the production of 
chemicals and pharmaceuticals has led to further interest in enzymes (Table 2.2) 
(Tucker, 2006; Woodley, 2008). 
Secondary metabolites are products of secondary metabolism in the host 
organism. Hence, biosynthetic enzymes involved in the synthesis of the secondary 
metabolites and their intermediates are useful molecular tools for industrial 
application (Riva, 2001). They serve as a readily available source of biocatalysts for 
biotransformation of preferred industrial substrates into desired products. In fact, with 
the advent of molecular techniques and protein engineering, enzymes from unrelated 
biosynthesis of these biomolecules could also be exploited for biotransformation of 




Table 2.2. Examples of industrial application of enzymes.  
Enzymes  Applications  References  
Acyltransferase LovD Conversion of monacolin J to simvastatin (Xie and Tang, 2007)  
Amylases  Production of high-fructose syrups and ethanol 
from starch 
(Pandey et al., 2000)  
D-amino acid oxidase  Deacylation of cephalosporin C to yield 
cephalosporin nucleus 7-ACA 
(Pollegioni et al., 2008)  
D-carbamoylase Production of D-p-hydroxyphenylglycine, a side-
chain precursor for semi-synthetic penicillins and 
cephalosporins 
(Ogawa and Shimizu, 
2002)  
Lipolase  Production of pregabalin, an active 
pharmaceutical ingredient of Lyrica1® for the 
treatment of neuropathic pain and epilepsy 
(Martinez et al., 2008)  
Nitrilase  Production of acrylamide from acrylonitrile (Singh et al., 2006)  
Penicillin acylase  Production of penicillin nucleus 6-APA (Sio and Quax, 2004)  
Proline 4-hydroxylase Production of trans-4-hydroxy-L-proline, an 
important precursor of antiphlogistics, 
carbapenem antibiotics, and angiotensin-
converting-enzyme inhibitors 
(Ogawa and Shimizu, 
2002)  















2.2. Streptomyces species: well known antibiotic producers 
Bacterial species from the genus Streptomyces are well known for the 
diversity of secondary metabolites they produce, particularly antibiotics (Demain, 
1999). A survey on the number of antimicrobial compounds discovered in various 
species of this genus showed a steady increase from the late 1940s and peaked in the 
1970s (Watve et al., 2001). However, there was a substantial decline in the late 1980s 
and 1990s. By assuming that the antibiotic screening efforts were encouraged by a 
previous year’s success and the probability of finding a new antibiotic is a function of 
the fraction of antibiotics undiscovered so far, a mathematical model was proposed by 
Watve and co-workers (2001) to estimate the total number of antimicrobial 
compounds Streptomyces species are capable of producing and the number that has 
yet to be discovered. Based on the model, the number of antibiotics potentially 
produced by streptomycetes was in the order of 100,000. Comparing to the estimated 
number of 3,000 natural antibiotics discovered by then, there were many more 
compounds to be uncovered from streptomycetes. Importantly, they believed that the 
decline in the number of antimicrobial compounds discovered was due to a decline in 
screening efforts rather than an exhaustion of compounds (Watve et al., 2001).  
 
2.2.1.  Streptomyces clavuligerus NRRL 3585 
Streptomyces clavuligerus NRRL 3585 (ATCC 27064) is a Gram positive 
bacterium belonging to the family Streptomycetaceae (Higgens and Kastner, 1971). It 
is a soil bacterium isolated in South America. It is named as such due to the 
morphology of its spore-forming hyphae that resemble little clubs, i.e., clavula in 
Latin means little club and the suffix -igerus means bearing. Its spores are grey to 
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greyish green and it produces at least four antibiotics, namely cephamycin C, 
clavulanic acid, holomycin and tunicamycin (Song et al., 2010).  
S. clavuligerus became an important industrial microorganism because of its 
ability to produce cephamycin C and clavulanic acid, which is a β-lactamase inhibitor. 
Hence, it was also selected for genome sequencing in the hope of providing more 
information for further research on this bacterium. A draft genome sequence of S. 
clavuligerus has recently been reported (Song et al., 2010). Its genome consists of a 
linear chromosome of 6.7 Mbp, which has a G+C content of 72.69%, and four 
plasmids. Its genome is the smallest among the Streptomyces species whose genomes 
have been completely sequenced to date. For example, S. coelicolor has 
approximately 8.7 Mbp (Bentley et al., 2002) and S. avermitilis has about 9 Mbp 
(Ikeda et al., 2003). A total of 7,898 protein-coding genes were annotated, contrasting 
with the 7,825 and 7,574 predicted genes in S. coelicolor and S. avermitilis, 
respectively (Bentley et al., 2002; Ikeda et al., 2003; Song et al., 2010).  With the 
completion of the whole genome and full annotation of the genes in S. clavuligerus, 
further advancement in drug discovery and exploitation of this bacterium for 
antibiotic production could be expected.    
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2.3. β-Lactam antibiotics 
The class of β-lactam antibiotics is made up of structurally diverse molecules 
possessing a common β-lactam ring. Drug discovery efforts since the serendipitous 
discovery of penicillin have found many natural products with antibiotic property and 
a number of them contain a β-lactam ring. These natural products were found to 
possess structures that are different from penicillin.   
 
2.3.1. General properties and sub-classifications 
The β-lactam ring in β-lactam antibiotics is the bioactive portion of the 
biomolecules. This class of antibiotics mainly interferes with the growth of bacteria 
by inhibiting the activity of penicillin-binding proteins (PBPs) responsible for 
bacterial cell wall biosynthesis. These PBPs are bacterial serine DD-peptidases. Since 
β-lactams are acylating inhibitors of PBPs, it is likely that β-lactams could also inhibit 
other serine proteases (Davies et al., 1991; Doherty et al., 1986; Veinberg et al., 
2003). In fact, this is possible by modifying the side chains, leaving the β-lactam ring 
intact. Hence, the modest growth inhibition observed on other microorganisms, e.g., 
fungi, was probably due to inhibition of the host’s proteases, leading to growth 
retardation or even cell death (Sanyal et al., 1992).  
Although the mechanism of action for all β-lactam antibiotics have yet to be 
completely understood, they have been divided into different groups based on their 
basic core structures (Figure 2.1). Penams are those that have a thiazolidine ring 
attached to the β-lactam ring, which are mainly the penicillins. Cephems are those 
with a dihydrothiazine ring attached to the β-lactam ring, which consist of 
cephalosporin, cephamycin and cephabacin. Clavams are similar to the penams, 
except that they possess an oxygen atom instead of a sulphur atom. An example of 
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clavams is clavulanic acid, which is a potent β-lactamase inhibitor with low 
antibacterial activity. Carbapenems also have a similar structure to the penams and 
clavams, except that they possess a carbon atom instead of a sulphur or oxygen atom 
in the five-membered ring. Furthermore, they have a double bond between C2 and C3. 
For those with a single bond, they are the carbapenams, which are often the 
intermediates in the carbapenem biosynthetic pathway.  
From these natural structural variations, synthetic derivatives were generated, 
e.g., penem, carbacephem and oxacephem, and assessed for their bioactivities (Figure 
2.1). However, due to their poor antimicrobial activities, they were not further 






































Figure 2.1. Basic structure of various β-lactam classes. 
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2.3.2. Targets of β-lactams: penicillin binding proteins (PBPs) 
PBPs are a group of membrane-bound enzymes involved in bacterial cell wall 
synthesis. They are named as such due to their ability to bind penicillin although they 
may play different roles in the process of cell wall synthesis. Collectively, they are 
involved in the formation of peptidoglycan, which is an important component of the 
bacterial cell wall in determining the final shape of the host bacteria. A peptidoglycan 
is made up of glycan chains, where each chain is composed of alternating N-
acetylglucosamine and N-acetylmuramic acid, cross-linked by oligopeptides attached 
to the N-acetylmuramic acid (Sauvage et al., 2008a).   
PBPs are classified into three main classes, A, B and C, and are sub-divided 
within each class based on sequence differences (Sauvage et al., 2008a). Class A and 
B PBPs, which are also known as high molecular mass PBPs, are multi-modular 
enzymes responsible for peptidoglycan formation and insertion into the pre-existing 
cell wall. Generally, class A PBPs are bifunctional enzymes that possess an N-
terminal glycosyltransferase domain, which catalyses the polymerisation of glycan 
chains, and a C-terminal penicillin-binding domain, which possesses a transpeptidase 
activity responsible for peptide cross-linking between two glycan chains. Hence, the 
main function of class A PBPs is the synthesis of peptidoglycan. However, the exact 
role and significance of each class A PBP in a bacterium possessing more than one 
class A PBP remains poorly understood although some studies have provided some 
clues. For example, mutation and deletion studies of the four class A PBPs, namely 
PBP1, PBP2c, PBP2d and PBP4, in Bacillus subtilis illustrated functional redundancy 
of these enzymes (Popham and Setlow, 1996). However, mutation of PBP1 alone 
increased its average cell length and decreased its cell diameter (Popham and Setlow, 
1995; Popham and Young, 2003). Interestingly, when all the class A PBPs were 
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deleted, B. subtilis was still viable and has a relatively normal peptidoglycan structure 
(McPherson and Popham, 2003). In contrast, loss of both PBP1a and PBP1b in E. coli 
is fatal, even though it has a third class A PBP, i.e., PBP1c (Denome et al., 1999).  
Like class A PBPs, Class B PBPs also have a C-terminal penicillin-binding 
domain with transpeptidase activity, while the functions of their N-terminal domains 
are still unclear although they are believed to be involved in cell morphogenesis by 
interacting with other proteins in the cell cycle (Macheboeuf et al., 2006; Sauvage et 
al., 2008a). The function of class B PBPs in a bacterium is mainly cross-linking of the 
peptidoglycan chains via the stem pentapeptide covalently attached to N-
acetylmuramyl portion of the glycan chain, but the exact role of each class B PBP 
remains vague due to redundancy. Nevertheless, some studies have provided a better 
understanding of the functions of class B PBPs in cell division. For example, in E. 
coli, which possesses two class B PBPs, PBP2 has been shown to be important for 
cell elongation and may have a role in the initiation of cell division (Den Blaauwen et 
al., 2003; Spratt and Pardee, 1975), whereas PBP3 is involved in septation (Di Lallo 
et al., 2003; Karimova et al., 2005; Spratt, 1975). In B. subtilis, there are six class B 
PBPs, where both PBP2a and PBPH have been shown to play redundant roles in 
defining its shape (Carballido-Lopez and Formstone, 2007; Wei et al., 2003b).  
Class C PBPs are also known as low molecular mass PBPs, containing a 
penicillin-binding domain with either a DD-endopeptidase or DD-carboxypeptidase 
activity (Popham and Young, 2003). In general, class C PBPs are involved in the 
regulation of peptidoglycan formation (Macheboeuf et al., 2006; Morlot et al., 2004). 
For example, PBP4 and PBP7 of E. coli are DD-endopeptidases that cleave the 
peptide cross-bridges between two glycan chains in the peptidoglycan cell wall 
(Sauvage et al., 2008a; Vollmer and Holtje, 2004; Vollmer et al., 2008). E. coli PBP5 
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is a DD-carboxypeptidase involved in cleaving the terminal amino acid residue of the 
stem pentapeptide in a peptidoglycan chain, preventing peptidogylcan cross-linking 
(Sauvage et al., 2008a; Spratt and Strominger, 1976). 
Most bacterial species have at least one PBP from each class and they are 
usually named using numbers, followed by an alphabet for sub-classes, if any. 
However, PBPs from two different bacterial species with the same numbering may 
not belong to the same class because they were initially numbered based on their 
migration patterns when separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Sauvage et al., 2008a). For example, Staphylococcus 
aureus PBP2 encoded by pbp2 is a class A PBP, while E. coli PBP2 encoded by pbpA 
is a class B PBP. Hence, this can be confusing and a standardised nomenclature will 
be useful, especially for phylogenetic studies. Interestingly, it has been noted that rod-
shaped bacteria tend to have higher total number of PBPs compared to the cocci 
bacteria and bacteria of similar shapes tend to have similar sets of PBPs (Zapun et al., 
2008b). As such, efforts in understanding the role of each set of PBPs in different 
bacteria and their phylogenies may help in designing new drugs that are efficacious 
against multiple PBPs in closely-related bacteria, thus achieving more effective 
treatment.  
 
2.3.3. Inhibitory action of β-lactam antibiotics and penicillin-binding domains 
of PBPs 
Penicillin and cephalosporin antibiotics are able to inhibit the activity of PBPs 
because of their structural similarity to the terminal D-Ala-D-Ala stem peptide of the 
peptidoglycan precursor and they bind to the penicillin-binding domain of PBPs 
(Strominger and Tipper, 1965). This subsequently leads to the deregulation of 
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bacterial cell wall synthesis, followed by activation of cell lysis. This hypothesis was 
strengthened by the recent crystallisation of E. coli PBP6 with a peptidoglycan 
substrate fragment containing the full pentapeptide, N-acetylmuramyl-(L-Ala-D-
isoGlu-L-Lys-D-Ala-D-Ala) (Chen et al., 2009). Superimposition of this structure and 
Streptomyces strain R61 DD-peptidase complexed with a non-covalently bound β-
lactam (1PW1) revealed a similar spatial orientation of the C3 carboxylate of the β-
lactam with that of the terminal D-Ala of the peptidoglycan substrate fragment, which 
forms hydrogen bonds with residues S106 and T210 of E. coli PBP6. This study has 
provided empirical evidence for the theory of molecular mimicry of β-lactam 
antibiotics to the terminal D-Ala-D-Ala moiety of the peptidoglycan in inhibiting 
bacterial PBPs (Chen et al., 2009).  
The inhibitory action of β-lactam antibiotics occurs in three steps and this can 
be described using the kinetic model depicted in Figure 2.2 (Frere et al., 1975). The 
formation of a non-covalent complex between PBP and β-lactam is described by the 
dissociation constant Kd, followed by the formation of the acylated PBP at the rate k2. 
Subsequently, deacylation occurs at the rate k3 to yield PBP and an inactivated β-
lactam. Often, k3 is slower than k2 and this leads to inhibition of the PBP by the β-
lactam since the active site of the PBP is occupied.  
The penicillin-binding domain of PBPs bears three conserved motifs, i.e. 
SXXK, SXN and K(S/T)G, present in the penicilloyl serine transferase superfamily, 
which includes class A, C and D β-lactamases (Macheboeuf et al., 2006; Massova and 
Mobashery, 1998). Although the primary sequences of the penicillin-binding domain 
of PBPs are very diverse, the structural folds of these domains are much conserved 
(Figure 2.3) (Sauvage et al., 2008a). The penicillin-binding domain is made up of two 
sub-domains, i.e., one is an anti-parallel five-stranded β-sheets surrounded by three α-
32	  
	  
helices and another is an all-helical domain (Sauvage et al., 2008a). The SXXK motif 
bears the active site serine residue responsible for catalysis and is positioned at the 
beginning of helix α2. The SXN motif is situated in a loop between helices α4 and α5, 
and the K(S/T)G motif is localised in β3 (Figure 2.4A) (Sauvage et al., 2008a).  
Many structural and molecular dynamic simulation studies have been 
attempted to understand the catalytic mechanism of PBPs upon binding of substrate 
analogues or β-lactam antibiotics (Contreras-Martel et al., 2009; Massova and 
Kollman, 2002; Oliva et al., 2003; Sauvage et al., 2008b; Zhang et al., 2007). The 
activation of the active site serine by abstraction of a proton is achieved by either the 
lysine residue of the SXXK motif or the carboxylate group of the β-lactam (Gordon et 
al., 2000). Recent studies on E. coli PBP5, which is a class C PBP, suggested that the 
former hypothesis is more likely (Zhang et al., 2007). The reaction begins with the 
binding of penicillin to the penicillin-binding domain, followed by the nucleophilic 
attack of the deprotonated active site serine on the β-lactam ring. This results in the 
formation of a stable acyl-enzyme complex. In contrast to class A TEM-1 β-
lactamase, PBPs generally lack the equivalent residue to the conserved residue E166 
in TEM-1 responsible for deacylation of β-lactams (Figure 2.4B). This provides an 
explanation for the inability or extremely slow deacylation rate of PBPs in 
hydrolysing β-lactams (Morlot et al., 2005). This is further supported by an 
approximately 10-100 fold increment in the deacylation rate of penicillin G when 
residue F450 of P. pneumoniae PBP2x was mutated to either an aspartic acid or a 
glutamic acid to mimic the corresponding position of residue E166 in TEM-1 β-
lactamase (Chesnel et al., 2002).  
Retrospectively, this is inadequate to explain the deacylation of peptidoglycan 
stem peptide by class C PBPs, which is a native reaction in these enzymes (usually 
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DD-carboxypeptidase or DD-endopeptidase activity). Structural studies using a 
deacylation-defective G105D mutant of E. coli PBP5 suggested the involvement of 
the SXN motif in the deacylation activity of PBPs for its native substrate (Davies et 
al., 2001; Nicholas et al., 2003). Further studies using a substrate analogue inhibitor 
covalently bound to the active site of E. coli PBP5 suggested a hydrogen-bonding 
network involving residues S110 of the SXN motif, K213 of the KTG motif, and a 
bridging water molecule to activate the hydrolytic water molecule as a mechanism of 
deacylation of native substrate by class C PBPs (Nicola et al., 2005). Since some class 
C PBPs are strictly carboxypeptidases, while others may possess endopeptidase 
activities, there remains the question of what determines their functional differences. 
It is even more puzzling for transpeptidase, which links two stem peptides together. 
This could be inferred by the substrate preference of carboxypeptidase for linear stem 
peptide in peptidoglycan, that of endopeptidase for interlinked stem peptide between 
two glycan chains of the peptidoglycan, and that of transpeptidase for two stem 
peptides to be interlinked. Hence, it is likely that the active site of carboxypeptidases 
cannot accommodate a bulky structure due to steric hindrance (Sauvage et al., 2007). 
Structural studies on Bacillus subtilis PBP4a, which is a class C PBP, led Sauvage 
and co-workers (2007) to propose the plausible role of residue T394 in determining its 
activity. This residue is hydrogen-bonded to residue T412 and indirectly contributes 
to the hydrogen-bond network that strengthens the active site. Interestingly, in DD-
carboxypeptidases, e.g. E. coli PBP5, PBP6 and PBP6b, a bulkier arginine residue is 
located at the analogous position of residue T394 in B. subtilis PBP4a, whereas in 
DD-endopeptidases, e.g. E. coli PBP4 and PBP7, it is either a threonine or a serine 
residue. Furthermore, majority of classes A and B PBPs have a threonine or a serine 
in the analogous position. Hence, it is likely that the type of residue at this analogous 
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position of 394 in B. subtilis PBP4a plays an important role in determining the 
substrate specificity, leading to the type of peptidase activity using a similar catalytic 
platform (Sauvage et al., 2007). Nevertheless, the exact mechanism of native substrate 
processing by the various classes of PBPs remains to be revealed. It has also been 
suggested that a different acylation-deacylation mechanism may be used by PBPs to 
interact with their native substrates and β-lactam antibiotics (Nicola et al., 2005). 
 
PBP β-­‐lactamPBP β-­‐lactam+ PBP-­‐β-­‐lactam PBP Inactivated	  β-­‐lactam+
k2 k3k1
k-­‐1
Kd =	  k-­‐1/ k1 	  
Figure 2.2. A reaction scheme for the kinetic interaction of a PBP with a β-lactam. 
The dissociation constant for the reversible formation of the non-covalent PBP-β-
lactam complex is described by Kd. The acylation rate is described by k2 and the 







Figure 2.3. Crystal structures of S. pneumoniae PBPs. These PBPs possess a common 
penicillin-binding domain in PBPs of class A (PBP1a and PBP1b), B (PBP2b and 
PBP2x) and C (PBP3). (PDB accession numbers: PBP1a – 2C5W; PBP1b – 2UWY; 







Figure 2.4. Crystal structures and active site residues of (A) S. pneumoniae PBP2x 
(1QME) and (B) E. coli TEM-1 β-lactamase (1BTL). Crystal structures and active site 
residues of these proteins are depicted in the left column and right column, 
respectively. The α2 helix, the loop between α4 and α5 helices, and β3 strand 
containing the SXXK, SXN and K(T/S)G motifs are coloured green, orange and red, 
respectively, in S. pneumoniae PBP2x. The corresponding folds in serine β-lactamase 
TEM-1 are similarly coloured with the loop possessing the conserved residue E166 
coloured blue. The atoms in the right column are in CPK colours; red - oxygen atom, 
blue - nitrogen atom, yellow - sulphur atom, white - carbon atom. The hydrogen 
bonds are depicted as green dotted lines.  
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2.4. Penam and cephem antibiotics  
Both penams and cephems are clinically important classes of antibiotics. 
However, the structural relationship between them was only realised in the late 1950s, 
about a decade after the discovery of cephalosporin C in C. acremonium (Abraham 
and Newton, 1961; Hamilton-Miller, 2000). The basic difference between penicillin 
and cephalosporin nuclei lies in the additional cyclic structure fused to the β-lactam 
ring, which allows the latter to resist degradation by penicillinase produced by 
penicillin-resistant bacterial strains. Hence, the cephalosporins are generally 
considered to have a broader antimicrobial spectrum than the penicillins (Marshall 
and Blair, 1999). In addition, a cephalosporin nucleus which has two sites for 
modification, compared with the penicillin nucleus which only has one, enables the 
synthesis of a wider variety of cephalosporins. These probably explain why 
cephalosporin is generally preferred over penicillin in the synthesis of new β-lactam 
antibiotic.  
 
2.4.1. Development of semi-synthetic penicillins 
Natural penicillins are structurally diverse and their biosyntheses are 
dependent on the types of side chain precursors available. The first clinically useful 
penicillin G was produced by supplying phenylacetic acid in the fermentation culture 
of P. chrysogenum. However, it was used only as a parenteral chemotherapeutic 
because of its instability under the acidic gastric conditions. Penicillin V was found to 
be more acid-stable and hence, could be administered orally. This attribute was 
mainly due to the C6 phenoxyacetyl side chain in penicillin V compared to penicillin 
G. However, both penicillins have narrow antimicrobial spectra and were only 
effective in treating diseases caused by Gram positive bacteria (Wright, 1999). 
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Following the use of penicillin G and penicillin V, the emergence of penicillin-
resistant staphylococci became a serious clinical problem (Chain, 1972). This 
resistance factor was found to be an inactivator of penicillin and was termed as 
penicillinase (Kirby, 1944). Thereafter, many studies were pursued with the intention 
of improving the antimicrobial spectrum of penicillin to include Gram negative 
bacteria, as well as penicillin-resistant staphylococci.  
Recognising the importance of C6 side chain of penicillin for its antibacterial 
property, successes in the development of more efficacious penicillins were brought 
about by the discovery of 6-APA production in the fermentation culture of P. 
chrysogenum (Rolinson and Geddes, 2007) (Figure 2.5). By chemically varying the 
structure of its C6 side chain, a structurally diverse group of semi-synthetic penicillins 
could be synthesised with different antimicrobial spectra. The semi-synthetic 
penicillins are mainly classified by structural similarity, which also reflects their 
antimicrobial spectra.  
Methicillin is the first semi-synthetic penicillin that has an ortho-
dimethoxyphenyl group as a side chain and was resistant to the action of 
staphylococcal penicillinase (Rolinson, 1998; Wright, 1999). It was clinically useful 
in inhibiting penicillin-resistant S. aureus in the early 1960s but its inhibitory activity 
was not as high as penicillin G against similarly tested susceptible pathogens. It was 
eventually replaced by other penicillinase-resistant penicillins, e.g., oxacillin and 
cloxacillin, which have higher bioactivity against staphylococci (Wright, 1999). 
However, strains of S. aureus that were resistant to methicillin and other penicillinase-
resistant penicillins eventually emerged and till now, still pose a problem to the 
healthcare industry (Appelbaum, 2006). They are known as methicillin-resistant S. 
aureus (MRSA) and the resistance mechanism they possessed was due to the 
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acquisition of a low affinity PBP to β-lactam antibiotics known as PBP2a encoded by 
mecA, instead of evolved β-lactamases (Llarrull et al., 2009; Matsuhashi et al., 1986; 
Ubukata et al., 1985; Ubukata et al., 1989).  
Ampicillin is the first semi-synthetic penicillin with a broader antimicrobial 
spectrum than penicillin G, in that it also inhibits a variety of Gram negative bacteria 
(Rolinson, 1998). It has a phenylglycyl side chain, which structurally differs from 
penicillin G by an amino group in the α-carbon of the side chain. However, it has a 
poor absorption property in the alimentary canal. Subsequently, the addition of a 
hydroxyl group in the para position of the aromatic ring of ampicillin converted it to a 
more efficacious amoxicillin. Amoxicillin had better absorption from the gut and 
resulted in higher levels in the blood than equivalent doses of ampicillin (Wright, 
1999). However, resistance to amoxicillin due to β-lactamases also became 
widespread in the 1970s. Fortunately, a β-lactamase inhibitor, which has a highly 
similar chemical structure to penicillin, was discovered. It was mainly produced by S. 
clavuligerus and was named clavulanic acid. This discovery led to the first 
combinatorial administration of amoxicillin and clavulanic acid, a β-lactamase 
inhibitor, to overcome the proliferation of β-lactamase-producing pathogens (Miller et 
al., 2001; Wright, 1999).  
Although both ampicillin and amoxicillin were considered to have broad 
antimicrobial spectrum, they do not have good inhibitory activity against P. 
aeruginosa, which is one of the leading causes of nosocomial infections, especially in 
immunocompromised and cystic fibrosis patients (Mesaros et al., 2007; Strateva and 
Yordanov, 2009). By replacing the amino group with a carboxyl group in the side 
chain of ampicillin, improved activity against P. aeruginosa was observed and this 
penicillin was named carbenicillin. Subsequently, by replacing the phenyl ring with a 
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thiophenyl ring in carbenicillin, ticarcillin was found to possess better anti-
pseudomonal activity than carbenicillin (Rolinson, 1998). By virtue of the carboxyl 
group in the side chain of both penicillins, they are classified as carboxypenicillins.  
Next, the addition of urea moieties to the α-amino group in the side chain of 
ampicillin yielded ureidopenicillins (azlocillin, piperacillin and mezlocillin), which 
have even higher activities against P. aeruginosa, while retaining its inhibitory 
activity against streptococci, enterococci and non-β-lactamase-producing 
staphylococci (Bush and Johnson, 2000; Tan and File, 1995; Wright, 1999). However, 
the development of semi-synthetic cephalosporins eventually superseded that of the 

















































































































































Figure 2.5. Chemical structures of penicillin nucleus 6-APA and major groups of 




2.4.2. Development of semi-synthetic cephalosporins  
Although cephalosporin C is the first cephalosporin discovered, its narrow 
antimicrobial spectrum limited its clinical application. Nevertheless, the discovery of 
cephalosporin C led to the development of numerous cephalosporin derivatives. It was 
recognised that, similar to the development of semi-synthetic penicillins, the 
availability of the cephalosporin core structure was important in modifying the side 
chain of cephalosporin to improve its antimicrobial spectrum and efficacy. The 
production of the cephalosporin core structure, i.e., 7-aminocephalosporanic acid (7-
ACA), was made possible by deacylation of the aminoadipyl side chain of 
cephalosporin C. Hence, 7-ACA was used as a precursor for the synthesis of many 
earlier semi-synthetic cephalosporins (Hamilton-Miller, 2008).  
Other than having a similar chemical structure and mode of action as 
penicillin, cephalosporins were found to be naturally resistant to penicillinase. These 
two attributes made it a more attractive lead compound in the development of new β-
lactam antibiotics (Hansch et al., 1990). Furthermore, cephalosporin has two alkyl 
sites amenable to chemical modification compared to penicillin, which has only one 
(Figure 2.6). This allows a larger variety of cephalosporin derivatives to be 
synthesised and assessed for better antimicrobial properties suitable for clinical 
applications. Hence, a plethora of β-lactam derivatives were developed and marketed, 
with an estimation of at least 50 different cephalosporins available in the market in 
2003 (Elander, 2003; Hamilton-Miller, 2000; Hamilton-Miller, 2008). 
Cephalexin is one of the earlier semi-synthetic cephalosporins available and 
has the same phenylglycyl side chain as ampicillin. Its antimicrobial spectrum 
encompasses that of ampicillin, except that its resistance to penicillinase bestowed 
upon itself a wider spectrum than ampicillin (Hansch et al., 1990). Similarly, 
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cefadroxil, which is a p-hydroxyl derivative of cephalexin, also possesses similar 
pharmacokinetic properties but has a wider spectrum than its penicillin counterpart, 
amoxicillin (Hansch et al., 1990). It became clear that in order to further improve the 
efficacy of cephalosporin, the structure of the side chains of cephalosporin has to be 
different from that of the semi-synthetic penicillins. Thereafter, the pool of 
structurally diverse semi-synthetic cephalosporins with different antimicrobial spectra 
and susceptibilities to the β-lactamases increased tremendously.  
The semi-synthetic cephalosporins are generally grouped into ‘generations’ 
based on their antimicrobial spectra and stability against β-lactamases, which is 
considered more useful for administrative reference (Figure 2.6). The first generation 
cephalosporins are made up of early cephalosporins that have similar antimicrobial 
spectra as that of cephalexin. They were considered broad spectrum antibiotics with 
the advantage of being more stable against penicillinase. The second and third 
generations have extended spectrum of the first generation cephalosporins, including 
many Gram negative bacteria, and are more resistant to the evolving β-lactamases. 
However, these improved cephalosporins suffered lower inhibitory activity against 
Gram positive bacteria. In contrast to the first three generations, the fourth generation 
cephalosporins, e.g., cefepime, have a broad antimicrobial spectrum including many 
Gram positive and Gram negative bacteria, as well as P. aeruginosa. They are also 
generally more resistant to the evolved β-lactamases that are active against earlier 
generation cephalosporins (Marshall and Blair, 1999). However, the issue with 
MRSA remained problematic until recently, when two new cephalosporins, namely 
ceftobiprole (Deresinski, 2008; Llarrull et al., 2009) and ceftaroline (Llarrull et al., 
2009; Villegas-Estrada et al., 2008), were developed. Both cephalosporins were tested 
and shown to be efficacious against MRSA due to higher binding affinity to the 
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resistant PBP2A. Ceftobiprole has also been shown to have activity against many 
Gram negative bacteria in vitro including P. aeruginosa (Barbour et al., 2009; Walkty 
et al., 2008). Both ceftobiprole and ceftaroline have been approved by the United 
States Food and Drug Administration for the treatment of skin and skin structure 
infections (Laudano, 2011; Stein et al., 2009).  
Other than MRSA, P. aeruginosa has also been reported with evolved 
resistance towards the fourth generation cephalosporins. This is primarily due to 
AmpC β-lactamase degrading these cephalosporins. By modifying the C3 side chain 
of ceftazidime, a new cephalosporin CXA-101 was designed and demonstrated to be 
resistant to the action of P. aeruginosa AmpC β-lactamase (Murano et al., 2008; Toda 
et al., 2008). Recently, it was also shown to be effective against various β-lactam-
resistant strains of P. aeruginosa (Giske et al., 2009; Livermore et al., 2009; 
Zamorano et al., 2010). Its efficacy was also tested in the presence of a β-lactamase 
inhibitor, tazobactam, against extended-spectrum β-lactamase-producing E. coli and 
Klebsiella pneumoniae. This study showed that the combination CXA-201 (consisting 
of an antibiotic and an inhibitor) was able to inhibit 96% of the test bacteria with a 
breakpoint of ≤ 1 mg/L (Titelman et al., 2011). Currently, CXA-201 is undergoing 






















































































































































































































































Figure 2.6. Chemical structures of cephalosporin nucleus 7-ADCA and different 




2.4.3. Industrial production of penicillin and cephalosporin nuclei  
Industrial production of semi-synthetic penicillins and cephalosporins began in 
the 1960s. The idea of producing semi-synthetic cephalosporins stemmed from the 
ability to synthesise a variety of semi-synthetic penicillins, using the penicillin 
nucleus 6-APA, with improved antimicrobial spectrum (Hamilton-Miller, 2000; 
Hamilton-Miller, 2008). However, unlike 6-APA, the cephalosporin nucleus is not 
readily produced in the cephalosporin producers (Rolinson and Geddes, 2007). It was 
clear then that the development of semi-synthetic cephalosporins as useful 
chemotherapeutics depended on the ability to obtain the cephalosporin nucleus.  
Naturally, cephalosporin C became the initial choice to obtain the 
cephalosporin nucleus. By using mild acid hydrolysis, cephalosporin C could be 
chemically deacylated to remove the aminoadipate side chain and yield 7-ACA 
(Morin et al., 1962). However, the amount of 7-ACA produced was very low. By 
using formic acid, a yield increment from 7% to 40% could be achieved (Morin et al., 
1962). This initial high yield preparation of 7-ACA allowed the synthesis of various 
semi-synthetic cephalosporins, i.e., thiophene-2-acetyl and furan-2-acetyl side-chains 
at C7β of cephem nucleus, that were tested for better efficacy than benzylpenicillin in 
the 1960s (Chauvette et al., 1962). The selected semi-synthetic cephalosporin was 
named cephalothin and was then further evaluated clinically as a broad spectrum 
cephalosporin (Chauvette et al., 1962).  However, this chemical deacylation method 
required organic solvents and produced toxic chemical wastes, which are undesirable. 
Hence, chemical deacylation of cephalosporin C was subsequently replaced by 
enzymatic methods.  
Currently, there are two approaches to enzymatic deacylation. The ideal 
method is the direct deacylation of the aminoadipate side chain using a cephalosporin 
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acylase. However, the natural cephalosporin acylases isolated from natural sources 
were not efficient (Barber et al., 2004). With the advancement in protein engineering, 
the activity of cephalosporin acylase could be improved, allowing it to be used 
industrially (Oh et al., 2003; Otten et al., 2002; Pollegioni et al., 2005; Sonawane, 
2006). Another approach is the oxidative deamination of cephalosporin C to keto-
adipyl-7-ACA by D-amino acid oxidase (Barber et al., 2004). In this reaction, 
hydrogen peroxide would be produced and lead to spontaneous oxidative 
decarboxylation of keto-adipyl-7-ACA, which would then formed glutaryl-7-ACA. 
Glutaryl-7-ACA is then deacylated using glutaryl acylase to finally yield 7-ACA 
(Figure 2.7). For semi-synthetic cephalosporins that require 3-vinyl substituted 
intermediates, e.g., cefdinir, 7-ACA has to be deacetylated to 7-
aminodeacetylcephalosporanic acid (7-ADOCA) using cephalosporin acetyl hydrolase 
or cephalosporin acetyl esterases (Figure 2.7) (Barber et al., 2004; Sonawane, 2006). 
Another setback with cephalosporin C production is its chemical instability in 
the fermentation cultures of A. chrysogenum. This instability leading to degradation 
could account for approximately 40% loss of the cephalosporin C produced (Usher et 
al., 1988). To compete with the market of 7-ACA production, penicillin G became the 
preferred substrate for the production of cephalosporin nucleus because it is easily 
available in bulk from a high yielding strain of P. chrysogenum. Penicillin G could be 
converted into a cephalosporin DAOC G by a chemical ring-expansion procedure. 
Subsequently, its side chain could be enzymatically deacylated to yield the 
cephalosporin nucleus, 7-ADCA (Figure 2.8). However, this chemical ring-expansion 
method involved multiple steps and produced toxic wastes. Hence, cheaper and 











































































































2.5. Biosynthesis of penicillin and cephalosporin  
The primary interest in understanding β-lactam biosynthesis originated from 
the structural similarity between penicillin and cephalosporin. Resolution of the 
chemical structure of cephalosporin C bearing a β-lactam ring fused with a 
dihydrothiazine ring further affirmed the possible genetic linkage between their 
biosyntheses (Abraham and Newton, 1961). Studies on the biosynthetic pathways of 
penicillin and cephalosporin producers mainly concentrated on P. chrysogenum, A. 
chrysogenum, S. clavuligerus, N. lactamdurans and L. lactamgenus. Despite 30 years 
of investigation, our understanding of the biosynthetic pathway of β-lactams is not 
complete because of the branching into varied pathways leading to different end-
products in different microorganisms, especially the cephamycin and cephabacin 
producers (Liras, 1999; Liras and Demain, 2009; Martin and Gutierrez, 1995; Martin 
et al., 2010). Nevertheless, the major pathway leading to the formation of the 
penicillin and cephalosporin core structures have been deciphered, allowing genetic 
manipulation of industrial strains for high yield production (Figure 2.9). 
 
2.5.1. β-Lactam biosynthetic pathways of fungi and bacteria  
Biosynthesis of penicillin begins with the fusion of three amino acids, i.e., L-
aminoadipic acid, L-cysteine and L-valine, into a tripeptide known as δ-(L-α-
aminoadipyl)-L-cysteinyl-D-valine (ACV), by ACV synthetase (ACVS) encoded by 
pcbAB (Figure 2.9) (Coque et al., 1991; Diez et al., 1990; Gutierrez et al., 1991; 
Loder and Abraham, 1971; Tobin et al., 1991). ACV is cyclised to isopenicillin N by 
isopenicillin N synthase (IPNS), which is encoded by pcbC gene (Castro et al., 1988; 
Diez et al., 1989). This is the formation of the first bioactive compound in the 
biosynthetic pathway. IPNS is a non-haem ferrous iron-dependent oxygenase, which 
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bears the conserved iron-binding motif HXD/EXnH. It also possesses the RXS motif, 
which is critical for the coordination of the co-substrate 2-oxoglutarate in the 
enzymatic reaction of 2-oxoglutarate dependent dioxygenases. Interestingly, IPNS 
does not require 2-oxoglutarate for its reactivity. Instead, the RXS motif is important 
for binding the valine carboxylate of ACV substrate (Roach et al., 1997; Roach et al., 
1995).  
In penicillin-producing organisms, e.g., P. chrysogenum, the end-product of its 
β-lactam biosynthetic pathway can be altered by feeding phenylacetic acid or 
phenoxyacetic acid to the fermentation culture to derive penicillin G or penicillin V, 
respectively, which are the earliest clinically useful penicillins. This is achieved by 
acyl-coenzyme A:IPN acyltransferase, which exchanges the aminoadipyl side chain of 
isopenicillin N to the respective coenzyme A-activated feeding substrate (Barredo et 
al., 1989) (Figure 2.9). This enzyme not only possesses IPN acyltransferase activity, it 
also bears amidohydrolase and 6-APA acyltransferase activities, and accepts a wide 
range of acyl-CoA derivatives and various non-CoA thioesters, highlighting a 
potential application in the synthesis of semi-synthetics (Alvarez et al., 1993; 
Whiteman et al., 1990). Although this enzyme is encoded by a single penDE gene in 
both fungi, P. chrysogenum IPN acyltransferase is auto-processed from a 40 kDa 
inactive proenzyme into a heterodimer consisting of α (29 kDa) and β (11 kDa) 
subunits, which differs from Aspergillus nidulans IPN acyltransferase that is active in 
its unprocessed form. This difference in functionality has been attributed to the 
protein sequence disparity in the proenzyme, which determines the autocatalytic 
activity (Fernandez et al., 2003). 
Currently, there are at least three different classes of natural cephem 
antibiotics. Cephalosporin C is the first cephem discovered and so named after the 
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earlier genus name of the producer A. chrysogenum, i.e., Cephalosporium 
acremonium (Campos Muñiz et al., 2007). Cephamycin C deviates from 
cephalosporin C as it possesses a methoxy group at C7α and a carbamoyl group at C3 
instead of an acetyl group (Figure 2.9). So far, it is mainly produced by actinomycetes 
viz Nocardia lactamdurans and Streptomyces species (Nagarajan et al., 1971; Stapley 
et al., 1972). The third group of cephem is cephabacin. Similar to cephamycin C, 
cephabacin differs from cephalosporin C at its C7α and C3 positions. It possesses a 
formylamino group at C7α and an oligopeptide moiety at its C3 position. Presently, 
cephabacins are only known to be produced by Gram-negative bacteria Lysobacter 
lactamgenus (Ono et al., 1984), Xanthomonas lactamgena (Ono et al., 1984) and 
Flavobacterium sp. (Palissa et al., 1989). Both cephamycin C and cephabacin have 
been demonstrated to be more resistant to the degradation of β-lactamases than 
cephalosporin C (Nozaki et al., 1985; Nozaki et al., 1984). 
In cephalosporin C-producing A. chrysogenum, isopenicillin N is converted 
into penicillin N by a two-component isopenicillin N epimerase system. This two-
component protein system is encoded by two genes, namely cefD1 and cefD2, which 
correspond to isopenicillinyl-CoA ligase and isopenicillinyl-CoA epimerase, 
respectively (Martin et al., 2004; Ullan et al., 2002). Penicillin N is then ring-
expanded to deacetoxycephalosporin C (DAOC) by a bifunctional 
deacetoxy/deacetylcephalosporin C synthase (DAOC/DACS) enzyme, where the five-
membered thiazolidine ring in penicillin N is converted to the six-membered 
dihydrothiazine ring in DAOC (Dotzlaf and Yeh, 1989). DAOC is subsequently 
hydroxylated at C3 position by the same enzyme to yield deacetylcephalosporin C 
(DAC). Then an acetyl group is added to the C3 hydroxyl group of DAC by DAC 
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acetyltransferase, which is encoded by cefG, to finally produce cephalosporin C 
(Gutierrez et al., 1992).  
In S. clavuligerus and N. lactamdurans, isopenicillin N is converted to 
penicillin N by a monomeric pyridoxal phosphate-dependent isopenicillin N 
epimerase, which is different from the A. chrysogenum epimerase system (Martin et 
al., 2004; Usui and Yu, 1989). Penicillin N is ring-expanded to DAOC, followed by 
hydroxylation to DAC using two separate monofunctional DAOCS and 
deacetylcephalosporin C synthase (DACS) enzymes (Coque et al., 1996; Cortes et al., 
1987; Jensen et al., 1985). These two steps are similar to that of the cephalosporin C 
biosynthetic pathway. Thereafter, a carbamoyl group is added to the C3 hydroxyl of 
DAC by DAC-carbamoyl transferase (Coque et al., 1995b), followed by 
methoxylation at C7α by O-carbamoyl-DAC-7-methoxyl transferase (Coque et al., 
1995a) (Figure 2.9). Studies have shown that the hydroxyl and methyl groups are 
derived from molecular oxygen and methionine, respectively (O'Sullivan et al., 1979; 
Whitney et al., 1972). This last step of methoxylation is carried out by two enzymes, 
CmcI and CmcJ, separately encoded by the cmcI and cmcJ genes, respectively. These 
two enzymes function as a duo-protein component in hydroxylating the C7α position 
of the cephem nucleus followed by methylation, although in N. lactamdurans, the 
CmcI enzyme alone has weak hydroxylation activity in the presence of 2-oxoglutarate 
(Coque et al., 1995a; Enguita et al., 1996). Interestingly, N. lactamdurans CmcI was 
also found to exhibit hydroxylase activity in the presence of NADH although no 
methyltransferase activity was detected for the CmcI-CmcJ complex (Coque et al., 
1995a). Fluorescence spectroscopic analysis of CmcI and CmcJ interaction illustrated 
conformational changes in CmcI with increasing concentrations of CmcJ, and the 
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binding of substrates S-adenosylmethionine and cephalosporin C was higher in the 
CmcI-CmcJ complex compared to the individual proteins (Enguita et al., 1996).  
Similar to the biosynthesis of cephamycin C, the biosynthesis of cephabacin 
differs from that of cephalosporin C after DAC is formed although it is still not clear 
if the formylamino or the oligopeptide moiety was added first (Figure 2.9). Recent 
efforts in deciphering the functionalities of enzymes involved in the synthesis of the 
oligopeptide moiety have shed light on their identities. The cpbI gene encodes the 
non-ribosomal peptide synthetase-polyketide synthase-hybrid complex (NRPS-PKS), 
in which the NRPS component is composed of three modules. Each of these modules 
has three domains responsible for catalysing condensation, adenylation and thiolation 
reactions. The cpbK gene encodes only a single NRPS module (Demirev et al., 2006). 
These two genes encode enzymes necessary for the formation of the oligopeptide 
moiety. However, the enzymes responsible for the addition of the formylamino and 
oligopeptide moieties to the C7α and C3 position of cephabacin F, respectively, have 
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Figure 2.9. Biosynthesis of penicillin, cephalosporin C, cephamycin C and cephabacin 
in respective microorganisms. In A. chrysogenum, the epimerisation of isopenicillin N 
to penicillin N involves two different enzymes encoded by cefD1 and cefD2 genes, 
and the ring-expansion followed by hydroxylation of penicillin N to DAC is catalysed 
by a bifunctional enzyme DAOC/DACS encoded by cefEF gene.   
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2.6. Deacetoxycephalosporin C synthase 
The committed step in the biosynthesis of cephem antibiotics is executed by 
monofunctional DAOCS in prokaryotes and bifunctional DAOC/DACS in A. 
chrysogenum. This enzymatic reaction is highly specific and has been proposed to 
replace the existing chemical ring-expansion of penicillin G in the industrial 
production of semi-synthetic cephalosporins (Table 2.3) (Andersson et al., 2001; 
Barber et al., 2004; Barends et al., 2004). However, the limitation in using DAOCS 
for enzymatic ring-expansion of penicillin G is its low catalytic activity since its 
native substrate is penicillin N. Hence, many studies have focused on its biochemical 





Table 2.3. Summary of DAOCS-related patents. 
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2.6.1. Biochemical characteristics of deacetoxycephalosporin C synthase  
Enzyme reaction conditions for the detection of ring-expansion activity have 
been modified over the last two decades. To achieve optimum conditions for the 
conversion of penicillin to a cephalosporin, Shen and co-workers (1984) derived a 
reaction mixture containing 50 mM Tris–HCl (pH 7.4), 10 mM KCl, 10 mM MgSO4, 
0.6 mM ascorbic acid, 0.8 mM ATP, 0.04 mM FeSO4, 0.6 mM 2-oxoglutarate, and 
0.28 mM penicillin N for detection of the ring-expansion activity of DAOCS from A. 
chrysogenum. They showed that an effective order of co-factor addition to the 
reaction mixture is important, i.e., simultaneous addition of iron (II) ion, ascorbic 
acid, and ATP followed by 2-oxoglutarate and then penicillin N, were obligatory to 
achieve the highest detectable activity (Shen et al., 1984). However, it was found that 
DAOCS was unable to convert penicillin G and other penicillin N analogues under 
the optimum conditions described for penicillin N (Dotzlaf and Yeh, 1989). Maeda 
and co-workers (1995) tested various conditions such as temperature, duration of 
reaction, buffers and concentration of penicillin G, but were still unable to catalyse 
the conversion of penicillin G to its respective cephem moiety. They were only able to 
detect ring-expansion activity when penicillin N or D-carboxymethylcysteinyl-6-APA 
was used as the substrate. As such, DAOCS isolated from various sources was 
thought to have a very narrow substrate specificity (Cortes et al., 1987; Dotzlaf and 
Yeh, 1989; Maeda et al., 1995). Subsequently, Cho and co-workers (1998) discovered 
reaction conditions that enabled the ring-expansion of penicillin N analogues. This 
was made feasible by increasing the concentration of iron(II) and the co-substrate, 2-
oxoglutarate in the reaction mixture, which enabled the conversion of penicillin G and 
14 other penicillin N analogues to their respective cephem moieties by S. clavuligerus 
NP1 resting cells (Table 2.4). Thereafter, Sim and Sim (2001) showed that omission 
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of KCl, MgSO4, dithiothreitol and ascorbic acid from Cho’s reaction conditions could 
significantly improve the conversion of penicillin G and ampicillin by GST-
scDAOCS fusion protein (Sim and Sim, 2001). Using these improved reaction 
conditions, Chin and Sim (2002) showed that the substrate specificity of scDAOCS is 
wider than previously thought (Table 2.4). 
Several assays have been used for the detection of cephalosporin formation by 
DAOCS. These include a hole-plate bioassay (Chin et al., 2001; Sim and Sim, 2001), 
thin-layer chromatography (Jensen et al., 1983), and reverse-phase high-pressure 
liquid chromatography (HPLC) (Chin et al., 2001; Fernandez et al., 1999; Jensen et 
al., 1983). A hole-plate bioassay relies on the use of agar plate seeded with β-lactam-
sensitive E. coli and penicillinase, which will degrade any remaining penicillin 
substrate.  A well is made in the centre of the agar plate, followed by loading of the 
enzyme reaction mixture. The antibiotic compounds present in the mixture will 
diffuse into the agar and inhibit the growth of E. coli, resulting in a zone of growth 
inhibition, which reflects the concentration of cephalosporin present. Thin-layer 
chromatography uses a cellulose paper as the solid phase and n-butanol-acetic acid-
water as the mobile phase to separate penicillin substrate and cephalosporin product 
based on their solubility differences in the mobile phase. After development, the paper 
is dried and placed face-down on an agar slab containing β-lactam-sensitive E. coli 
and penicillinase to detect for growth inhibition. Reverse-phase HPLC is similar to 
thin-layer chromatography, except that it uses a C18 column instead of cellulose paper 
and the separation of compounds is under high pressure. The elution of respective 
penicillin substrate and cephalosporin product is monitored using a 
spectrophotometer, which will read out the level of absorption at a specific 
wavelength of light against retention time. However, these assays are laborious, 
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cumbersome, and yield limited data points. Furthermore, a large number of samples 
are required for kinetic studies. A continuous and direct spectrophotometric assay for 
the determination of penicillin N conversion by DAOCS was first reported by 
Baldwin and Crabbe (1987). However, this assay contained sodium azide as one of 
the components in the reaction mixture, which probably limited its application. 
Subsequently, another spectrophotometric assay was devised by Dubus and co-
workers (2001) to probe the kinetic properties and substrate and co-substrate 
selectivities of the recombinant scDAOCS. They showed that scDAOCS has a Km 
value of 0.89 mM and a kcat value of 0.079 s-1 for penicillin G conversion, and a Km 
value of 4.86 mM and a kcat value of 0.120 s-1 for ampicillin conversion. Interestingly, 
they also showed that the substrate specificity of scDAOCS included acetyl-6-APA, 
with a Km value of 3.28 mM and a kcat value of 0.060 s-1 for its conversion. 
Although many studies have shown that the substrate specificity of scDAOCS 
is broad, kinetic studies have illustrated its low catalytic efficiency towards penicillin 
G compared with its natural substrate, penicillin N (Lee et al., 2002; Lee et al., 2001a; 
Lipscomb et al., 2002; Lloyd et al., 1999b; Wei et al., 2003a; Wei et al., 2005). In a 
recent study by Wei and co-workers (2005), the Km and kcat values for penicillin G 
conversion were reported to be 2.58 mM and 0.0453 s-1, and for penicillin N 
conversion, the reported values were 0.014 mM and 0.307 s-1, respectively. Hence, 
further studies on this enzyme have moved towards understanding its structure-
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2.6.2. Limitations of native deacetoxycephalosporin C synthase 
A few DAOCS genes have been cloned and characterised. Among these, only 
one is of eukaryotic origin, while the rest are from prokaryotes (Table 2.5). Earlier 
studies on DAOCS were mainly performed using those from C. acremonium, S. 
clavuligerus, or N. lactamdurans. Although S. cattleya NRRL 8057 (Khaoua et al., 
1991; Williamson et al., 1985) and Streptomyces katsurahamanus T-272 (Ward and 
Hodgson, 1993) were reported to produce cephamycin C, and Streptomyces sp. strain 
DRS-1 (Roy et al., 1997) possessed ring-expansion activity, the genes encoding 
DAOCS from these streptomycetes have yet to be cloned and characterised. Three 
cefE genes from Streptomyces jumonjinensis, Streptomyces ambofaciens, and 
Streptomyces chartreusis (Hsu et al., 2004) were cloned and characterised within the 
last decade (Table 2.5). Although DAOCSs of these three organisms have high 
protein sequence identities with that of S. clavuligerus, they were less active than that 
of S. clavuligerus in converting penicillin G under the respective prescribed assay 
conditions despite the presence of highly conserved amino acid residues reported to be 
involved in binding penicillin G (Figure 2.10) (Hsu et al., 2004; Chin et al., 2003). 
This suggests that the binding of penicillin G does not solely depend on these 
conserved amino acid residues. Furthermore, penicillin G used in these studies is not a 
natural substrate of these enzymes and their activities in converting their natural 
substrate have yet to be demonstrated. Thus, it is difficult to rationalise the differences 
in activities observed among the DAOCSs from various sources, especially when 
scDAOCS is the only enzyme with its three-dimensional structure resolved. 
Comparison of the catalytic efficiency of scDAOCS in converting its native 
substrate penicillin N and penicillin G revealed a striking difference of approximately 
1200-fold. The Km and kcat values of scDAOCS for penicillin G was about 180-fold 
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higher and 7-fold lower than that of scDAOCS for penicillin N, respectively (Table 
1.1). It is very likely that the substrate binding pocket of scDAOCS is not ideal for 
penicillin G since the substrate binding affinity for penicillin G, as reflected by the Km 
value, was much lower.  
 







identitya  Activity References 
S. clavuligerus NRRL 3585 P18548 311 100% Active (Kovacevic et al., 1989) 
S. jumonjinensis NRRL 5741 AF317908 311 81.7% Active (Chin et al., 2003) 
S. chartreusis (102SH3) AY318743 311 76.5% Active (Hsu et al., 2004) 
S. ambofaciens (29SA4) AY318742 311 81.4% ND (Hsu et al., 2004) 
N. lactamdurans  Z13974 314 70.1% Active (Coque et al., 1993) 
L. lactamgenus YK90 CAA39984 319 56.1% Active (Kimura et al., 1996) 
A. chrysogenumb P11935 332 53.8% Active (Samson et al., 1987) 
ND-not determined 
aPrimary protein sequence identities were obtained using MatGAT (Campanella et al., 2003) and 
expressed as percentage of S. clavuligerus DAOCS sequence  
bA bifunctional enzyme encoded by cefEF, which possesses both deacetoxycephalosporin C synthase 






Figure 2.10. Multiple sequence alignment of annotated DAOCSs from S. clavuligerus 
NRRL3585 (Scl), S. chartreusis 102SH3 (Sch), S. ambofaciens 29SA4 (Sam), S. 
jumonjinensis NRRL5741 (Sju), N. lactamdurans (Nla), L. lactamgenus YK90 (Lla) 
and A. chrysogenum (Ach). The accession numbers of these sequences are in Table 
2.5. The substrate binding residues reported by Hsu and co-workers (2004) are 
highlighted in grey colours. The secondary structure of scDAOCS is presented above 
its primary sequence based on the structural results reported by Valegard and co-
workers (2004) (PDB: 1UNB). The secondary structures of residues 81-90 and 167-
177 were highly disordered and were not determined (Valegard et al., 2004). The 




2.6.3. Structural studies of deacetoxycephalosporin C synthase  
DAOCS belongs to a family of enzymes that utilises an iron (II) ion as a co-
factor and 2-oxoglutarate as a co-substrate to catalyse oxidative reactions, i.e., 2-
oxoglutarate dependent dioxygenases. The enzymes in this family have a 
characteristic “jelly-roll” structure made up of eight β-sheets, with four β-sheets on 
each side of the barrel (Figure. 2.11). The β-barrel accommodates the conserved 
HXD/EXnH and RXS motifs essential for iron (II) ion and 2-oxoglutarate binding, 
respectively (Hausinger, 2004); in the case of scDAOCS, they are H183, D185, H243, 
R258, and S260 (Sim and Sim, 2000; Sim et al., 2003). Other antibiotic-producing 
enzymes in this family, for example clavaminate synthase (CAS) and carbapenem 
synthase, also have similar structural features (Clifton et al., 2003; Lloyd et al., 
1999a). Furthermore, a number of flavonoid synthesising enzymes also belongs to this 
family (Turnbull et al., 2004), e.g., flavanone 3β-hydroxylase (Owens et al., 2008), 
flavone synthase (Britsch, 1990), flavonol synthase (Chua et al., 2008) and 
anthocyanidin synthase (Wilmouth et al., 2002).  
The iron-binding centre in this family of enzymes essentially provides 
versatility and flexibility in catalysing a variety of oxidative reactions that include 
desaturation, ring-expansion, and hydroxylation. These are achieved by the generation 
of a reactive iron species that is required to attack the substrates. The resulting 
oxidative reaction would depend on the internal architecture of the enzyme, where the 
spatial arrangements of the substrate relative to the activated iron centre are important 
considerations for eliciting reactions. The sequence of events from iron (II) ion and 2-
oxoglutarate binding to substrate oxidation may also differ slightly between enzymes, 
for similar reasons. For example, in CAS, simultaneous 2-oxoglutarate and substrate 
binding are necessary to activate the iron centre, whereas in DAOCS, binding of 2-
64	  
	  
oxoglutarate and penicillin substrates are mutually exclusive, as supported by 
structural studies (Valegard et al., 2004; Zhou et al., 2001). 
To date, a total of 17 crystal structures of scDAOCS have been reported and 
deposited in the Protein Data Bank (PDB) (Table 2.6). The first structure published by 
Valegard and co-workers (1998) provided an important view of the tertiary folding of 
the enzyme and physical evidence of residues involved in the iron centre and 
interaction with the co-substrate. The study revealed that scDAOCS apoenzyme exists 
as a trimeric unit, where the C-terminus of one molecule (residues 308–311) 
penetrates the active site of its neighbouring molecule in a cyclical fashion. However, 
upon addition of iron (II) and 2-oxoglutarate, scDAOCS dissociates into monomers. 
These observations were supported by gel filtration and dynamic laser light scattering 
studies, which revealed the existence of an equilibrium between the monomeric and 
trimeric scDAOCS in the absence of iron (II), and a shift towards the monomeric 
form upon addition of the co-factor (Lloyd et al., 1999b). These findings implied that 
monomeric scDAOCS is the catalytically active form facilitating the oxidative 
reaction. 
The lack of a substrate in the crystal structure has, then, limited understanding 
on the catalytic mechanism of scDAOCS. The stable native trimeric structure of 
scDAOCS made crystallisation of an enzyme–substrate complex difficult, as the 
active site is partially occupied by the C-terminal tail of the neighbouring enzyme. 
Truncation of the C-terminal tail helped to prevent trimer formation but the method 
resulted in a loss of enzymatic activity. Oster and co-workers (2004) reported that the 
attachment of a His-tag at the N-terminus of scDAOCS disrupts trimer formation and 
liberates the C-terminal arm of the apoenzyme. However, analyses of the biochemical 
and structural data revealed significant changes in the substrate-binding affinity and 
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orientation of the penicillin nucleus in the His-tagged scDAOCS–substrate complex 
structure compared with those in the native enzyme–substrate structure published by 
the same group (Valegard et al., 2004). These discrepancies suggest caution when 
selecting the appropriate structural template for subsequent studies. More importantly, 
the data illustrated that the activity of scDAOCS very much depends on the stability 
of the enzyme maintained by equilibrium in a pool of monomeric and trimeric forms 
of scDAOCS, which can be disrupted with the introduction of a relatively small His-
tag at the N-terminus of the enzyme. Nevertheless, in both types of structures, the C-
terminus remained disordered in the enzyme–substrate complex. This implies a 
degree of flexibility that may be crucial for catalytic activity, as supported by 
mutagenesis studies (Chin and Sim, 2002; Chin et al., 2001; Lee et al., 2002; Lee et 
al., 2001a). 
The elucidation of scDAOCS structures with iron (II), 2-oxoglutarate, and 
penicillins was achieved by soaking the crystals of apo-scDAOCS with iron (II), 
followed by soaking in solution containing 2-oxogluatrate and either penicillin G or 
ampicillin. The structural information obtained provides the basis of the current 
“booby-trap” mechanism hypothesis (Valegard et al., 2004). The postulated 
mechanism involves initial activation of the iron centre by 2-oxoglutarate binding, 
followed by oxidative decarboxylation of 2-oxoglutarate to generate oxidising ferryl 
species with succinate and carbon dioxide as by-products. Succinate remains bound 
and stabilises the reactive iron species until the penicillin substrate enters the active 
site. Binding of penicillin to the reactive iron species via the sulphur group 
subsequently expels succinate and leads to oxidative ring-expansion of the penicillin 
substrate. This study also illustrated the sharing of overlapping binding sites for 
substrate and co-substrate, which implies mutual exclusivity in substrate and co-
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substrate binding. This requirement of an ordered sequential binding for catalysis 
supported earlier findings on the importance of the order of adding reagents in the 
enzyme (Shen et al., 1984). Furthermore, the difference in the orientation of penicillin 
substrates in DAOCS complexes formed with or without 2-oxoglutarate suggests that 
2-oxoglutarate is necessary to influence the orientation of penicillin binding. This is in 
accordance to the requirement of 2-oxoglutarate to activate the iron centre in order to 
elicit oxidative ring-expansion. Hence, the orientation of the penicillin substrate in 
DAOCS formed in the presence of 2-oxoglutarate, which also resembles the 
orientation of product DAOC co-crystallised with DAOCS, advocated a productive 
ring-expansion of penicillin (Valegard et al., 2004). 
Apart from providing insights to the mechanism of catalysis, the crystal 
structures of DAOCS with penicillins have also served as platforms to identify 
important residues that interact with the substrate. Some of these residues have the 





Figure 2.11. Crystal structure of scDAOCS (PDB: 1UNB). This figure depicts the 
characteristic β-barrel and conserved HXD/EXnH and RXS motifs in the Fe (II)/2-
oxoglutarate dependent dioxygenase enzyme family. Residues H183, D185 and H243 
are involved in binding Fe (II) ion whereas S260 and R258 stabilise the binding of 2-




Table 2.6. Crystal structures of DAOCS deposited in PDBa. 
Enzyme Crystallised form Resolution (Ǻ) PDBb References 
     
scDAOCS Apoprotein 1.3 1DCS (Valegard et al., 1998) 
 Fe (II) 1.5 1RXF 
 Fe (II), 2-oxoglutarate 1.5 1RXG 
     
     
scDAOCSc     
R258Q Fe (II), α-keto-β-methyl-butanoate 1.5 1HJG (Lee et al., 2001b) 
R258Q Fe (II), α-keto-β-methyl-pentanoate 1.6 1HJF 
     
     
scDAOCS     
ΔR306 Fe (II), 2-oxoglutarate 2.1 1E5I (Lee et al., 2001a) 
ΔR307A Fe (II), succinate, CO2 1.96 1E5H 
     
     
scDAOCS Fe (II), succinate 1.5 1UO9 (Valegard et al., 2004) 
 Fe (II), penicillin G 1.6 1UOF 
 Fe (II), deacetoxycephalosporin C 1.7 1UOG 
 Fe (II), 2-oxoglutarate, penicillin G 1.7 1UOB 
 Fe (II), 2-oxoglutarate, ampicillin 1.5 1UNB 
     
     
scDAOCSd Apoprotein 2.3 1W28 (Oster et al., 2004) 
 Fe (II) 2.51 1W2A 
 Fe (II), ampicillin 2.7 1W2N 
 Fe (II), deacetoxycephalosporin C 3.0 1W2O 
     
     
scDAOCS 5-hydroxy-4-keto valeric acid 1.53 2JB8 (Cicero et al., 2007) 
     
aThe list of crystal structures are arranged according to chronological order 
bPDB accession number 
cscDAOCS with mutational alteration 




2.7. Deacetylcephalosporin C synthase 
In the β-lactam biosynthetic pathway, deacetoxycephalosporin C (DAOC) is 
hydroxylated to deacetylcephalosporin C (DAC) by deacetylcephalosporin C synthase 
(DACS), which is also known as DAOC hydroxylase. This enzyme adds a hydroxyl 
group to C3 of the dihydrothiazine ring of DAOC. A similar reaction is also carried 
out by DAOC/DACS from A. chrysogenum. However, DAOC/DACS is a bifunctional 
enzyme that also possesses the ring-expansion activity of DAOCS. Currently, only 
four monofunctional bacterial DACSs have been annotated (Table 2.7). Since 
scDAOCS and A. chrysogenum DAOC/DACS show a high degree of structural 
similarity, it is difficult to predict the amino acid residues responsible in conferring 
the ring-expansion and hydroxylation activities. Hence, by characterising the S. 
clavuligerus DACS (scDACS), we may get further insight into the regions required 
for activity or substrate binding and how they differ from those involved in DAOCS 
activity. 
 
Table 2.7. Summary of annotated deacetylcephalosporin C synthases. 
Organism GenBank accession no. 
Protein 
length Activity References 
S. clavuligerus NRRL 3858 M63809; P42220 318 Active (Baker et al., 1991; Kovacevic and Miller, 1991) 
Streptomyces 65PH1 AY318744  312 ND (Hsu et al., 2004) 
N. lactamdurans P42219 310 Active (Coque et al., 1996)  
L. lactamgenus YK90 CAA39985 313 UD (Kimura et al., 1996) 
A. chrysogenuma  P11935 332 Active (Samson et al., 1987) 
ND-not determined  
UD-undetected  
aA bifunctional enzyme encoded by cefEF, which possesses both deacetoxycephalosporin C synthase 





2.7.1. Biochemical and structural relationships of scDACS and scDAOCS 
The open-reading frame of cefF gene of S. clavuligerus NRRL 3858 has been 
deciphered and deposited in GenBank (Kovacevic and Miller, 1991). It is located in 
the cephamycin C biosynthetic gene cluster but transcribed in an opposite direction 
from cefE gene (Figure 2.12). It encodes a protein with a molecular mass of 34, 584 
Da (Kovacevic and Miller, 1991). Its protein primary sequence bears approximately 
59% identity to that of scDAOCS. At the DNA level, cefF gene bears approximately 
71% identity to that of cefE gene (Kovacevic and Miller, 1991). Hence, it was 
postulated that both cefE and cefF genes might have evolved from a gene duplication 
event in S. clavuligerus.  
Earlier studies on scDACS depended on the purification of the native protein 
from cell-free extracts of S. clavuligerus by three anion-exchange chromatographies, 
ammonium sulphate fractionation and two gel filtrations. Similar to scDAOCS, 
scDACS requires ferrous iron, molecular oxygen and 2-oxoglutarate for its activity 
(Baker et al., 1991). The Km values of scDACS for DAOC and 2-oxoglutarate were 59 
and 10 µM, respectively (Baker et al., 1991). Other than hydroxylating DAOC to 
DAC, it could also hydroxylate a DAOC analogue 3-exomethylenecephalosporin C to 
DAC at approximately 37% relative activity of DAOC hydroxylation (Baker et al., 
1991). Although scDACS is structurally homologous to scDAOCS with 74% amino 
acid sequence similarity, it could only ring-expand penicillin N at about 3% activity 
of DAOC/DACS (Baker et al., 1991). Interestingly, the DAOC hydroxylation activity 
of scDACS was inhibited in the presence of penicillin N with a Ki of 0.12 mM, 
indicating a competitive occupancy of the substrate binding site of scDACS (Baker et 





pcbC pcbAB cefDcefF cefEcmcJ cmcIcmcHccaRblplat ORF11
 
Figure 2.12. Cephamycin C biosynthetic gene cluster of S. clavuligerus NRRL3585. 
The arrows refer to the promoters and direction of gene transcription of respective 
polycistronic genes.  
 
 
2.7.2. Bifunctional DAOC/DACS enzyme of Acremonium chrysogenum 
Cephalosporin C is the first cephem antibiotic to be discovered. It was 
produced by A. chrysogenum, a fungus discovered by Giuseppe Brotzu, an Italian 
scientist, in 1945. It was found to inhibit the growth of a number of Gram negative 
bacteria, e.g. Salmonella typhi, Salmonella paratyphi B, Yersinia pestis, Brucella 
melitensis and Vibrio cholera, where such bioactivity was not found in earlier 
penicillins (Hamilton-Miller, 2000). However, due to the lack of expertise and 
finances to purify the bioactive compound produced by A. chrysogenum, this fungus 
was subsequently brought to Oxford University where studies on the bioactive 
compound were continued.  
The first bioactive compound isolated from A. chrysogenum was named 
cephalosporin P due to its narrow antibacterial spectrum against mainly Gram positive 
bacteria. Only the second bioactive compound isolated was able to account for the 
antibacterial spectrum observed by Brotzu. This compound was named cephalosporin 
N due to its antibacterial spectrum including Gram negative bacteria, but was later 
changed to penicillin N since its structure was determined to be a penicillin. 
Interestingly, a third compound was found in the purest preparation of penicillin N, 
which has significantly different physical properties from penicillin N, e.g., ultraviolet 
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absorption spectrum and pH stability. It was also more resistant to penicillinase than 
penicillin N although it has a weaker antibacterial activity. Being the third antibiotic 
isolated from A. chrysogenum, this compound was named cephalosporin C (Hamilton-
Miller, 2000). 
Studies on the biosynthesis of cephalosporin led to the discovery of the 
enzymes involved. Purification of the native enzyme involved in the biosynthesis of 
cephalosporin led to the postulation that the enzyme was a bifunctional enzyme since 
the physical enzyme could not be separated. However, in S. clavuligerus, ring-
expansion and hydroxylation is carried out by two separate enzymes. 
Interestingly, DAOC/DACS is structurally homologous to monofunctional 
DAOCS and DACS; it bears 57% and 54% amino acid sequence identities to 
scDAOCS and scDACS, respectively (Lloyd et al., 2004). It also possesses an 
additional 20 amino acid residues at its C-terminus that has been shown to be 
important for its hydroxylation activity but not for its ring-expansion activity, via 
truncation studies using penicillin G as a substrate (Chin et al., 2003; Lloyd et al., 
2004).   
Mutational studies of DAOC/DACS have also provided some clues to the 
determinants of ring-expansion and hydroxylation in DAOC/DACS (Table 2.8). This 
was aided by multiple sequence alignment of DAOCSs and DACSs of S. clavuligerus 
and N. lactamdurans. Amino acid residues that were common in DAOCs and differ 
consistently from DACS were selected for analyses (Lloyd et al., 2004). For example, 
methionine is common among DACSs at position 306 of DAOC/DACS, while it is 
isoleucine in the corresponding position in DAOCSs. By replacing residue M306 with 
isoleucine, which corresponds to residue I305 in scDAOCS, hydroxylation of DAOC 
by DAOC/DACS was abolished accompanied with the halving of its ring-expansion 
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activity (Lloyd et al., 2004). This indicated the importance of the methionine residue 
in hydroxylation activity and for higher ring-expansion activity. Another example is 
residue W82 of DAOC/DACS, where the corresponding residue in DAOCSs and 
DACSs is consistently serine and alanine residues, respectively. Upon mutation of 
residue W82 to either serine or alanine residues, predominant ring-expansion or 
hydroxylation activity was retained (Lloyd et al., 2004).   
In another study, a similar approach to the mutational study of the C-terminal 
residues N304, R306 and R307 of scDAOCS was adopted for understanding the 
importance of C-terminal residues N305, R307 and R308 of DAOC/DACS (Chin and 
Sim, 2002; Wu et al., 2005).  These three residues were each mutated to leucine 
residue and only N305L and R308L single mutations showed significant improvement 
in the conversion of penicillin G and other analogues (Wu et al., 2005). 
Further analyses were carried out on residue R308 of DAOC/DACS to 
understand its role in controlling substrate specificity by mutation to the other 19 
amino acids (Wu et al., 2011). Only R308L, R308I, R308T and R308V mutations 
showed significant improvement in the conversion of penicillin G and other 
analogues, with R308I mutation showing more than a seven-fold increase in the 
relative activity and a three-fold increase in kcat/Km value of penicillin G conversion 
when compared to the wild-type DAOC/DACS. It is postulated that the four amino 
acid residues, which all possess short aliphatic side-chains, may improve hydrophobic 
interactions with the substrates, thus enhancing the ring-expansion activity of 
DAOC/DACS (Wu et al., 2011). However, the determining factors in defining the 
ring-expansion and hydroxylation activities of monofunctional DAOCSs and DACSs, 




Table 2.8. Relative ring-expansion and hydroxylation activities of wild-type and 
mutant DAOC/DACSs using penicillin G and DAOC as respective substrates (Lloyd 
et al., 2004). 
 
Enzyme Relative ring-expansion activity (%)  Relative hydroxylation activity (%) 
Wild-type  100 100 
W82A 5.5 71 
W82S 44 18 
N305L 107 85 
M306I 59 <2 
∆310 203 50 
∆328	   64 45 
∆310/M306I	   185 3 
∆310/N305L/M306I	   370 2 
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2.8. Enzyme improvement strategies for improving DAOCS    
Biocatalysis has become increasingly important for the pharmaceutical 
industries especially in the last decade to reduce hazardous waste and to be socially 
responsible in protecting the environment (Tucker, 2006). However, the industrial 
application of enzymes has been hampered by several reasons, namely limited 
enzyme availability, substrate specificity, catalytic rate and operational stability 
(Chaput et al., 2008). Advances in protein engineering have provided many options to 
overcome these factors, and many strategies have been proposed. For example, one 
common aim in protein engineering is to improve the thermostability of an enzyme 
for industrial production of chemical compounds (Bottcher and Bornscheuer, 2010). 
This enzyme has to function at elevated temperatures, which can reduce the chances 
of microbial contamination during the process. Many studies demonstrated that a rigid 
enzyme will be more stable at higher temperature. Hence, specific stabilising 
interactions such as disulphide bonds can be rationally introduced into the structure of 
the enzyme if its tertiary structure is available (Kazlauskas and Bornscheuer, 2009). 
Importantly, the technique of introducing changes in the protein sequence was 
revolutionised from earlier chemical or physical random mutagenesis methods to 
SDM at the genetic level (Peracchi, 2001).   
 
2.8.1. Mutagenesis: a key technology in improving enzyme’s functions 
The advent and rapid progress of recombinant DNA technology has overcome 
the need to purify the native protein from the organism-of-interest and allowed the 
possibility to produce a large amount of recombinant protein in a heterologous host, 
e.g., E. coli, which is safer to handle and has high proliferation rate. A significant 
methodology was devised and reported by Michael Smith in 1978, which earned him 
76	  
	  
a Nobel Prize in Chemistry in 1993 together with Kary Mullis, who invented 
polymerase chain reaction (Shampo and Kyle, 2003). This method introduces specific 
mutations at desired positions of a gene, resulting in changes in the translated protein 
sequence (Hutchison et al., 1978). This allowed for a precise study on the effect of 
changes at a specific position of a protein to provide clues on the function of the 
protein. This method has also led to a new area of research known as “protein 
engineering”, which exploits this technique to modify an existing protein such that it 
possesses desired properties such as improved stability and activity or alteration in 
substrate specificity. The field of protein engineering has also expanded intensively 
due to the development of bioinformatics, X-ray crystallography and nuclear 
magnetic resonance (NMR), which provides important structural information of the 
protein for protein design and engineering. Together, this advancement in technology 
has provided the opportunity for the pharmaceutical industries to exploit enzymatic 
processes for greener production of pharmaceutical products.  
 
2.8.2. Two main approaches that drive protein engineering: rational versus 
directed evolution 
Natural enzymes have evolved to function in vivo and not outside their natural 
environment. Hence, they are often poorly suited for industrial application, 
particularly for industrially preferred substrates and industrial processes (Chaput et 
al., 2008). Protein engineering thus becomes a very important tool to overcome these 
limitations.  
Generally, there are two approaches in protein engineering, i.e., rational 
approach and directed evolution approach (Bornscheuer and Pohl, 2001; Jestin and 
Vichier-Guerre, 2005). The directed evolution approach mainly exploits random 
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mutagenesis techniques to generate at least one mutation in the protein and couple 
with a screening or selection process to obtain the mutant protein with desired 
functionality. Hence, it can be performed without prior knowledge of the enzyme 
tertiary structure but often requires a large recombinant library to increase the chance 
of obtaining a clone with the desired property. The rational approach uses SDM to 
incorporate specific mutation(s) at relevant site(s) in a protein in order to confer a 
desired property. In this approach, structural information of the protein is necessary to 
allow precise sequence modification of the enzyme to achieve the desired property 
(Table 2.9). Often, this approach is hampered by inadequate knowledge in the 
structure-function relationship of the protein, resulting in a lower success rate of 
obtaining desired protein function compared to the directed evolution approach. In 
addition, the knowledge available in protein science has yet to allow the precise 





Table 2.9. Examples of structure-aided mutagenesis studies in improving enzymes for 
industrial applications. 
 
Protein Properties of protein altered Applications References Related patents 
α-Amylase Thermostability  Industrial processes of starch 
hydrolysis 
Declerck et al. 
1995, 1997, 2000. 
6,008,026 (USPTO*) 
β-Amylase Thermostability  Industrial processes of starch 
hydrolysis 






acid to cephalosporin C 
Enzymatic production of 7-
aminocephalosporanic acid 
from cephalosporin C 
Oh et al. 2003; 
Otten 2004.  
WO/2005/014821 
(WIPO*) 
DAOCS Substrate specificity: 
from penicillin N to 
penicillin G 
Enzymatic production of 7-
ADCA from penicillin G 
Chin et al. 2001, 
2004; Wei et al. 
2003, 2005; Hsu et 
al. 2004. 
6,905,854 (USPTO) 
DNA polymerase Improvement of the 3'-5' 
exonuclease activity 
Polymerase chain reaction Park et al. 1997. - 
Glucoamylase  Thermostability  Industrial processes of starch 
hydrolysis 
Chen et al. 1996. 6,352,851 (USPTO) 
6,537,792 (USPTO) 
Laccase  Shifting optimal pH of 
activity 
Degradation of lignin; 
development of oxygen 
cathodes in biofuel cells, green 
biodegradation of xenobiotics, 
biosensors, organic synthesis 
Madzak et al. 2006. - 
Lactate oxidase Thermostability and 
catalytic efficiency 
A component of 
electrochemical sensor systems 
for monitoring lactate 
concentration in blood 
Hamamatsu et al. 
2006; Kaneko et al. 
2005. 
-  
Lipase Increase activity at oil-
water interface 
Detergent lipase Martinelle et al. 
1996; Svendsen A. 
1996. 
7,312,062 (USPTO) 
Penicillin acylase Catalytic efficiency Enzymatic production of 6-
APA from penicillins 
Gabor and Janssen. 




Subtilisin  Stability  Detergent protease; model 
system for protein engineering 
studies 
Almog et al. 1998, 
2002; Bryan et al. 
1992; Bryan PN. 
2000; Takagi et al. 
2000; Maurer KH. 
2004. 
6,541,234 (USPTO) 




2.8.3. Enzyme modification to improve the substrate binding and catalytic 
activity of DAOCS: directed evolution approach 
The directed evolution approach mimics the evolutionary process of proteins 
by exploiting random mutagenesis techniques, for example homologous and non-
homologous recombinations, error-prone PCR, and chemical and physical 
mutagenesis methods, coupled with an efficient screening or selection method to 
obtain proteins with the desired properties. The first law of this approach, “you get 
what you screen for”, always applies. Hence, the screening method is an important 
part of the whole experiment. The design of the screening method has to ensure 
efficient detection of a product, which is a reflection of the desired property of the 
protein, and yet, the outcome is not always guaranteed. Often, a large library of 
recombinants is required and the number of desired recombinants could be very low. 
Nevertheless, this approach has also provided some important information on the 
structure–function relationship of DAOCS. 
 
2.8.3.1.  Homologous recombination 
The first reported attempt to improve the activity of DAOCS by the directed 
evolution approach was probably the construction of hybrid DAOCS of S. 
clavuligerus and N. lactamdurans by Adrio and co-workers using in vivo homologous 
recombination (Adrio and Demain, 2002; Adrio et al., 2002). This technique exploited 
the advantage of natural recombination at homologous regions of closely related 
sequences in a host organism to generate a recombinant enzyme. Rapid visual 
screening was set up by exploiting a tyrosinase melC gene from S. glaucescens, which 
encodes the ability to secrete the black pigment, melanin. The melC gene was inserted 
between the two cefE genes in a pJA680 vector and recombination of the two cefE 
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genes would result in loss of pigment production by the host organism. Using S. 
lividans strain 1326, a recombinant strain W25 was generated and found to have 
higher penicillin G conversion activity than the S. clavuligerus NP1 strain (Adrio and 
Demain, 2002; Adrio et al., 2002). Further analyses revealed that this recombinant 
strain preferred a lower reaction temperature (<30°C), a lower iron (II) concentration, 
and a higher level of 2-oxoglutarate for penicillin G conversion than S. clavuligerus 
NP1 strain (Gao et al., 2003). 
A similar method was adopted by Hsu and co-workers (2004) to improve the 
substrate specificity of DAOCS for penicillin G, except that it is an in vitro 
recombination method and more than two gene sequences were used for shuffling. 
The cefE genes from S. clavuligerus (ATCC 27064), N. lactamdurans (ATCC 27382), 
S. jumonjinensis (ATCC 29864), S. ambofaciens (102SH3), and S. chartreusis 
(29SA4), the cefF gene from S. clavuligerus (ATCC 27064), which encodes for 
deacetylcephalosporin C synthase, and the cefEF gene from A. chrysogenum (ATCC 
11550), were used for the shuffling experiment. These shuffled genes were 
heterologously expressed in E. coli cells and the transformants were screened for 
penicillin G conversion activity. After two rounds of gene shuffling and screening, 
two clones, FF1 and FF8, showed no substrate inhibition and were subjected to 
kinetic and sequence analyses. FF1 had an increment in kcat/Km value of 
approximately nine-fold when compared with scDAOCS and FF8 had a 118-fold 
increment, which is probably the highest improvement recorded so far for penicillin G 
conversion. Comparison of the amino acid sequence of FF8 with that of scDAOCS 
revealed that only two of the 35 substitutions, i.e., residues M73 and I305, are at 




2.8.3.2.  Chemical mutagenesis 
Chemical mutagenesis using hydroxylamine was attempted by Wei and co-
workers (2003) with the objective of modifying scDAOCS for optimum ring-
expansion activity towards penicillin G. The mutant library was first screened by a 
simple high-throughput paper disk-based bioassay, followed by a second screening 
method using thin-layer chromatography with radio-labelled penicillin G as a 
substrate. From 5,500 clones screened, six were found to have increased conversion 
activity and these were because of three point mutations, G79E, V275I, and C281Y. 
As these three sites are located away from the substrate binding pocket, the 
improvement achieved could have been due to a global effect of these mutations on 
the conformation of the active site (Wei et al., 2003a). 
 
2.8.3.3.  Error-prone PCR combined with gene shuffling 
Error-prone PCR exploits the altered fidelity of DNA polymerase in the 
presence of manganese ions to incorporate mismatched nucleotides during PCR 
amplification of the gene of interest. Wei and co-workers (2005) used a ratio of 
Mg(II) ions to Mn(II) ions of 12:1 in the error-prone PCR process to induce 
mutations. Approximately 6,000 clones were subjected to a screening process, where 
six types of point mutations (M73T, T91A, M188V, M188I, H244Q, G300V) and six 
types of double mutations (D53H/C281Y, M73T/P145L, A106T/C155Y, 
A106T/M188V, D107G/L277Q, Y184H/C281R) were identified. Subsequently, 
single mutations based on the double mutations were constructed to assess the effect 
of each substitution. Among these mutations, the L277Q mutant had the highest 
catalytic efficiency for penicillin G (six-fold increment), whereas the M73T, G79E, 
T91A, Y184H, M188V, and H244Q mutants had approximately two- to five-fold 
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increment in kcat/Km values when compared with the wild-type enzyme. Other 
mutations either had activities similar to that of the wild-type enzyme or exhibited 
substrate inhibition. Gene shuffling of these single mutants, including those reported 
previously, i.e., G79E, V275I, C281Y, N304K, I305L, and I305M mutants (Wei et 
al., 2003a), was then conducted to generate random combinations. Approximately 
10,000 clones were screened and only one quaternary mutant 
(C155Y/Y184H/V275I/C281Y) with enhanced activity and without substrate 
inhibition was subjected to kinetic analysis. For this mutant, the kcat/Km value for 
penicillin G conversion was a further seven-fold higher than for the C281Y single 
mutant, which had the highest kcat/Km value among these four single mutants (six-fold 
higher than that of the wild-type enzyme). Table 2.10 summarises the kinetic data for 
selected examples of mutant scDAOCSs with improved activities obtained by Wei 




Table 2.10. Kinetic parameters of bioengineered DAOCSs in penicillin G conversion 
(Hsu et al., 2004; Wei et al., 2003a; Wei et al., 2005). 
 
Mutations Km (mM) kcat (s-1) kcat/Km (M-1s-1) Relative kcat/Km 
Wild-type  2.58  0.0453  18 1 
M73T 0.74 0.0627 85 4.7 
G79E 0.75 0.0315 42 2.3 
T91A 1.36 0.0522 38 2.1 
C155Y 1.76  0.0476  27 1.5 
Y184H 0.95  0.0798  84 4.7 
M188V 0.76 0.0456 60 3.3 
H244Q 1.39 0.0698 50 2.8 
V275I 1.68  0.0502  30 1.7 
L277Q 1.02  0.1036  102 5.7 
C281Y 0.68  0.0744  109 6.1 
N304K 0.22  0.0564  256 14.2 
I305L 0.66  0.0759  115 6.4 
I305M 0.75  0.1452  194 10.8 
V275I/I305M 0.25  0.1458  583 32.4 
C155Y/Y184H/V275I/C281Y 0.19  0.1398  736 40.9 
FF8a 0.014  0.0297  2,121 117.8 




2.8.3.4.  Comparison of random mutagenesis methods 
Comparing these techniques, hydroxylamine mutagenesis generated the least 
number of mutants with improved penicillin G conversion activities. This chemical 
targets mainly the cytosine residues in DNA, which limits the repertoire of mutations 
(Tessman et al., 1965). In contrast, error-prone PCR generated a reasonably large 
number of mutants with improved activities. However, this method has errors biased 
toward AT to GC changes (Cirino et al., 2003). Furthermore, codon redundancy and 
possible introduction of stop codons lower the efficiency of this method in generating 
desired mutations. Gene shuffling has been successfully employed in generating an 
efficient recombinant DAOCS with catalytic efficiency in penicillin G conversion 
comparable with that of scDAOCS in penicillin N conversion. Although it is still not 
clear which amino acid differences between this recombinant enzyme and scDAOCS 
are responsible for this substantial improvement, this technique is a promising route in 
generating recombinants with desired substrate specificity, especially when more 
DAOCS orthologues are available for shuffling. 
Together, these studies suggest that the substrate specificity of DAOCS is not 
solely governed by the substrate-binding residues. Amino acid residues outside the 
substrate-binding site may also affect the substrate specificity of the enzyme and these 
residues are often difficult to identify via the rational approach (Figure 2.13). 
However, the effects of the mutations identified cannot be rationalised without 
structural information about the enzyme. In order to understand the molecular basis of 
such mutations in influencing the function of the enzyme, further analyses requiring 




Figure 2.13. Spatial locations of useful mutations in scDAOCS (PDB: 1UNB) 
identified by using directed evolution approaches. Among the mutations listed in 
Table 2.11, only M73T, N304K and I305M/L mutations are localised in the substrate 






2.8.4. Enzyme modification to improve the substrate binding and catalytic 
activity of DAOCS: rational approach 
The three-dimensional structure of the DAOCS-Fe(II)-2-oxoglutarate complex 
was resolved in the late 1990s (Lloyd et al., 1999b; Valegard et al., 1998) but the lack 
of bound substrate hindered many subsequent studies. It was recognised that the 
crystal structure of DAOCS resembles that of IPNS (Roach et al., 1997; Valegard et 
al., 1998). The crystal structure of the DAOCS–Fe(II)–2-oxoglutarate complex was 
superimposed on that of the IPNS–Fe(II)–ACV complex to predict the possible 
substrate binding pocket of scDAOCS (Chin et al., 2001; Valegard et al., 1998). 
Subsequently, various mutational studies aimed at understanding the substrate binding 
mechanism of DAOCS have revealed certain amino acid residues that are important 
for catalysis and others that are amenable to modification to improve the functions of 
the enzyme (Table 2.11).  
In one of the studies, residues R74, R160, R266, and N304 were selected for 
SDM studies based on the close proximity to the L-α-aminoadipyl branch of ACV and 
their hydropathic properties (Chin et al., 2001). This study showed that only the 
N304L mutation increased its penicillin analogue conversion activity. The R74L, 
R160L, and R266L mutations abolished the activity of scDAOCS and this indicated 
the importance of these residues in binding the penicillin substrate. Similarly, Lee and 
co-workers (2002) also showed that the N304A mutation was able to increase the 
activity of the enzyme. Thereafter, Wei and co-workers (2003) also adopted the same 
approach and reported that the N304K, I305L, and I305M mutations were able to 
increase the activity of scDAOCS (Table 2.10). Although results from various 
structural studies suggested that the C-terminal of scDAOCS (residues 301–311) 
might be involved in guiding the substrate into the substrate binding pocket (Lee et 
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al., 2001a), the rationale behind these mutations could not be clearly explained in the 
absence of a crystal structure of DAOCS complexed with a penicillin substrate.  
In order to elucidate the molecular basis of substrate interaction by residue 
N304, Chin and co-workers (2004) performed a study using a complete library of 
amino acid alterations and found that mutation to basic residues (arginine and lysine) 
has better effects than mutation to aliphatic residues (alanine, leucine, and 
methionine) in the conversion of seven hydrophobic penicillins. In the absence of the 
structural information on substrate interaction, these replacements harbouring a 
strictly basic or aliphatic side chain were postulated to likely incorporate favourable 
hydrophobic or charged interaction between these mutant enzymes and their prime 





Table 2.11. Summary of mutagenesis studies of scDAOCS substrate binding pocket.  
Mutation  Substrate  Assay method Findings  References  
R74L Penicillin G Bioassay Penicillin conversion abolished Chin et al., 2001 
M180F Penicillin N & 
penicillin G 
HPLC Penicillin N conversion reduced 
by half; penicillin G conversion 
abolished 
Lee et al., 2002 
R160Q Penicillin N & 
penicillin G 
HPLC Both penicillin conversions 
abolished 
Lipscomb et al., 
2002 
R160L Penicillin G Bioassay  Penicillin conversion abolished Chin et al., 2001 
R162A, 
R162Q 
Penicillin N & 
penicillin G 
HPLC Both penicillin conversions 
abolished 
Lipscomb et al., 
2002 






Penicillin G Bioassay ~120 to 260% of wild-type 
activity 
Chin et al., 2004 
I305L, 
I305M 
Penicillin G HPLC 1.7- and 3.2-fold increased in 
kcat, and 3.9- and 3.2 fold 
decreased in Km, respectively 




Chapter 3: Materials and methods  
 
3.1.  Materials 
3.1.1.  Bacterial cultures 
The bacterial strains used for cloning, expression of recombinant proteins and 
bioassay are listed in Table 3.1. 
 
Table 3.1. List of bacterial strains used.  
 
Strain Characteristics Reference/Source 
S. clavuligerus NRRL 
3585 (ATCC 27064) 
Cephamycin C and clavulanic acid 
producer 
American Type Culture 
Collection 
Escherichia coli BL21 
(DE3) 
Expression host, F-, carries T7 RNA 
polymerase gene under control of the 
lacUV5 promoter 
Studier and Moffatt, 1986, 
Novagen 
E. coli Ess Mutant of E. coli, a β-lactam 
supersensitive strain 
Aharonowitz and Demain, 
1978; a gift from Prof. 
Demain A. (Drew University) 
E. coli TOP10  Cloning host, F-, used in TOPO cloning Invitrogen  
Micrococcus luteus 
ATCC 381 
Gram positive bacterium, spherical, 
catalase positive, form bright yellow 
punctiform colonies of <1 mm 
American Type Culture 
Collection 
E. coli K12 Gram negative bacterium, straight rods, 
lactose fermenter with acid production, 
methyl red positive, Voges-Proskauer 
negative, Simmons citrate negative 




Gram positive bacterium, spherical, 
occurring in clusters, catalase positive, 
form light yellow colonies of ~1 mm 
American Type Culture 
Collection 
Enterobacter aerogenes Gram negative bacterium, straight rods, 
lactose fermenter with acid production, 
methyl red negative, Voges-Proskauer 
positive, Simmons citrate positive 
Department of Microbiology, 
laboratory isolate 
Salmonella cholerasuis 
subsp. cholerasuis (Smith) 
Weldin serovar Infantis 
ATCC 51741 
Gram negative bacterium, straight rods, 
non-lactose fermenter, methyl red 
positive, Voges-Proskauer negative, 
Simmons citrate positive 




Gram positive bacterium, spherical, 
occurring in pairs, catalase negative  





3.1.2.  Chemicals 
Chemicals of analytical/reagents grade were obtained from BDH Limited, UK 
(BDH), Bio-Rad Laboratories Private Limited, Singapore (Bio-Rad) and Sigma-
Aldrich Private Limited, Singapore (Sigma). HPLC-grade solvents were purchased 
from Fisher-Scientific. Chemicals of DNA and electrophoresis grade were obtained 
from UltraPure™, GIBCO Bethesda Research Laboratories, USA (BRL). Culture 
media were obtained from Oxoid Limited, UK. Antibiotics were purchased from 
Sigma-Aldrich Private Limited, Singapore. Unless otherwise stated, all buffers and 
culture media were sterilised by autoclaving for 15 min at 121ºC. Thermolabile 
components were filter-sterilised using Millipore™ syringe filters with a pore size of 
0.22 µm, and were stored at -20ºC. They were thawed prior to use and were 
aseptically added to autoclaved solutions. 
 
3.1.3.  Plasmid vectors 
The plasmid vectors used in this study are listed in Table 3.2. The restriction 
maps of pCR®-Blunt, pGEX-6P-1 and pGK vectors are illustrated under Appendix I. 
 
3.1.4.  Oligonucleotide primers  
The oligonucleotide primers used for SDM (Table 3.3), gene amplification and 
sequencing experiments (Table 3.4) were synthesised by 1st Base Private Limited, 






Table 3.2. List of plasmid vectors used.  
 
Vector Characteristics Reference/Source 
pGEX-6P-1 Ampr, lacIq, tac promoter preceding gluthathione-
S-transferase (GST) open-reading frame, 
PreScission™ protease recognition site 
(LEVLFQ↓GP) at C-terminus of GST, preceding 
MCS 
GE Healthcare 
pGK A derivative of pGEX-6P-1, Kanr Loke and Sim, 2000 
pscEXP-GST pGK vector carrying scDAOCS gene in the MCS Sim and Sim, 2001 
pscEXPN304L-GST pGK vector carrying N304L scDAOCS mutant 
gene in the MCS 
Chin et al., 2001 
pscEXPN304A-GST pGK vector carrying N304A scDAOCS mutant 
gene in the MCS 
Chin et al., 2004 
pscEXPN304K-GST pGK vector carrying N304K scDAOCS mutant 
gene in the MCS 
Chin et al., 2004 
pscEXPN304M-GST pGK vector carrying N304M scDAOCS mutant 
gene in the MCS 
Chin et al., 2004 
pscEXPN304R-GST pGK vector carrying N304R scDAOCS mutant 
gene in the MCS 
Chin et al., 2004 
pscEXPR306L-GST pGK vector carrying R306L scDAOCS mutant 
gene in the MCS 
Chin et al., 2002 
pCR®-Blunt II 
TOPO® 
Cloning vector, Kanr, topoisomerase I covalently 
bound to the vector allows direct insertion of 




Table 3.3. Mutagenic primers used in generating scDAOCS mutants. 
Gene Mutations Direction Sequence of mutagenic primers* 
scDAOCS V275I Forward 5’-CTTCACCTTCTCCATCCCGCTGGCGCGC-3’ 
  Reverse  5’-GCGCGCCAGCGGGATGGAGAAGGTGAAG-3’ 
 V275L Forward 5’-CACCTTCTCCCTCCCGCTGGCGCGC-3’ 
  Reverse  5’-CGCCAGCGGGAGGGAGAAGGTGAAGTC-3’ 
 C281F Forward 5’-CTGGCGCGCGAGTTCGGCTTCGATGTC-3’ 
  Reverse  5’-GACATCGAAGCCGAACTCGCGCGCCAG-3’ 
 C281Y Forward 5’-CTGGCGCGCGAGTACGGCTTCGATGTC-3’ 
  Reverse  5’-GACATCGAAGCCGTACTCGCGCGCCAG-3’ 
 I305M Forward 5’-GCAACTACGTGAACATGCGCCGCACATCC-3’ 
  Reverse  5’-GGATGTGCGGCGCATGTTCACGTAGTTGC-3’ 
 R306A Forward 5'-CTACGTGAACATCGCCCGCACATCCAAGG-3' 
  Reverse 5'-CCTTGGATGTGCGGGCGATGTTCACGTAG-3' 
 R306K Forward 5'-CTACGTGAACATCAAGCGCACATCCAAGG-3' 
  Reverse 5'-CCTTGGATGTGCGCTTGATGTTCACGTAG-3' 
 R306I Forward 5’-AACTACGTGAACATCATCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGATGATGTTCACGTAGTT-3’  
 R306V Forward 5’-AACTACGTGAACATCGTCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGACGATGTTCACGTAGTT-3’  
 R306F Forward 5’-AACTACGTGAACATCTTCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGAAGATGTTCACGTAGTT-3’  
 R306C Forward 5’-AACTACGTGAACATCTGCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGCAGATGTTCACGTAGTT-3’  
 R306W Forward 5’-AACTACGTGAACATCTGGCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGCCAGATGTTCACGTAGTT-3’  
 R306Y Forward 5’-AACTACGTGAACATCTACCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGTAGATGTTCACGTAGTT-3’  
 R306H Forward 5’-AACTACGTGAACATCCACCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGTGGATGTTCACGTAGTT-3’  
 R306M Forward 5’-AACTACGTGAACATCATGCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGCATGATGTTCACGTAGTT-3’  
 R306N Forward 5’-AACTACGTGAACATCAACCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGTTGATGTTCACGTAGTT-3’  
 R306D Forward 5’-AACTACGTGAACATCGACCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGTCGATGTTCACGTAGTT-3’  
 R306E Forward 5’-AACTACGTGAACATCGAGCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGCTCGATGTTCACGTAGTT-3’  
 R306Q Forward 5’-AACTACGTGAACATCCAGCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGCTGGATGTTCACGTAGTT-3’  
 R306S Forward 5’-AACTACGTGAACATCAGCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGCTGATGTTCACGTAGTT-3’  
 R306T Forward 5’-AACTACGTGAACATCACCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGGTGATGTTCACGTAGTT-3’  
 R306G Forward 5’-AACTACGTGAACATCGGCCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGGCCGATGTTCACGTAGTT-3’  
 R306P Forward 5’-AACTACGTGAACATCCCGCGCACATCCAAGGCA-3’  
  Reverse 5’-TGCCTTGGATGTGCGCGGGATGTTCACGTAGTT-3’  
 N304AR306L Forward 5’-GGGCAACTACGTGGCCATCCTCCGCACATC-3’ 
  Reverse  5’-GATGTGCGGAGGATGGCCACGTAGTTGCCC-3’ 
 N304KR306L Forward 5’-GGGCAACTACGTGAAGATCCTCCGCACATC-3’ 
  Reverse  5’-GATGTGCGGAGGATCTTCACGTAGTTGCCC-3’ 
 N304LR306L Forward 5’-GGGCAACTACGTGCTCATCCTCCGCACATC-3’ 
  Reverse  5’-GATGTGCGGAGGATGAGCACGTAGTTGCCC-3’ 
 N304MR306L Forward 5’-GGGCAACTACGTGATGATCCTCCGCACATC-3’ 
  Reverse  5’-GATGTGCGGAGGATCATCACGTAGTTGCCC-3’ 
 N304RR306L Forward 5’-GGGCAACTACGTGAGGATCCTCCGCACATCCAAGG-3’ 
  Reverse  5’-CCTTGGATGTGCGGAGGATCCTCACGTAGTTGCCC-3’ 
scDACS T308N Forward 5’-CAACTACGTCAACATGCACGCGAAGAAC-3’ 
  Reverse  5’-CTTCGCGTGCATGTTGACGTAGTTGGTG-3’ 
 T308R Forward 5’-CAACTACGTCAGGATGCACGCGAAGAAC-3’ 
  Reverse  5’-CTTCGCGTGCATCCTGACGTAGTTGGTG-3’ 
 H310R Forward 5’-CGTCACCATGCGCGCGAAGAACGAGCCG-3’ 
  Reverse  5’-GTTCTTCGCGCGCATGGTGACGTAGTTG-3’ 
 H310L Forward 5’-CGTCACCATGCTCGCGAAGAACGAGCCG-3’ 
  Reverse  5’-GTTCTTCGCGAGCATGGTGACGTAGTTG-3’ 
 T308NH310R Forward 5’-CTACGTCAACATGCGCGCGAAGAACGAGCCG-3’ 
  Reverse  5’-GTTCTTCGCGCGCATGTTGACGTAGTTGGTG-3’ 
 T308RH310R Forward 5’-CAACTACGTCAGGATGCGCGCGAAGAACGAG-3’ 
  Reverse  5’-GTTCTTCGCGCGCATCCTGACGTAGTTGGTG-3’ 
*The underlined bold triplets indicate the mutated codons. 
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Table 3.4. List of oligonucleotide primers used in gene amplification and cycle 
sequencing.  
 
Primer ID Sequences*  Description  
OL74 5'-GCTAGTTATTGCTCAGCGG-3' pGK T7 terminator region 
reverse primer, for sequencing  
OL334 5'-GGGCTGGCAAGCCACGTTTGGTG-3' pGK tac promoter region 
forward primer, for sequencing  
OL111 5’-GACTACTCGATGTGCTACT-3’ scDAOCS internal forward 
sequence primer, for sequencing 
OL112 5’-ACTGGAGGTGCGGCTGCTG-3’ scDAOCS internal reverse  
sequence primer, for sequencing 
OL963 5’-G↓GATCCATGGCGGACACGCCCGTACCG-3’ Cloning of cefF, forward primer 
with BamHI restriction site 
OL964 5’-G↓AATTCTCATCCGGCCTGCGGCTCGTTC-3’ Cloning of cefF, reverse primer 
with EcoRI restriction site 
OL993 5’-AAGGACATCGAGTAGTCCGTGTAG-3’ scDACS internal reverse 
sequence primer, for sequencing  
M13F 5’-GTAAAACGACGGCCAG-3’ pCR®-Blunt II TOPO® M13 
forward primer, for sequencing 
M13R 5’-CAGGAAACAGCTATGAC-3 pCR®-Blunt II TOPO® M13 
reverse primer, for sequencing 
*The underlined sequences indicate specific restriction endonuclease recognition sites. 
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3.1.5.  Enzymes  
Restriction endonucleases were purchased from Promega Private Limited, 
Singapore, Stratagene, USA, Fermentas International Inc., Canada and New England 
Biolabs Inc., USA. PreScission™ protease was purchased from GE Healthcare 
Private Limited, Singapore. Pyrococcus furiosus (Pfu) DNA polymerase was 
purchased from Promega Private Limited, Singapore, and Difco™ Penase was 
purchased from Becton Dickinson, USA. T4 DNA ligase was purchased from 
Invitrogen Singapore Private Limited, Singapore. All enzymes were used according to 
the manufacturer’s specifications. 
 
3.1.6.  Test kits  
The test kits used in this study are listed in Table 3.5. The test kits were used 
according to manufacturer’s instructions unless otherwise stated. 
 
Table 3.5. List of test kits used. 
 
Test kit Purpose Source 
QuikChange™ SDM kit Site-directed mutagenesis Stratagene 
Wizard™ Plus SV Minipreps DNA 
Purification System 
Plasmid purification Promega 
ABI PRISM™ BigDye® Terminator 
v3.1 cycle sequencing kit 
DNA sequencing  Applied Biosystems 
MicroSpin™ GST purification module Fusion protein purification GE Healthcare  
QIAquick® Gel Extraction kit Extraction of DNA from agarose gel Qiagen  
GFX™ Genomic Blood DNA 
purification kit  
Genomic DNA extraction Amersham Pharmacia 
Calbiochem® InnoZyme™ Human 
Neutrophil Elastase Immunocapture 
Activity Assay kit 
Assessment of protease inhibitors 
on human neutrophil elastase 




3.1.7.  Analytical instruments  
The liquid chromatography system used was ÄKTA purifier (GE Healthcare 
Private Limited, Singapore) consisting of a UV-900 detector and an Autosampler 
A900, and a 5 µm, 4.6 x 150 mm Sun-Fire™ C18 column from Waters Asia Limited, 
USA. The operation and data acquisition of the chromatographic process were 
controlled by UNICORN 5.0 (GE Healthcare Private Limited, Singapore).  
A filter-based GENios™ (with a 260 or 595 nm absorbance filter) or Safire™ 
microplate readers from Tecan Group Limited, Switzerland, was used for 
determination of protein concentration, protease inhibition assay and enzyme kinetic 
studies. The operation and data acquisition of the spectrophotometric processes were 
controlled by Magellan™ software (Tecan). For the determination of nucleic acid 
concentration, a NanoDrop-1000 spectrophotometer from Thermo Scientific, USA, 
was used.   
 
3.2.  Methods 
3.2.1.  Growth and maintenance of bacterial cultures 
Purity of the bacterial cultures is of utmost importance to ensure the accuracy 
of the results. Hence, aseptic technique was employed in the handling of all bacterial 
cultures. Colony morphology and Gram staining was used to identify the bacterial 
cultures based on the characteristics described in Table 3.1.  
All E. coli strains were grown in liquid Luria-Bertani (LB) medium containing 
1% (w/v) tryptone, 0.5% (w/v) yeast extract and 1% (w/v) NaCl, and LB agar plates 
with 1.5% (w/v) agar. Other bacterial cultures were grown in nutrient broth (NB) or 
on nutrient agar (NA) plates, unless otherwise stated. All bacterial liquid cultures 
were grown at 37°C on a rotary shaker set at 250 rpm while all bacterial solid cultures 
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were grown at 37°C in an oven incubator. For the selection of E. coli clones 
harbouring pGK or pCR®-Blunt vectors, kanamycin was included in the culture 
medium at a final concentration of 50 µg/mL. For the selection of clones harbouring 
pGEX-6P-1 vector, ampicillin was included in the culture medium at a final 
concentration of 100 µg/mL. Stocks of bacterial strains were stored in 20% (v/v) 
glycerol at -80°C. S. clavuligerus NRRL 3585 was grown in a liquid culture medium 
containing 0.4% (w/v) yeast extract, 1% (w/v) malt extract and 0.4% (v/v) glycerol, 
and incubated at 28°C on a rotary shaker set at 250 rpm for 3 days.  
 
3.2.2.  Transformation of E. coli cells  
The preparation of electrocompetent cells with the highest competence 
generally requires the cells to be in the early to mid-logarithmic growth phase. 
Avoiding the late log phase is crucial, as cell competence will be significantly 
reduced. A single well-isolated E. coli colony was inoculated into 5 mL of sterile LB 
broth and incubated overnight at 37°C with shaking at 250 rpm. 1 mL aliquot of the 
overnight culture was then added to a sterile flask containing 100 mL of LB broth. 
This is incubated at 37°C with agitation at 250 rpm until the O.D.600 reached 0.5-0.6 
absorbance units, which corresponds to the early to mid-logarithmic phase of E. coli 
BL21 (DE3) strain. 
Following that, the flask containing the bacterial culture was then chilled on 
ice for 30 min and centrifuged at 6000 rpm for 5 min at 4°C. The supernatant was 
discarded and then, the cell pellet was resuspended in 50 mL of ice-cold 10% (v/v) 
glycerol. This washing step was repeated twice with the cell pellet resuspended in 10 
mL of ice-cold 10% (v/v) glycerol after the first wash, followed by a final 
resuspension volume of 400 µL of ice-cold 10% glycerol after the second wash. The 
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resuspended competent cells were then aliquoted into 50 µL aliquots. The competent 
cells were stored frozen at -80ºC. 
Electrocompetent E. coli cells were allowed to thaw on ice and 1-2 µL of 
plasmid DNA or ligation mixture was added to 50 µL of cells in a chilled 0.2 cm 
Gene Pulse cuvette (Bio-Rad). The Bio-Rad Gene Pulser® was adjusted to 2.5kV and 
a short pulse of current was rendered across the cuvette. Then, 1 mL of LB broth was 
added to the mixture. This step is crucial to ensure the maximal recovery of 
transformants. The cells were then allowed to recover at 37ºC for 1 h with shaking at 
250 rpm. Selection of transformed colonies was carried out by plating 100 µL of the 
transformation mixture onto LB plates containing appropriate antibiotics. The plates 
were subsequently incubated overnight at 37°C and transformed colonies were 
isolated the following day. 
 
3.2.3.  Agarose gel electrophoresis of DNA 
Electrophoresis using agarose gels is a simple technique that uses an electric 
field to separate and resolve DNA from approximately 200 bp to 50 kbp in size 
depending on the concentration of the agarose gel prepared. For this study, analysis of 
DNA samples was done using standard agarose gels (BRL, electrophoresis grade) of 
0.8% (w/v) concentration. 
For each preparation, a desired amount of agarose was dissolved in TAE 
buffer (40 mM Tris pH 8.0, 40 mM sodium acetate and 1 mM EDTA pH 8.0) by 
heating in a microwave oven. When molten agarose was cooled to lukewarm 
temperature, ethidium bromide was added to a final concentration of 0.1 µg/mL 
before it was poured into a casting tray and allowed to set for at least 30 min. Samples 
of DNA were mixed with DNA loading dye (Fermentas International Inc., Canada) 
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before loading into the agarose gel and subjected to a voltage of 80-100 volts for a 
preferred time. Examination of the separated DNA bands was conducted under UV 
illumination and an image of the agarose gel was captured using Bio-Rad Molecular 
Imager Gel Doc XR system, which is controlled by the Quantity One software (Bio-
Rad). 
 
3.2.4.  Generation of mutants 
3.2.4.1.  Generation of single mutants: site-directed mutagenesis 
SDM was performed using the QuikChange™ SDM kit (Stratagene) with 
modifications as previously reported by Loke and Sim (2001). Sequences of the 
oligonucleotide primers used for SDM are shown in Table 3.3. Both primers were 
designed to carry the desired mutation and anneal to the same sequence on opposite 
strands of the template. The cefE gene from S. clavuligerus NRRL 3585 was 
previously cloned into pGK expression vector (pscEXP-GST) (Sim and Sim, 2001) 
and this was used as the mutagenesis template in this study. Pfu DNA polymerase was 
used in the SDM process to replicate both plasmid strands with high fidelity without 
displacing the mutagenic primers. The SDM reaction mixture contained 2.5 µL of 
10X reaction buffer, 1 µL of each primer (100 pmole/µL), 1 µL of DNA template, 1 
µL of dNTPs, 1 µL of Pfu DNA polymerase and deionised water to give a final 
reaction volume of 25 µL. These reaction mixtures were then subjected to thermal 
cycling using a Perkin-Elmer GeneAmp® PCR System 2400 in which the parameter 
included 30 s at 95ºC to activate the DNA polymerase, followed by 28 cycles of 
temperature changes: 30 s at 95ºC, 60 s at 57.5ºC, 14 min at 72ºC. Thereafter, the 
product was digested with 10 U of DpnI at 37ºC for 3 h to remove the methylated 
parental plasmid template. The DpnI-treated mixture was then transformed into 
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competent E. coli BL21 (DE3) cells and selected using appropriate antibiotics. The 
transformants were then grown in larger quantity and harvested for DNA plasmid 
extraction using Wizard® Plus SV Minipreps DNA Purification System (Promega). 
The site-specific nucleotide modifications in the recombinant plasmids were verified 
via DNA sequencing described under Chapter 3.2.4.3.   
 
3.2.4.2.  Generation of double mutants: restriction enzyme digestion and 
DNA ligation 
Double mutations consisting of either V275I or C281Y mutation with the C-
terminal single mutations were generated by restriction endonuclease digestion, 
followed by DNA ligation. Recombinant vectors carrying V275I, C281Y, and the C-
terminal single mutations (N304A, N304K, N304L, N304M, N304R, I305M, R306L, 
and R307L) were digested using the PfoI and BamHI restriction endonucleases 
(Fermentas International Inc., Canada) according to manufacturer’s instructions. The 
digested samples were separated by agarose gel electrophoresis. After this, the desired 
DNA fragments were excised and purified from the agarose gel using QIAquick® Gel 
Extraction kit (Qiagen Singapore Private Limited, Singapore). The purified fragments 
were then ligated using T4 DNA ligase (Invitrogen) according to manufacturer’s 
recommendations. The ligated products were then transformed into the 
electrocompetent E. coli BL21 (DE3) cells following the procedure described in 
Chapter 3.2.2.  
 
3.2.4.3.  DNA sequencing  
DNA sequencing was done using ABI PRISM™ BigDye® Terminator v3.1 
cycle sequencing kit (Applied Biosystems), following manufacturer’s 
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recommendations. Briefly, about 250-500 ng of the mutagenised plasmid DNA was 
mixed with 4 µL of BigDye® Terminator Ready Reaction Mix, 3.2 pmole of the 
sequencing primer, and deionised water added to a final volume of 10 µL in a 0.2 mL 
microfuge tube. The tubes were then placed in a Perkin-Elmer GeneAmp® PCR 
System 2400 and heated for 1 min at 96°C. Thermal cycling using the following 
conditions, 96ºC for 10 s, 50°C for 5 s and 60°C for 4 min for 30 cycles, was 
performed. After the reaction was completed, the sample tubes were placed on hold at 
4°C. 
To purify the extension products, the entire 10 µL reaction content was 
transferred to a 1.5 mL microfuge tube containing 1.5 µL of 3 M sodium acetate (pH 
4.6), 7.25 µL of deionised water and 31.25 µL of 95% (v/v) ethanol. The mixture was 
then vortexed and incubated at room temperature for 15 min, after which the mixture 
was centrifuged at 12000 rpm for 20 min. The ethanol was aspirated and the retained 
pellet was rinsed with 250 µL of 70% (v/v) ethanol to remove the presence of salts 
before drying at 50ºC for 10 min. The dried extension products were then sent to 
sequence-analysis service provided in the Department of Microbiology, National 
University of Singapore, using an ABI PRISM™ 3100 Genetic Analyzer (Applied 
Biosystems). 
 
3.2.5.  Recombinant protein expression and purification 
3.2.5.1.  Induction of recombinant protein expression 
Recombinant clones of wild-type and mutant scDAOCSs were inoculated into 
5 mL of LB broth containing the appropriate antibiotic and grown at 37°C overnight 
with agitation at 250 rpm. Thereafter, 1 mL of the overnight culture was inoculated 
into 50 mL of LB broth containing the appropriate antibiotic and grown at 37°C with 
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agitation at 250 rpm until the O.D.600 of the culture reached a value of 0.6-0.8 
absorbance units. This is followed by the addition of IPTG to a final concentration of 
100 µM to induce the expression of wild-type and mutant scDAOCS genes. The 
cultures were incubated at room temperature with agitation at 250 rpm for 15 h. 
 
3.2.5.2.  Affinity purification of recombinant protein 
The induced cultures were harvested by centrifugation at 8000 rpm for 5 min 
at 4ºC and the supernatant was discarded. The cell pellet was rinsed twice with 10 mL 
1X PBS buffer and finally resuspended in 2 mL of 1X PBS buffer. The cell 
suspension was then transferred into a Bijou bottle prior to sonication. Lysis of the 
cell was performed by sonication with a 1/8” probe while keeping the cells on ice. 
The cells were disrupted at an intensity of 10 µm for eight 10 sec pulses, with a 10 sec 
rest period between pulses. The cell lysates were then centrifuged at 12000 rpm for 20 
min at 4ºC to remove the cell debris. The clear supernatant obtained was referred to as 
soluble protein fraction and transferred into clean microfuge tubes. The soluble 
protein fraction was then stored at -20ºC. 
The wild-type and mutant scDAOCS fusion proteins were purified from 
soluble protein fraction by affinity chromatography using MicroSpin™ GST 
purification module (GE Healthcare Private Limited) according to the manufacturer’s 
instructions. Protein concentrations were measured by the Bio-Rad protein assay and 
bovine serum albumin (Sigma-Aldrich) was used as the reference protein standard. 





3.2.5.3.  SDS-PAGE analysis of recombinant protein 
The protein fractions were separated and analysed using SDS-PAGE. The 
procedure of separating proteins on a polyacrylamide gel was based on the method 
reported by Laemmli (1970). The glass plates, alumina plates and spacers were 
assembled according to the manufacturer’s instructions (Hoefer® Inc, USA). The 
composition of the various buffers used for gel preparation is shown in Appendix II. 
In an Erlenmeyer flask, the 10% acrylamide solution for the resolving gel without 
SDS, TEMED and ammonium persulphate (APS) was prepared and degassed for 15 
min. Subsequently, a prescribed amount of SDS was added, followed by TEMED and 
APS. Without delay, the solution was mixed thoroughly and poured into the gap 
between the glass plates. The acrylamide was carefully overlaid with 70% (v/v) 
ethanol to get a level-loading surface. The gel was left to polymerise at room 
temperature for at least 1 h.  
Thereafter, the ethanol overlay was discarded and any remaining 
unpolymerised gel was washed away with deionised water. The 4% stacking gel 
solution was prepared in the same manner as the resolving gel solution. The stacking 
gel solution was poured onto the polymerised resolving gel and a clean Teflon comb 
was immediately inserted to create wells for loading protein samples. The gel was 
then left to polymerise at room temperature for at least 1 h. When the polymerisation 
of acrylamide was completed, the comb was removed and the wells were rinsed with 
deionised water to remove any unpolymerised acrylamide. After mounting the gel 
onto the electrophoresis apparatus (SE 260 Mighty Small II System, Hoefer®), Tris-
glycine electrophoresis buffer (25 mM Tris-base, 250 mM glycine, 0.1% (w/v) SDS) 
was added to fill up the top and bottom reservoirs. Each protein sample was mixed 
with 1X SDS-PAGE gel loading buffer (50 mM Tris-HCl pH 6.8, 100 mM DTT, 2% 
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(w/v) SDS, 0.1% (w/v) bromophenol blue, 10% (v/v) glycerol) and denatured by 
boiling for 5 min before loading into the wells. Precision Protein Standards™ (Bio-
Rad) was used as a marker.  
The electrophoresis was carried out at a constant current of 20 mA per gel 
until the bromophenol blue dye front reached the bottom of the resolving gel. The gel 
was then removed from the electrophoresis setup and stained with Coomassie Blue 
staining solution (0.25% (w/v) Coomassie Brilliant Blue R-250, 45% (v/v) methanol, 
10% (v/v) acetic acid) for 30 min. The gel was destained by soaking in destaining 
solution (30% methanol, 10% acetic acid) until distinct protein bands appeared. The 
gel images were captured using Bio-Rad Molecular Imager Gel Doc XR system, 
which is controlled by the Quantity One software (Bio-Rad). This program was also 
used to estimate the relative expression levels of the wild-type and mutant scDAOCS 
recombinant fusion proteins. Hence, to determine the percentage of recombinant 
fusion protein expressed in the soluble fraction, the protein band containing the 
recombinant fusion protein was marked out and compared to the entire lane 
containing the respective soluble protein fraction. Protein concentrations were 
measured by the Bio-Rad protein assay, following the manufacturer’s 
recommendation and bovine serum albumin (Sigma) was used as the reference protein 
standard. 
 
3.2.6.  Enzyme activity determination  
3.2.6.1.  Bioassay of ring-expanded products from DAOCS reaction 
The standard reaction mixtures reported by Sim and Sim (2001) were adopted 
because these conditions are optimal for the ring-expansion of the thiazolidine ring in 
penicillin nucleus to a dihydrothiazine ring in cephalosporin nucleus. Briefly, the 
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enzyme reaction mixture contained 50 mM Tris (pH 7.4), 1.8 mM iron (II) sulphate, 
0.8 mM ATP, 1.28 mM α-ketoglutarate, 4 mg/mL penicillin substrate and 0.8 mg/mL 
purified GST-scDAOCS. The penicillin substrates used were penicillin G, ampicillin, 
phenethicillin, and carbenicillin. The individual reagents were added in the order 
described previously (Sim and Sim, 2001). The reaction mixtures were incubated at 
30°C, shook at 200 rpm for about 15 min. The reaction was stopped by adding an 
equal volume of methanol. The activities of wild-type and mutant scDAOCSs were 
determined via hole-plate bioassay as previously described (Sim and Sim, 2001). In 
the hole-plate bioassay, E. coli Ess strain was used as the test organism (a gift from 
Professor Arnold Demain, Drew University) and seeded to a final concentration of 
1% (v/v) using a culture diluted to an O.D.600 of 0.1 absorbance unit. Difco™ Penase 
was added to a final concentration of 100,000 IU/mL in the bioassay plates to remove 
the unconverted penicillin substrates. Cephalosporin C was used as the reference 
standard. One unit of enzyme activity is defined as the amount of enzyme that forms 
the equivalent of 1 µg of cephalosporin C per minute under the prescribed conditions. 
The specific activity of each enzyme was determined from at least three independent 
experiments with duplicates. 
 
3.2.6.2.  Reverse-phase HPLC analysis 
A more sensitive and quantitative non-biological high performance liquid 
chromatography (HPLC) was used to affirm the results obtained from bioassays. The 
liquid chromatography system used was AKTA purifier (Amersham Biosciences) 
consisting of a UV-900 detector and an Autosampler A900, and a 5 µm 4.6 X 150 
mm2 Sun-Fire™ C18 column from Waters (USA). The operation and data acquisition 
of the chromatographic process were controlled by UNICORN 5.0 (Amersham 
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Biosciences). The chromatographic condition described by Chin and Sim (2002) was 
adopted. Briefly, each injection volume was 20 µL and the mobile phase flow-rate 
was set at 1 mL/min. Separation was effected at approximately 4°C using 10 mM 
KH2PO4 (pH 2.0, adjusted with concentrated phosphoric acid) containing 0.06 mM 
tetrabutylammonium bromide), mixed with methanol at a ratio of 80:20 (v/v) in the 
isocratic mode for 5 min followed by a 15 min linear gradient from 100% of the initial 
solution to 100% methanol. Detection of cephalosporin products was performed at a 
wavelength of 260 nm. The availability of the cephem moiety of ampicillin 
(cephalexin) permitted only the conversion of ampicillin to be precisely determined 
via the HPLC method. One unit of enzyme activity is defined as the amount of 
enzyme that forms 1 µg of cephalexin per minute under the prescribed conditions. 
The specific activity of each enzyme was determined from at least three independent 
experiments with duplicates.  
 
3.2.6.3.  Enzyme kinetic analysis 
The kinetic assays were performed using the spectrophotometric method 
reported by Dubus et al. (2001), assuming the molar extinction co-efficient, ε, to be 
6100 M-1 cm-1 for the conversion of ampicillin to cephalexin. The final reaction 
mixture contained 1 mM Tris(2-carboxyethyl)phosphine hydrochloride (TCEP), 50 
mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.5), 50 mM 
(NH4)2SO4, 100 µM ascorbic acid, 25 µM FeSO4⋅7H2O and 100 µM 2-oxoglutarate. 
The final concentration of enzyme used was 2.5 µM. The final concentration of 
ampicillin substrates used ranged from 0.1 to 10 mM. The kinetic assay was 
performed using a 96-well format filter-based spectrophotometer from Tecan 
(GENios™), with a 260 nm absorbance filter and temperature fixed at 30°C. The 
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kinetic parameters were determined from at least three independent measurements 
with triplicates and calculated using the Hanes-Woolf plot. 
 
3.2.7.  Cloning of cefF encoding DACS from S. clavuligerus   
3.2.7.1.  Extraction of genomic DNA of S. clavuligerus NRRL 3585 
Liquid culture of S. clavuligerus NRRL 3585 was prepared as described in 
Chapter 3.2.1 and was harvested by first breaking up the mycelia using a glass 
homogeniser, followed by centrifugation at 12000 rpm for 5 min to pellet all the cells. 
Thereafter, the cell pellet was washed with TE buffer pH 8.0 (10 mM Tris-HCl, 1 mM 
EDTA) and resuspended in 40 µL of lysozyme buffer (10 mM Tris-HCl (pH 8.0), 1 
mM EDTA, 100 mM NaCl, 5% (v/v) Triton X-100). Then, 10 µL of 10 mg/mL 
lysozyme solution was added and the sample was incubated at 37°C for 15 min before 
heat inactivation at 55°C for 15 min. 5 µL of 5 mg/mL RNase solution was then 
added and incubated at room temperature for another 15 min. Finally, the genomic 
DNA of S. clavuligerus was extracted using GFX™ Genomic Blood DNA 
purification kit (Amersham Pharmacia) following the manufacturer’s recommended 
protocol.  
 
3.2.7.2.  PCR amplification of cefF gene  
The gene amplification primers were designed based on the 5’- and 3’-ends of 
cefF open reading frame encoding deacetylcephalosporin C synthase from S. 
clavuligerus ATCC 27064 (synonymous to NRRL 3585, GenBank accession number 
M37186) reported by Kovacevic and Miller (1991). Restriction sequences of BamHI 
and EcoRI were added at the 5’-ends of the designed cefF forward primer OL963 and 
reverse primer OL964, respectively (Table 3.4). This allows cloning of the amplified 
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DNA into the expression vector pGK and expression of scDACS as recombinant GST 
fusion protein. A PCR reaction mixture containing 1X Pfu DNA polymerase PCR 
buffer with MgSO4 (Promega), 100 µM dNTP mix, 400 nM forward primer OL963, 
400 nM reverse primer OL964, 8% (v/v) DMSO, 0.06 U/µL Pfu DNA polymerase 
and 1 µL of extracted S. clavuligerus genomic DNA, was prepared and subjected to a 
touch-down PCR amplification programme starting with an initial denaturation at 
95°C for 1 min, followed by eight cycles of 95°C (45 s), 65-61°C (30 s) and 72°C (2 
min), 27 cycles of 95°C (45 s), 60°C (30 s) and 72°C (2 min), and a final extension 
step at 72°C for 5 min. A negative control replacing genomic DNA with sterile 
deionised water was included. After PCR amplification, agarose gel electrophoresis 
was used to detect for the amplified product.  
 
3.2.7.3.  TOPO® cloning of PCR-amplified cefF gene  
The PCR product of approximately 1 kb was excised and extracted from the 
agarose gel using QIAquick® Gel Extraction kit (Qiagen). The purified PCR product 
was then ligated into pCR®-Blunt II TOPO® vector using Zero Blunt® TOPO® PCR 
Cloning kit (Invitrogen), following manufacturer’s recommendation. The ligated 
product was then transformed into One Shot® TOP10 Chemically Competent E. coli 
cells (Invitrogen) according to manufacturer’s instruction. The kanamycin-selected 
transformants were grown in LB broths for the extraction of recombinant plasmids. 
The recombinant plasmids were extracted using Wizard® Plus SV Minipreps DNA 
Purification System (Promega) according to the manufacturer’s instruction. The 
extracted DNA plasmids were then subjected to restriction endonuclease analysis 





3.2.7.4.  Sub-cloning of cefF gene into expression vector  
Three samples that showed a release of approximately 1 kb DNA after 
BamHI/EcoRI double digestion were excised and extracted using QIAquick® Gel 
Extraction kit (Qiagen). The purified DNA was then ligated into an expression vector 
pGK using T4 DNA ligase (Invitrogen). A ligation reaction mixture containing 2 µL 
5X Invitrogen DNA ligase buffer, 5 µL DNA insert, 3 µL BamHI/EcoRI double-
digested pGK and 0.5 µL of 1 U/µL Invitrogen T4 DNA ligase was prepared and 
incubated at 16°C for 24 h. Thereafter, the ligated product was transformed into the 
electrocompetent E. coli BL21 (DE3) cells following the procedure described in 
Chapter 3.2.2. The kanamycin-selected transformants were screened for the presence 
of cefF DNA insert using RE analysis described in Chapter 3.2.7.3. Those clones 
harbouring the recombinant plasmid were fully sequenced to verify the authenticity of 
cefF gene insert using the sequencing primers listed in Table 3.4.  
 
3.2.7.5.  Protein expression and purification 
Since scDACS was cloned into the same expression vector as scDAOCS, the 
expression of recombinant scDACS was determined by following the procedure 
described in Chapter 3.2.5. PreScission™ Protease (GE Healthcare) was used to 
cleave the recombinant scDACS from the fusion partner GST, according to 
manufacturer’s recommendations.  
 
3.2.7.6.  Hydroxylation activity of scDACS 
Since the reaction mechanism of DACS is very similar to that of DAOCS 
(Lloyd et al. 2004; Baker et al. 1991), except for the difference in their substrate 
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preferences, the standard reaction mixture reported by Sim and Sim (2001) for the 
detection of scDAOCS activity was adopted in this study except that the substrate was 
replaced by cephalexin. HPLC analysis was done as described in Chapter 3.2.6.2, to 
detect for the hydroxylated product formed.  
 
3.2.8.  Bioactivities of expanded cephalosporin products 
3.2.8.1.  Determination of the antimicrobial spectra of penicillin substrates 
and their respective expanded cephalosporin moieties 
In order to determine the efficacies of the penicillin substrates and their 
respective bioconverted cephalosporin products, the amount of cephalosporin 
products formed has to be determined. This was achieved by using reverse-phase 
HPLC method, which separates the penicillin substrate and its respective 
bioconverted cephalosporin product based on their hydrophobicity differences, and 
the detection of the cephem ring at OD600.  
A similar hole-plate bioassay format, described in Chapter 3.2.6.1., was 
employed with slight modification. Mueller-Hinton II agar (MHA) (Difco™) was 
used instead of LB agar, and was prepared according to manufacturer’s 
recommendation. Difco™ Penase was added to the culture medium to a final 
concentration of 100,000 IU/mL to remove the unconverted penicillin substrates. The 
test bacteria, listed in Table 3.1, were streaked onto the MHA plates according to the 
format illustrated in Figure 3.1. Then, 180 µL of enzyme reaction mixture, prepared 
as described in Chapter 3.2.6.1., were added to the well in the centre of the agar plate. 
Same volume of equimolar concentration of penicillin substrates was prepared and 
added to another set of bioassay plates without Difco™ Penase added. This is to 
determine the effect of penicillin on the test bacteria and allow comparison with that 
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of the respective bioconverted cephalosporin product. The bioassay plates were 
incubated at 37°C for 24 h. This allows the diffusion of the penicillin substrates and 
the bioconverted cephalosporin products into the agar medium, while the test bacteria 
grow. The unconverted penicillin substrates in the enzyme reaction mixture will be 
degraded by Difco™ Penase and the growth of the test bacteria along the respective 
streak lines will reflect the effect of the cephalosporin products. The zone of growth 
inhibition was determined by measuring the distance of the streak line from the well 
to the start-point of bacterial growth and expressed in millimetre. The antimicrobial 
spectra of the expanded cephalosporin products were determined from at least three 











Figure 3.1. Inoculation format of test bacteria for hole-plate bioassay. Each arrow 
indicates the inoculation of a bacterial culture in an outward direction from the edge 
of the well. (1. M. luteus ATCC 381; 2. E. coli Ess; 3. S. aureus ATCC 9144; 4. E. 













3.2.8.2.  Determination of the efficacies of penicillin substrates and their 
respective expanded cephalosporin moieties 
In order to compare the efficacies of the expanded cephalosporin products 
with their respective penicillin substrates more accurately, a colony-forming unit 
(CFU) assay method was used (Lin et al., 2008; Yenugu et al., 2003; Porter et al., 
1997). This method employed a standardised number of CFUs used for testing the 
inhibitory effect of each antibiotic in a smaller scale compared to hole-plate bioassay. 
The test organisms used were E. coli BL21 and E. coli BL21-AmpR, which has been 
transformed with a plasmid, pGEX-6P-1 (GE Healthcare Life Sciences). pGEX-6P-1 
plasmid carries an ampicillin-resistance gene, which is constitutively expressed in E. 
coli. Approximately 100 CFU of test organism suspended in 2X Mueller-Hinton (II) 
broth were mixed with equal volume of antibiotic solution and incubated at 37°C. For 
experiments with E. coli BL21, the incubation time was one hour, whereas for those 
with E. coli BL21-AmpR, it was three hours. At the end of incubation, the samples 
were plated using pour-plate method and Luria-Bertani molten agar. The solidified 
agar plates were then incubated at 37°C for 24 hours before the number of CFUs was 
counted. For those samples that were incubated for three hours, 2-10x dilutions were 
done after incubation. Then, 100 µL aliquots of neat and diluted samples were plated 
to ensure countable number of colonies in the agar plates. For diluted samples, only 
plates with 30-300 colonies were counted and used for the calculation of the original 




3.2.8.3.  Assessing additional properties conferred on expanded 
cephalosporin products: elastase inhibition assay 
Calbiochem® InnoZyme™ Human Neutrophil Elastase Immunocapture 
Activity Assay kit (Merck Pte Ltd) was used to assess the potential protease inhibitory 
effect of cephalosporin on human neutrophil elastase (HNE). The inhibition assay was 
set up based on manufacturer’s instruction, with slight modification. A Costar® 96-
well half-volume black microplate (Corning Incorporated Life Sciences, USA) was 
used. The reaction mixture contained a final concentration of 2 ng HNE and 1X 
methoxy-succinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin (MeOSuc-AAPV-
AMC) fluorogenic substrate in the assay buffer provided in the kit. The test sample 
was prepared as described in Chapter 3.2.6.1., except that methanol was not added to 
stop the reaction. Instead, the reaction mixture was filtered through a Microcon® 
centrifugal filter (Millpore™) with a molecular weight cut-off of 30 kDa to remove 
any protein, which may act as a substrate for HNE. Then 10 µL of filtrate were added 
to each reaction mixture and the elastase activity was detected over an hour. 
Phenylmethanesulfonyl fluoride (PMSF) is a serine protease inhibitor and has been 
reported to inhibit HNE (Kim and Kang, 2000). A final concentration of 5mM PMSF 
was used as a positive control to inhibit the proteolytic activity of HNE. The 
proteolytic activity of HNE is expressed in nanomolar per minute.  
 
3.2.9. Biocomputational analysis 
Comparative analyses of gene and protein sequences as well as protein 
structures were carried out using biocomputational programs. The nucleotide 
sequences of known genes and the amino acid sequences of known proteins were 
retrieved from GenBank Database (http://www.ncbi.nlm.nih.gov/genbank/). The 
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amino acid sequences of annotated DAOCSs and DACSs from different organisms 
were retrieved from the GenBank database, and the accession numbers were as 
follows: S. clavuligerus DAOCS, P18548; A. chrysogenum DAOC/DACS, P11935; S. 
chartreusis DAOCS, AY318743; S. ambofaciens DAOCS, AY318742; S. 
jumonjinensis DAOCS, AF317908; N. lactamdurans DAOCS, Q03047; L. 
lactamgenus DAOCS, CAA39984; S. clavuligerus DACS, P42220; Streptomyces sp. 
isolate 65PH1 DACS, AY318744; N. Lactamdurans DACS, P42219; and L. 
lactamgenus DACS, CAA39985. The nucleotide and amino acid sequences obtained 
were aligned using CLUSTAL W Multiple Sequence Alignment Program (version 
1.7) (Thompson et al., 1994) based on segment of similarity between sequences to 
compare its conservedness. MatGAT programme was used to generate the 
similarity/identity matrices of annotated DAOCSs and DACSs (Campanella et al., 
2003). Self-optimised prediction program (SOPMA) (http://au.expasy.org/tools/) 
(Geourjon and Deléage, 1995) was employed to predict secondary structures of 
proteins after mutations. This program affirmed an accurate prediction of 69% of 
amino acids for a three-state description (α-helix, β-sheet and coil) of the secondary 
structure. 
Viewing and manipulation of three-dimensional structures were using the 
SwissPdb Viewer program version 3.7 (Guex et al., 1999). The protein structures can 
be presented as wire frame, space-filled or ribbon models. The program also provided 
different features, which facilitated the analyses of protein structure such as 
superimposition of proteins and virtual mutation. SwissPdb Viewer and the user 
manual are available at the ExPASy Molecular Biology server (http://spdbv.vital-
it.ch/). Since the tertiary structure of DACS has yet to be resolved, the tertiary 
structure of scDACS was modelled using Swiss-Model, which is an automated 
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knowledge-based protein modelling server (http://swissmodel.expasy.org/) (Kiefer et 
al., 2009).  
Amino acid residues interacting with the penicillin substrate were determined 
using the LIGPLOT program (Wallace et al., 1995). This program automatically 
generates a schematic diagram of protein-ligand interactions mediated by hydrogen 
bonds and hydrophobic contacts. Mutational models were generated using SwissPdb 
Viewer and were further assessed using LIGPLOT to validate the changes in the 
protein-ligand interactions. 
 
3.2.10. Reproducibility of results  
All the experiments carried out in this project were repeated at least thrice to 
ensure the reproducibility of the results, unless stated otherwise. The cloned and 
mutated cefE and cefF gene sequences were fully sequenced on both strands to ensure 
authenticities of the sequences. All enzyme assays and calculation of enzyme 







Chapter 4: Improving the ring-expansion activity of 
scDAOCS 
 
DAOCS is an industrially important enzyme for the production of 
cephalosporin precursor, 7-ADCA. As the chemical ring-expansion of penicillin G to 
yield 7-ADCA is expensive and polluting, enzymatic ring-expansion method using 
DAOCS is deemed as an environmentally safe alternative (Velasco et al., 2000). 
Although deacylation of cephalosporin C is also employed to yield the other 
cephalosporin precursor 7-ACA, the cost of production is considered high due to the 
instability of cephalosporin C in the fermentation culture that results in lower yield 
(Elander, 2003).  
The limitation of DAOCS for industrial application is its substrate specificity. 
Although the substrate specificity of DAOCS is considered wide, its ring-expansion 
activity for penicillin G and other analogues is too low for industrial application. 
Hence, DAOCS needs to be structurally modified to improve its catalytic activity for 
penicillin G. Many earlier studies were done to characterise the enzyme and certain 
mutations were found to enhance its ring-expansion activity for hydrophobic 
penicillins, particularly at the C-terminus of the enzyme (Wu et al., 2005; Chin et al., 
2004; Chin and Sim, 2002; Lee et al., 2002; Chin et al., 2001).   
The C-terminus of DAOCS has often been implicated to play a crucial role in 
selecting, binding and orienting the penicillin substrate during catalysis (Chin et al., 
2004, 2001; Valegard et al., 2004, 1998; Chin and Sim, 2002; Wei et al., 2003; Lee et 
al., 2002; Lipscomb et al., 2002; Lloyd et al., 1999). However, earlier studies of the 
C-terminus of scDAOCS were performed without any structural information of 
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scDAOCS-penicillin complex (Chin et al., 2004, 2001; Chin and Sim, 2002; Wei et 
al., 2003; Lee et al., 2002). Thereafter, the crystal structure of scDAOCS complexed 
with penicillin G and ampicillin were resolved, and our understandings of the 
structural mechanisms that influence the properties of this enzyme were increased 
(Valegard et al., 2004). The structural data have also facilitated investigation and 
interpretation of the effects of enzyme modifications with precise spatial 
consideration. However, the mechanisms of the improvements achieved from the 
mutations of the C-terminal residues of scDAOCS, i.e., N304 and R306, were still not 
clear. 
Approaches such as homeologous recombination, chemical mutagenesis, 
error-prone PCR and gene shuffling have been used to improve the catalytic 
properties of scDAOCS for penicillin G conversion (Adrio et al., 2002; Gao et al., 
2003; Hsu et al., 2004; Wei et al., 2003). However, it is difficult to determine the 
exact mechanism that contributes to such enhancement using these methods. Hence, 
further studies were done in this project to further understand the principles that 
govern the structure-function relationship in scDAOCS to yield a more superior 
enzyme for industrial application and even produce new cephalosporins. Two main 
regions were selected. The first region is the C-terminus of scDAOCS and the second 
region is the small sub-domain where mutations at residues V275 and C281 have 
resulted in higher ring-expansion activity (Wei et al., 2003). Figure 4.1 shows the 
spatial location of amino acid residues selected for this study. A rational approach 
using SDM was adopted to improve the substrate recognition of scDAOCS for 
penicillin G and other penicillins such as ampicillin, carbenicillin and phenethicillin, 





Figure 4.1. Spatial location of amino acid residues V275, C281, N304, I305, R306 
and R307 in scDAOCS (1UNB). The iron-binding motif H183XD185XnH243 is 
coloured green while the co-substrate-binding motif R258XS260 is coloured light 
green. The amino acid residues studied is coloured orange. The substrate ampicillin 
and co-substrate α-ketoglutarate (α-KG) are coloured brown and purple, respectively. 
 
 
4.1.  Identification of potential sites for the improvement of scDAOCS in 
hydrophobic penicillin conversions  
Development of X-ray crystallography and NMR has allowed resolution of the 
molecular structure of a protein, which is invisible to the naked eye. Biocomputational 
tools have provided a means to rapidly collate the various structural levels of a protein 
for comparative analysis and prediction. Combining these two technologies, protein 
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molecular structures could be virtually conceptualised, examined and categorised 
based on their structural similarities. This has also permitted a more rational approach 
to improve the functionalities of a protein and to further understand the principles that 
govern the structure-function relationship of proteins. 
Survey on mutational studies of enzymes with known tertiary structures 
revealed that mutations closer to the active site or substrate binding site of an enzyme 
often improved the enantioselectivity, substrate selectivity and alternate catalytic 
activity (Morley and Kazlauskas, 2005). Hence, to alter or improve the substrate 
preference of scDAOCS, it will be more productive to focus on its substrate binding 
pocket. Since the difference between penicillin N and hydrophobic penicillins, e.g. 
penicillin G, lies in their side-chains, it is only logical to focus on the region of the 
substrate binding pocket of scDAOCS that interacts with the side-chain of the 
penicillin substrates (Figure 4.2). The amino acid residues in the substrate binding 
pocket of scDAOCS complexed with penicillin G (1UOB) and ampicillin (1UNB) 
were examined using SwissPdb Viewer and only residues T72, M73, S102, L158, 
R160, R162, F264, N304 and I305 surround the side chain of the penicillin substrates 
(Figure 4.3). Then LIGPLOT (Wallace et al., 1995) (Figure 4.4) and Ligand-Protein 
Contacts (Sobolev et al., 1999; http://bip.weizmann.ac.il/oca-bin/lpccsu) (Table 4.1) 
programs were used to predict the amino acid residues that interact with the penicillin 
substrates and their modes of interaction. Since the prediction criteria differ slightly 
between each program, the results from each analysis were compared and the 
common amino acid residues predicted by these programs in the two structures were 
identified (Table 4.2). Only residues M73, L158, R162 and F264 were consistently 
identified by the three programs to interact with the penicillin substrates.  
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Interestingly, many earlier studies have identified the C-terminal amino acid 
residues to be potential sites for enzyme improvement (Wei et al., 2003; Chin and 
Sim, 2002; Chin et al., 2001; Lee et al., 2002, 2001), which were not consistently 
reflected in the in silico predictions. For example, single mutations of C-terminal 
residues N304, R306 and R307 to a leucine were demonstrated to improve the 
conversion activity of scDAOCS for various hydrophobic penicillin substrates (Chin 
and Sim, 2002). In order to gain a better understanding of the mechanisms behind 
these improvements, residue N304 was selected for further analysis since it lies 
closely to the side chain of the penicillin substrate. Using a rational approach, a 
complete library of amino acid replacements was done on this position and mutations 
to alanine, lysine, methionine and arginine were found to also improve the conversion 
activity of scDAOCS to different extents (Chin et al., 2004). However, only the 
enzyme specific activities of these mutants were determined and reported using a 
bioassay, which is a non-continuous product detection method. Hence, an enzyme 
kinetic assay developed by Dubus and co-workers (2001) was employed in this study 
to determine the kinetic properties of these improved mutant enzymes, i.e., N304A, 
N304K, N304L, N304M and N304R. Upon understanding the basis of the 
improvement in N304 modification, this approach was also adopted to study the role 



























Figure 4.2. Schematic diagrams of scDAOCS substrate binding pocket bound with (a) 
penicillin N and (b) penicillin G. Both blue and red arcs represent the substrate 
binding pocket of scDAOCS. The blue arc represents region of the substrate binding 





Figure 4.3. Close-up view of substrate binding residues in scDAOCS crystal 
structures complexed with (a) penicillin G (1UOB) and (b) ampicillin (1UNB). Only 
the residues surrounding the side chains of both substrates are presented. Residues 
T72, M73, S102, L158, R160, R162, F264, N304 and I305 are located in the vicinity 
of the side-chain of both substrates. The backbones and side chains of amino acid 
residues are in white and orange colours, respectively. Both ampicillin and penicillin 





Figure 4.4. LIGPLOT analyses of scDAOCS crystal structures complexed with (a) 
penicillin G (1UOB) and (b) ampicillin (1UNB). 
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Table 4.1. Ligand-Protein Contacts analyses of scDAOCS complexed with (a) penicillin G 
(1UOB) and (b) ampicillin (1UNB). 
 
(a)   Specific contacts 
Residue  Distance Surface HB Arom Phob DC 
M73 2.7 31.9 - - + - 
S102 3.3 3.8 - - - - 
L158 3.6 14.8 - - + - 
R160 0.4 489.5 - - + + 
R162 1.8 50.2 + - - + 
F164 4.3 3.5 - - - - 
M180 3.0 45.9 - - + + 
T190 4.2 0.2 - - + - 
I192 3.0 34.5 - - + + 
L204 4.4 2.5 - - + - 
F225 4.2 0.7 - - + - 
V245 4.3 1.9 - - + + 
V262 3.6 28.3 - - + + 
F264 3.3 36.4 - + + - 
N304 4.2 8.5 - - + + 
I305 4.0 15.7 - - + + 
 
(b)   Specific contacts 
Residue  Distance Surface HB Arom Phob DC 
T72 3.6 7.9 - - - - 
M73 2.5 47.8 - - + - 
R74 4.5 1.1 - - - - 
L158 2.6 34.5 - - + - 
R160 0.7 368.0 + - + + 
R162 1.8 69.6 + - - + 
F164 6.2 0.4 - + -  
M180 3.1 28.4 - - + + 
T190 3.8 1.1 - - + - 
I192 2.9 47.2 - - + + 
L204 4.5 0.7 - - + - 
F225 4.1 0.7 - - + - 
V245 3.5 4.5 - - + + 
V262 3.3 37.7 - - + + 
F264 3.1 31.9 - + - - 
N304 3.4 19.9 + - - + 
I305 4.2 12.7 - - - + 
Legend: 
Distance- nearest distance (Å) between atoms of the ligand and the residue 
Surface- contact surface area (Å2) between the ligand and the residue 
HB   - hydrophilic-hydrophilic contact (hydrogen bond) 
Arom - aromatic-aromatic contact 
Phob - hydrophobic-hydrophobic contact 
DC   - hydrophobic-hydrophilic contact (destabilising contact) 
+/-  - indicates presence/absence of a specific contact 
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Table 4.2. Comparison between the predicted substrate binding residues in scDAOCS 
crystal structures complexed with penicillin G (1UOB) and ampicillin (1UNB). The 
amino acid residues that are identified by all three programmes are highlighted in 
grey. The amino acid residues located in the vicinity of the side-chain of both 
penicillin substrates illustrated in Figure 4.3 are underlined.  
 
 LPC analyses LIGPLOT analyses SwissPdb Viewer (within 5Å) 
Residue 
No. 1UOB 1UNB 1UOB 1UNB 1UOB 1UNB 
T72 - ü - - ü ü 
M73 ü ü ü ü ü ü 
R74 - ü - - ü ü 
S102 ü - - - ü ü 
L158 ü ü ü ü ü ü 
R160 ü ü - - ü ü 
R162 ü ü ü ü ü ü 
F164 ü ü - - ü - 
M180 ü ü ü ü ü ü 
T190 ü ü - ü ü ü 
I192 ü ü ü ü ü ü 
L204 ü ü - - ü ü 
F225 ü ü - - ü ü 
V245 ü ü - - ü ü 
V262 ü ü ü ü ü ü 
F264 ü ü ü ü ü ü 
N304 ü ü - - ü ü 





4.2. In silico structural analyses of scDAOCS mutants 
When the primary sequence of a protein is changed, the secondary and tertiary 
structures of the protein may be affected. Consequently, the function of the protein 
will be altered. With the lack of equipment to determine the actual secondary and 
tertiary structures of a protein after mutations, prediction of these structures will be 
useful in understanding the functional changes observed in mutant scDAOCSs.  
Analysis of the mutated protein sequences using the improved SOPMA 
program (Combet et al., 2000; Geourjon and Geleage, 1995) suggested no significant 
alteration in their secondary structures (Appendix III). Alterations in the secondary 
structures of the mutant enzymes with improved catalytic activity were also observed 
in those with reduced activity. This suggests that the alterations in the catalytic 
properties of the mutant scDAOCSs are not just a function of changes in the 
secondary structures. The spatial orientation of an amino acid residue and its stereo-
chemical effect on its neighbouring residues and substrates may collectively alter the 
function of the protein.  
Three-dimensional modelling of the mutant enzymes using Swiss-Model 
program (Arnold et al., 2006; Schwede et al., 2003; Guex and Peitsch, 1997; 
http://swissmodel.expasy.org/) also did not reveal any significant changes in their 
tertiary structures (data not shown). The in silico mutational results obtained using 
SwissPdb Viewer will be illustrated together with the discussion of the assay results 
in the respective chapters, in order to facilitate the understanding of the effects of the 




4.3. Generation and verification of mutant scDAOCS sequences  
The cefE gene from S. clavuligerus NRRL 3585 was previously cloned into 
pGK expression vector (pscEXP-GST) (Sim and Sim, 2001). SDM was performed 
using the QuikChangeTM SDM kit (Stratagene) with modifications as previously 
reported (Loke and Sim, 2001). The recombinant expression vector pscEXP-GST was 
used as the mutagenesis template. The mutagenic oligonucleotide primers were 
synthesised by 1st Base (Singapore) or Sigma-Proligo (Singapore) (Table 3.3). The 
mutagenised plasmids were transformed into Escherichia coli BL21 (DE3) strain. The 
site-specific nucleotide modifications were verified using the ABI PRISM™ dye 
terminator cycle sequencing kit and ABI PRISM™ 3100 Genetic Analyzer as 
described in Chapter 3.2.4.2. The mutated genes were fully sequenced to ascertain 
that no other mutation has been incorporated during the PCR amplification process. 
 
4.4.  Heterologous expression and purification of wild-type and mutant 
scDAOCSs  
After the mutation sites were confirmed via DNA sequencing, recombinant E. 
coli BL21 (DE3) clones harbouring the wild-type and mutant scDAOCS constructs 
were induced for protein expression. High-level soluble expression of wild-type and 
mutant GST-scDAOCS fusion proteins was obtained as revealed by intense protein 
bands of approximately 60 kDa in SDS-PAGE analyses (Figure 4.5). The cell lysates 
containing GST-scDAOCS fusion proteins were then subjected to affinity 
chromatography purification using the MicroSpin™ GST purification module. The 
molecular masses of the purified fusion proteins were approximately 60 kDa, and the 
proteins were at least 90% pure as estimated by the Quantity One program. These 
results showed that the mutations did not significantly affect the soluble expression of 
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Figure 4.5. SDS-PAGE analysis of cell-free extracts and purified fractions of E. coli 
BL21 (DE3) clone expressing recombinant wild-type and mutant GST-scDAOCSs. 
Lane M: Precision Protein Standards™ Bio-Rad 161-0318; Lane 1: cell-free extract 
of E. coli clone expressing recombinant wild-type scDAOCS; Lane 2: cell-free extract 
of E. coli clone expressing recombinant N304R mutant scDAOCS; Lane 3: cell-free 
extract of E. coli clone expressing recombinant R306L mutant scDAOCS; Lane 4: 
cell-free extract of E. coli clone expressing recombinant N304RR306L mutant 
scDAOCS; Lane 5: purified recombinant wild-type scDAOCS; Lane 6: purified 
recombinant N304R mutant scDAOCS; Lane 7: purified recombinant R306L mutant 
scDAOCS; Lane 8: purified recombinant N304RR306L mutant scDAOCS. Similar 
profiles were also obtained for other scDAOCS mutants generated in this project.  
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Chapter 5: A complete library of amino acid 
alterations at R306 in scDAOCS demonstrates its 
structural role in the ring-expansion activity 
	  
5.1. A complete library of amino acid alterations R306 of scDAOCS 
The conversions of hydrophobic penicillin substrates namely ampicillin, 
penicillin G, phenethicillin, and carbenicillin by the wild-type and mutant scDAOCSs 
were tested via hole-plate bioassay with E. coli Ess strain as the test microorganism. 
All experimental data were confirmed by at least three independent measurements. 
The specific activity of wild-type scDAOCS for penicillin G, ampicillin, 
phenethicillin, and carbenicillin conversions were 9.51 ± 0.47 U/mg, 3.03 ± 0.17 
U/mg, 7.33 ± 0.29 U/mg, and 1.10 ± 0.20 U/mg, respectively. The specific activities 
of the mutant enzymes were compared with that of the wild-type enzyme and 
expressed as relative activities (Table 5.1).  
As demonstrated in the previous study (Chin and Sim, 2002), the replacement 
of R306 to leucine enhanced its ring-expansion activity. It showed similar 
improvements in the ampicillin, penicillin G, phenethicillin, and carbenicillin ring-
expansion activities at the levels of 186, 105, 173, and 283% that of the wild-type 
scDAOCS, respectively (Table 5.1). Upon mutation to a proline, the conversion 
activities of the mutant enzyme for all four substrates were not detectable using the 
current assay condition. Other mutants possessed varying levels of activities when 
compared to the wild-type enzyme. Generally, replacing arginine with other charged 
residues reduced the conversion activity of the enzyme drastically except for lysine, 
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which retained about half the activity of the wild-type enzyme. The replacement with 
polar residues reduced the conversion activity of scDAOCS to 16–62% that of the 
wild-type enzyme for ampicillin conversion, whereas the substitution to an amino acid 
with aromatic side chain retained the activity at the levels of 55–90%. The trend of the 
relative activities of the mutant enzymes observed in ampicillin conversions was 
similarly observed in penicillin G, phenethicillin, and carbenicillin conversions. It is 
noteworthy that two additional mutations, R306I and R306M, managed to improve 
the activity of scDAOCS at the levels of 102–283% for all four substrates. 
To validate the ring-expansion activity of the improved mutants, i.e., R306L, 
R306I, and R306M, the respective reaction mixtures were subjected to HPLC 
analyses. The substrate (ampicillin) and product (cephalexin) could be discriminated 
at resolved retention times of approximately 19 and 18 min, respectively (Figure 5.1). 
Since the retention time of the converted product coincided with that of the 
cephalexin standard, this authenticated the identity of the product in the enzyme 
reactions. Furthermore, the chromatographic results demonstrated that only 
cephalexin was produced by the mutant scDAOCSs at higher concentrations than that 
of the wild-type enzyme. The specific activities of wild-type, R306I, R306L, and 
R306M mutant scDAOCSs for ampicillin conversion were 6.41, 9.11, 10.90, and 7.23 
U/mg, respectively (Table 5.2). The R306L, R306I, and R306M mutant scDAOCSs 
showed improvement in the conversion of ampicillin at the levels of 170, 142, and 
113% of the wild-type enzyme, respectively. These results were comparable to those 
obtained via bioassays (Table 5.1). 
The enzyme kinetic assay reported by Dubus and co-workers (2001) was 
similarly adopted to determine the changes in the kinetic parameters of scDAOCS 
after mutations. The Km values of R306I (2.64 mM), R306L (1.09 mM) and R306M 
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(5.68 mM) mutant scDAOCSs for ampicillin conversion were significantly reduced 
compared to that of the wild-type enzyme (8.33 mM) (Table 5.3), indicating a 
significant improvement in the substrate binding affinity of the enzyme. 
Consequently, the kcat/Km values of R306I, R306L, and R306M mutant scDAOCSs 
for ampicillin conversion were approximately 2.6-, 5.1-, and 1.2-folds higher than that 
of the wild-type enzyme. Among these three mutants, R306L mutant scDAOCS has 
the highest catalytic efficiency. 
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Table 5.1. Relative activities of the wild-type and mutant scDAOCSs determined by 
hole-plate bioassay. 
 
Relative activity (%)a 









Mutations Amino acid side chain Ampicillin Penicillin G Phenethicillin Carbenicillin 
Wild-type CH2 CH2 CH2 NH C
NH
NH2  100 100 100 100 
R306K CH2 CH2 CH2 CH2 NH2 50 53 45 32 
R306G H  21 27 19 ND
b 
R306A CH3  46 37 30 27 
R306S CH2 OH  39 37 27 30 
R306C CH2 SH  18 13 11 ND 
R306T CH CH3
OH




34 28 36 32 
R306D CH2 C OH
O
 
8 4 4 ND 
R306N CH2 C NH2
O
 16 14 12 16 
R306E CH2 CH2 C OH
O
 
8 7 6 ND 
R306Q CH2 CH2 C NH2
O
 
62 67 54 62 
R306M CH2 CH2 S CH3 113 102 115 122 
R306L CH2 CH CH3
CH3
 
186 105 173 283 
R306I CH
CH3






16 10 8 ND 
R306F CH2  55 41 44 39 









ND ND ND ND 
aThe relative activity of each mutant enzyme is expressed as the percentage of the specific activity of 
the mutant enzyme relative to that of the wild-type enzyme, which was set at 100%.  
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Figure 5.1. HPLC chromatogram of wild-type scDAOCS reaction (red) vs time 0 
(blue) for ampicillin conversion. Appearance of new peak (arrow) in the 
chromatogram indicates the cephalosporin product. The retention time of the product 
from ampicillin conversion corresponds to that of cephalexin standard (Rt = 18.20 ± 
0.10). The products of various mutant scDAOCSs showed the same retention times as 





Table 5.2. Specific activities of the wild-type and mutant scDAOCSs (R306I, R306L 
and R306M) for ampicillin conversion determined by HPLC analyses. 
 
Enzyme type Specific activitya (U/mg) Relative activityb (%) 
Wild-type 6.41 ± 0.60 100 
R306I 9.11 ± 1.65 142 
R306L 10.90 ± 1.29 170 
R306M 7.23 ± 0.49 113 
aOne unit of activity is the amount of DAOCS required to form the equivalent of 1µg of cephalexin per 
minute. The specific activities are shown as the mean ± standard deviation of at least three independent 
experiments with duplicates. 
bThe relative activity of each mutant enzyme is expressed as the percentage of the specific activity of 





Table 5.3. Kinetic parameters of the wild-type and mutant scDAOCSs (R306I, R306L 
and R306M) for ampicillin conversion. 
 
Enzyme Km (mM)a kcat (s-1)a kcat/Km (M-1s-1) Relative kcat/Km 
Wild-type 8.33 ± 0.92 0.056 ± 0.002 6.76 1.0 
R306I 2.64 ± 0.64 0.046 ± 0.003 17.50 2.6 
R306L 1.09 ± 0.11 0.037 ± 0.003 34.22 5.1 
R306M 5.68 ± 0.58 0.047 ± 0.001 8.27 1.2 





























5.2. The role of amino acid residue R306 in the activity of scDAOCS 
An earlier study on the modification of the C-terminus of scDAOCS showed 
that R306L mutation improved the ring-expansion activity of scDAOCS in penicillin 
G, ampicillin, carbenicillin and phenethicillin conversions (Chin and Sim, 2002). 
However, due to the lack of a crystal structure complexed with a substrate during the 
earlier study, the position of 306 relative to the substrate binding site was not clear. 
The recently elucidated crystal structure of scDAOCS complexed with penicillin G 
and ampicillin revealed that R306 residue is located away from the catalytic site 
(Figure 5.2). It is surrounded by five hydrophobic residues Y184, L186, W297, I298 
and V303, and is partially exposed to the aqueous environment. The side chain of 
residue R306, being surrounded by these five hydrophobic residues, may help to 
preserve the interaction between the β7 (Y184 and L186, which forms part of the co-
factor binding motif), α10 (W297 and I298), and β15 (V303) strands (Figure 5.2). 
This interaction is necessary to stabilise the integrity of the H183XD185XnH243 
motif to ensure proper binding and activation of the iron (II) ion. Furthermore, these 
six positions are well-conserved in all annotated DAOCSs (Figure 5.3), indicating the 
importance of this hydrophobic cleft. Therefore, any mutations at position 306 of 
scDAOCS would exert an indirect effect on the catalytic property of the enzyme. 
Generally, there are two factors that influence the dynamics of residue R306 in 
its contribution to the function of scDAOCS. Firstly, amino acid residues adjacent to 
residue R306 (residues I305 and R307) will affect the spatial orientation of residue 
R306. Secondly, interaction of the side chain of residue R306 with the external 
environment and its surrounding residues will indirectly affect the polypeptide 
backbone of the C-terminus. Since the earlier study on the C-terminus of scDAOCS 
has revealed that the replacement of arginine with hydrophobic leucine at this site 
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improved its specific activity (Chin and Sim, 2002), this improvement was likely due 
to the side chain of leucine interacting with its surrounding residues and indirectly, 
affecting the C-terminus in interacting with the penicillin substrate. Hence, it could be 
postulated that the replacement of R306 to amino acid residues with aliphatic side 
chains similar to leucine will yield a comparable effect, for example R306I and 
R306M mutations. Conversely, substitutions to polar and charged residues will have 
adverse effects on the activity of scDAOCS.  
The structural role of R306 in the catalytic property of scDAOCS was thus 
deduced from observing the effect of replacing it with the other 19 proteinogenic 
amino acids. From the hole-plate bioassay results, the trend observed was that both 
the length and hydrophobicity of the side chain of the amino acid residue are 
important in influencing the function of the enzyme. Firstly, residue R306 was 
replaced with proline, which confers rigidity to the protein structure as its side chain 
is joined to its α-amino group. This rigidity tends to confer a kink into the protein 
structure and often disrupts the function, and sometimes solubility, of the protein 
when mutated at critical positions (Reiersen and Rees, 2001). Since the activity of 
R306P mutant was lost and its solubility was unaffected, this implied that the 
conformation of the C-terminal end of scDAOCS is crucial for its catalytic property. 
Secondly, replacement of R306 with glycine resulted in 80% reduction in the specific 
activities of the enzyme for all four substrates. This suggests the need for a longer side 
chain at this position to control the dynamics of the C-terminal tail or to shield the 
hydrophobic cleft from the aqueous environment. Evidently, a slight augmentation in 
the enzyme activity was gained when R306 was replaced with alanine. 
Thirdly, replacement with charged residues resulted in tremendous decrease in 
the conversion activity of scDAOCS, retaining less than 20% of the wild-type activity 
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for all substrates. This supported the postulation that charged residues are detrimental 
to this site, probably by perturbing the integrity of the hydrophobic cleft. However, 
this was not observed for both arginine and lysine residues. It has been reported that 
the pKa of the side chain of arginine or lysine would be lowered if they were to be 
buried in a hydrophobic environment (Guillen Schlippe and Hedstrom, 2005). This 
would render the amino group in the side chains of both residues to be unprotonated 
and uncharged. Consequently, the integrity at this region might be preserved. 
However, the relative activity of R306K mutant was approximately half of that of the 
wild-type enzyme. This suggests that the structural behaviour of lysine in a protein is 
different from that of arginine. It could be possible that the lysine side chain, being 
aliphatic, is rotated away from the hydrophobic region, hence exposing the 
hydrophobic region to the aqueous environment. In contrast, the arginine side chain, 
which has a planar conformation, will be able to shield the hydrophobic region. 
Fourthly, when the carboxyl group of the acidic residues (glutamate and 
aspartate) were substituted to an amide (to become glutamine and asparagine 
respectively), there were small increments in the conversion activities, further 
supporting the postulated detrimental effect of charged residues. Interestingly, by 
comparing the length of structurally similar residues of various R306 mutants, it was 
observed that the activity of the enzyme improves in tandem with an increase in 
carbon atoms in the side chain of the substituted amino acid. For example, in the 
asparagine and glutamine replacements, where both residues are similar in their 
structures except that glutamine is longer in its side chain by an alkyl carbon, the 
activity of R306Q mutant enzyme was much higher than that of the R306N mutant 
enzyme. A similar trend was also observed when R306S mutant was compared with 
R306T mutant, or R306V mutant with R306I and R306L mutants. 
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Lastly, when the polar side chain was replaced with a non-polar side chain, for 
example methionine, leucine, or isoleucine, the conversion activities of the mutant 
enzymes were higher than that of the wild-type enzyme. These results supported the 
hypothesis that replacement of R306 with amino acids structurally similar to leucine 
was able to improve the enzyme activity via hydrophobic interaction with the 
surrounding residues. As reflected by their Km values for ampicillin conversion, the 
improvements obtained were due to the enhancement in the substrate binding affinity 
of the enzyme upon these mutations. Hsu and co-workers (2004) have also reported a 
similar observation where A246V mutation in the shuffled DAOCS FF8 clone might 
have resulted in better hydrophobic packing with the surrounding residues, namely 
L178, F201, V202, L204, H244, and A247. Since both H244 and A247 residues are 
close to the iron ligand H243, the improved hydrophobic packing might exert an 
effect on the function of the enzyme similar to R306L mutation, leading to enhanced 
conversion activity. Although non-polar amino acids are expected to interact well 
with the hydrophobic region formed by residues Y184, L186, W297, I298 and V303, 
replacements of R306 with aromatic amino acid residues, i.e., phenylalanine, tyrosine, 
and tryptophan, have showed otherwise; possibly due to the bulkiness of the side 
chains or the torsion angles of the side chains towards the external environment 
instead of the hydrophobic cleft.  
Together, these results corroborate the mechanism and importance of the 
length and hydrophobicity of the amino acid side chain at position 306 in maintaining 
the integrity of the hydrophobic cleft, which in turn, is capable of affecting the ferrous 
iron-binding motif. These results also support the notion of engineering the position 





Figure 5.2. Close-up view of residue R306 (purple) surrounded by five hydrophobic 
residues Y184, L186, W297, I298, and V303 (green). This arrangement strengthens 
the β7 (where residues H183 and D185 of the iron-binding motif reside), α10 and β15 




Figure 5.3. Part of the multiple alignments of annotated DAOCS primary sequences. 
The five hydrophobic residues Y184, L186, W297, I298 and V303 (highlighted in 
green, scDAOCS numbering), surrounding residue R306 (highlighted in purple) in 
scDAOCS, are highly conserved. Scl, S. clavuligerus; Sch, S. chartreusis; Sam, S. 
ambofaciens; Sju, S. jumonjinensis; Nla, N. lactamdurans; Lla, L. lactamgenus; Ach, 
A. chrysogenum (DAOC/DACS). (* indicates a fully conserved position; : indicates a 




Chapter 6: Relevance of single mutations at amino 
acid positions 275, 281, 304 and 305 of scDAOCS 
leading to improved penicillin conversion activities 
	  
6.1.  Kinetic properties of N304 mutant scDAOCSs 
In an earlier study on residue N304 of scDAOCS, mutation to a basic amino 
acid, i.e. lysine or arginine, gave the highest improvement in the enzyme’s specific 
activity among the five mutants N304A, N304K, N304L, N304M and N304R in the 
four hydrophobic penicillin conversions (Chin et al., 2004).	  The specific activities of 
scDAOCS mutants for ampicillin conversion determined by HPLC are comparable to 
those determined by bioassay (Chin et al., 2004).  
In order to better understand the mechanism of these improvements, kinetic 
analyses of all improved mutants, i.e., N304A, N304K, N304L, N304M and N304R 
single mutants, were done using the enzyme kinetic assay reported by Dubus and co-
workers (2001). The results showed that all the five single mutants have lower Km 
values than the wild-type enzyme (Table 6.1). This indicates that these mutations 
improved the substrate binding affinity of scDAOCS for ampicillin. N304K and 
N304R mutations yielded the highest improvement in the substrate binding affinity of 
scDAOCS with approximately 13- (0.54 mM) and 26-fold (0.26 mM) reduction in Km 
values, respectively, compared to the wild-type enzyme (6.94 mM). These led to 
higher catalytic efficiencies, as reflected by higher kcat/Km values than the wild-type 
enzyme (Table 6.1).  
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Since lysine and arginine residues are basic amino acids, it is likely that the 
positively-charged side chains of these two amino acids enhanced the interaction of 
the enzyme with the penicillin substrates via ionic interaction. However, in silico 
structural and mutational analyses using SwissPdb Viewer and LIGPLOT suggested 
otherwise. Based on the crystal structures of scDAOCS complexed with ampicillin 
and penicillin G, the amino acid residue at position 304 of scDAOCS is likely to 
interact with the side chain of the penicillin substrate (Valegard et al., 2004). Hence, it 
is unlikely that there will be any ionic interaction between lysine or arginine residues 
with the hydrophobic side chain of ampicillin. Furthermore, LIGPLOT results 
indicate that both lysine and arginine are able to bind the penicillin substrate via 
hydrophobic interaction (Figure 6.1). 
 
Table 6.1. Kinetic parameters of wild-type and N304 mutant scDAOCSs for 
ampicillin conversion.  
 
Enzyme Km (mM)a kcat (s-1)a kcat/Km (M-1s-1) Relative kcat/Km 
Wild-type 6.94 ± 0.70 0.059 ± 0.004 8.6 1.0 
N304A 1.09 ± 0.08 0.040 ± 0.002 36.5 4.2 
N304K 0.54 ± 0.03 0.038 ± 0.003 70.1 8.2 
N304L 1.65 ± 0.30 0.041 ± 0.001 24.8 2.9 
N304M 5.12 ± 0.52 0.054 ± 0.003 10.5 1.2 
N304R 0.26 ± 0.01 0.052 ± 0.001 197.1 22.9 





Figure 6.1. Schematic diagrams of predicted residues interacting with ampicillin 
substrate in scDAOCS (1UNB) using SwissPdb Viewer (left column) and LIGPLOT 
program (right column). (A) The predicted substrate-interacting residues in wild-type 
scDAOCS did not include residue N304. After in silico mutation using SwissPdb 
Viewer, the mode of interaction was assessed by using LIGPLOT program and the 
mutated residues were circled: (B) N304R mutant and, (C) N304K mutant.  
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6.2. The importance of amino acid position 304 of scDAOCS 
The involvement of residue N304 in substrate interaction was not clear. 
Although it resides close to the side chain of the penicillin substrate, it was predicted 
not to form any non-covalent bonds with the substrate based on the crystal structures 
of scDAOCS complexed with penicillin G and ampicillin (Valegard et al., 2004). 
However, many studies have suggested otherwise (Chin et al., 2004; Chin and Sim, 
2002; Lee et al., 2002; Chin et al., 2001). Bearing in mind that penicillin N is the 
native substrate of scDAOCS and not penicillin G or ampicillin, the structural 
conformation observed in the crystal structure of scDAOCS-penicillin G or 
scDAOCS-ampicillin complexes does not reflect the ideal or optimal interaction 
between the enzyme and the substrate. These structures probably reflect the minimal 
interaction of the enzyme with a penicillin substrate in order to be resolved together.  
In a previous study, the replacement of residue N304 with a non-polar residue 
(leucine, methionine or alanine) or a basic charged residue (lysine or arginine) could 
improve the catalytic activity of the enzyme (Chin et al., 2004). Although both of the 
mutant enzymes with a basic residue substitution had higher relative activities than 
the mutant enzymes with a non-polar residue substitution, structural analyses did not 
suggest that there was any ionic interaction or hydrogen bonding between the basic 
residues and the penicillin substrate. Studies have shown that perturbation of its pKa 
might occur when the arginine residue is buried in the hydrophobic catalytic core of 
an enzyme, leading to deprotonation of the guanidinium group at a lower pH (Guillen 
Schlippe and Hedstrom, 2005). Hence, it could be the aliphatic region of the side 
chains of both arginine and lysine residues having hydrophobic interaction with the 
hydrophobic side chains of the penicillin substrates that leads to improved substrate 
binding affinity of the enzyme. This hypothesis was further supported by the 
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LIGPLOT prediction results, which suggested that there are hydrophobic interactions 
between the designated residues and the penicillin substrate. Therefore, a decrease in 
the Km value of scDAOCS after N304X mutation will corroborate this plausible 
interaction between these amino acid residues and the penicillin substrates.  
In this study, the kinetic parameters of these mutants were determined. The Km 
values of the mutants were considerably lower than that of the wild-type enzyme. This 
indicated substantial improvement in the substrate binding affinity of the enzyme. 
This also supported the notion that a mutation of asparagine at position 304 to a 
hydrophobic amino acid residue improves the substrate binding affinity of scDAOCS 
for hydrophobic penicillins via better hydrophobic interaction. Interestingly, Wei and 
co-workers (2003) also demonstrated that N304K mutation was able to improve 
substrate binding affinity of scDAOCS for penicillin N by 3.5-fold and increased the 
catalytic efficiency by about 4-fold. This further supported the involvement of residue 
N304 in interacting with the native substrate. However, the exact mechanism for this 
improvement is not structurally clear and will only be elucidated upon crystallisation 
of scDAOCS with penicillin N.  
This study has provided an important insight for modifying an enzyme’s 
substrate specificity, facilitated by the availability of an enzyme-substrate crystal 
structure. Although a substrate may be bound by an enzyme, the interaction mode 
may not always be optimum, especially for a non-native substrate. Being able to 
recognise the plausible site for modification is critical in enhancing the substrate 
interaction to improve enzymatic activity. Subsequently, the question of substitution 
to the right amino acid residue becomes easier since there are only 19 proteinogenic 
amino acids left to consider. By considering the properties of each amino acid, 




6.3. Relevance of V275I, C281Y and I305M single mutations leading to 
improved penicillin conversion activities 
Wei and co-workers (2003) demonstrated that the V275I, C281Y and I305M 
mutations improved the conversion activity of scDAOCS only with penicillin G. It is 
not clear whether the effects of these mutations would be the same for the conversion 
of other penicillin substrates. In this study, the substrate specificity of these mutant 
enzymes was determined using the hole-plate bioassays and was found to include 
ampicillin, phenethicillin, and carbenicillin (Table 6.2). HPLC analyses of ampicillin 
conversions by these mutants were done to affirm the hole-plate bioassay results 
(Table 6.3). The bases of improvement observed in these mutants were also explored 
using enzyme kinetic assays (Table 6.4). These results were also compared with other 
improved single mutants studied in this project.  
The conversion activities of V275I, C281Y and I305M mutants were higher 
than that of the wild-type enzyme for the ring-expansion of penicillin G, ampicillin, 
carbenicillin and phenethicillin (Table 6.2). The improvement observed for the 
C281Y and I305M single mutants for the conversion of different penicillins was 
greater than that observed for the V275I mutant. Compared to the relative activities of 
other single mutants, the relative activity of C281Y showed the greatest improvement 
for carbenicillin conversion (572%), followed by the I305M mutant (450%). For 
ampicillin conversion and phenethicillin conversion, the activities of the N304R 
mutant were dominant. However, this mutant was only as efficient as the C281F 
mutant for penicillin G conversion. These results were similarly observed in the 
HPLC analyses (Table 6.3). 
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Structural analyses of these three residues using SwissPdb Viewer revealed 
that I305 is approximately 4.5 Å from the β-lactam ring of the penicillin substrate 
(Figure 6.2). After mutation to methionine, the side chain, which is longer than that of 
isoleucine, is closer to the β-lactam ring of the penicillin substrate. Thus, the 
methionine residue could potentially stabilise or orient the penicillin substrate in a 
more receptive manner for ring-expansion. Interestingly, I305L mutation also showed 
improvement in the conversion activity of scDAOCS using penicillin G although at a 
level lower than I305M mutant (Wei et al., 2003). This suggests that the branching 
point at Cγ of the side chain in leucine is more effective in interacting with the 
penicillin substrate compared to isoleucine, which is branched at Cβ of its side chain.  
The molecular mechanisms of V275I and C281Y single mutants that 
contribute to the increased catalytic activity of the enzyme are still unclear. Since the 
two residues are not located at the active site of scDAOCS, it is reasonable to 
postulate that their effects are structure-based. Residue V275 is located in a small sub-
domain on the β13 strand and surrounded by residues F273, V285, and L287 in the 
polypeptide chain extending from strand β13 to strand β14 (Figure 6.3). The 
interaction of these residues is important in maintaining the integrity of this small sub-
domain, which extends to the C-terminal end of the enzyme. When V275 was 
replaced with leucine, which is structurally similar to isoleucine, comparable relative 
activity was observed. Since V275 residue is strictly conserved among the annotated 
DAOCSs, it is likely that an aliphatic residue at this position is important for the 
interaction with the surrounding hydrophobic residues to maintain the integrity of this 
sub-domain. However, the relative activities of the V275I mutant for conversion of all 
penicillins are about two-fold higher than those of V275L. This suggests that the 
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branching variation in the side chains of isoleucine and leucine at this position is 
important for influencing the enzyme activity. 
Residue C281 is also located within the small sub-domain between the α9 
helix and the β14 strand (Figure 6.3). In silico mutational analyses revealed that a 
hydrogen bond was formed between the hydroxyl group on the side chain of tyrosine 
and the backbone oxygen of V238 when C281 was mutated to a tyrosine. This 
hydrogen bond could possibly help to stabilise the polypeptide chain leading to 
residue H243, which is critical for iron (II) coordination. This is consistent with the 
results reported by Wei and co-workers (2003). To further validate the contribution of 
the hydrogen bond, C281 was changed to phenylalanine, which resembles tyrosine 
structurally except that the hydroxyl group on the aromatic ring is absent. 
Interestingly, the C281F mutant exhibited specific activity similar to that of the 
C281Y mutant. This implied that the improved activity obtained was not due to the 
predicted hydrogen bond formation. Since phenylalanine is non-polar, the interactions 
of either tyrosine or phenylalanine at position 281 with its surrounding residues are 
likely to be due to hydrophobic and van der Waals forces. 
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Table 6.2. Relative activities of wild-type and mutant scDAOCSs determined by 
bioassay. 
 















































Ampicillin Penicillin G Phenethicillin Carbenicillin 
Wild-type 100 100 100 100 
V275I 129 157 150 227 
V275L 85 130 99 113 
C281Y 166 251 280 572 
C281F 191 264 300 518 
N304Ab 192 163 163 242 
N304Kb 270 237 211 404 
N304Lb 163 129 173 235 
N304Mb 120 92 127 161 
N304Rb 346 263 360 398 
I305M 313 234 318 450 
R306Lc 186 105 173 283 
R307Lc 133 124 122 108 
N304AR306L 214 114 319 393 
N304KR306L 245 80 380 482 
N304LR306L 145 40 185 218 
N304MR306L 194 72 245 232 
N304RR306L 256 92 344 514 
V275IN304A 265 233 330 721 
C281YN304A 294 383 714 911 
V275IN304K 334 294 635 867 
C281YN304K 376 428 948 1180 
V275IN304L 225 141 245 524 
C281YN304L 330 211 471 1001 
V275IN304M 160 174 261 230 
C281YN304M 225 277 428 485 
V275IN304R 360 381 698 814 
C281YN304R 430 441 1041 1309 
V275II305M 406 420 685 1057 
C281YI305M 491 495 1109 1347 
V275IR306L 343 168 379 665 
C281YR306L 394 191 555 1010 
V275IR307L 172 169 238 333 
C281YR307L 274 334 520 786 
aThe relative activity of each mutant enzyme is the mean specific activity of the mutant enzyme relative 
to that of the wild-type enzyme, which was defined as 100%. The mean specific activity of each 
enzyme was determined using at least three independent experiments with duplicates. 
bscDAOCS mutant obtained from a previous study (Chin et al., 2004). 
cscDAOCS mutant obtained from a previous study (Chin and Sim, 2002).  
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Table 6.3. Specific and relative activities of wild-type and mutant scDAOCSs for 
ampicillin conversion determined by HPLC. 
 
Enzyme  Specific activitya (Umg-1) Relative activityb (%) 
Wild-type 5.67 ± 0.59 100 
V275I 7.76 ± 0.19 137 
V275L 4.42 ± 0.25 78 
C281Y 12.30 ± 0.42 217 
C281F 12.21 ± 0.63 215 
N304Ac 9.84 ± 0.21 173 
N304Kc 13.07 ± 0.37 230 
N304Lc 10.24 ± 0.34 180 
N304Mc 6.34 ± 0.18 112 
N304Rc 12.92 ± 0.32 228 
I305M 17.24 ± 0.68 304 
R306Ld 9.83 ± 0.28 173 
R307Ld 6.08 ± 0.17 107 
N304AR306L 15.33 ± 2.07 270 
N304KR306L 17.82 ± 1.31 314 
N304LR306L 9.51 ± 0.42 168 
N304MR306L 12.70 ± 0.96 224 
N304RR306L 17.67 ± 2.34 311 
V275IN304A 11.42 ± 2.80 201 
C281YN304A 13.38 ± 3.52 236 
V275IN304K 13.19 ± 2.38 233 
C281YN304K 14.61 ± 2.13 257 
V275IN304L 10.26 ± 1.05 181 
C281YN304L 12.20 ± 3.05 215 
V275IN304M 8.26 ± 0.93 146 
C281YN304M 13.26 ± 1.51 234 
V275IN304R 18.06 ± 1.77 318 
C281YN304R 20.39 ± 2.80 359 
V275II305M 25.48 ± 1.38 449 
C281YI305M 28.21 ± 0.77 497 
V275IR306L 19.99 ± 1.38 352 
C281YR306L 21.72 ± 1.34 383 
V275IR307L 12.39 ± 1.67 218 
C281YR307L 18.24 ± 1.45 322 
aOne unit of activity was defined as the amount of DAOCS required to form the equivalent of 1 µg of 
cephalexin per min at 30°C. The specific activities are the means ± standard deviations of at least three 
independent experiments with duplicates. 
bThe relative specific activity of each mutant enzyme is expressed as the percentage of the specific 
activity of the mutant enzyme relative to that of the wild-type enzyme, which was defined as 100%. 
cscDAOCS mutant obtained from a previous study (Chin et al., 2004). 





























Table 6.4. Kinetic parameters of wild-type and mutant scDAOCSs for ampicillin 
conversion.  
 
Enzyme Km (mM)a kcat (s-1)a kcat/Km (M-1s-1) Relative kcat/Km 
Wild-type 6.94 ± 0.70 0.059 ± 0.004 8.6 1.0 
V275I 3.41 ± 0.17 0.044 ± 0.001 12.8 1.5 
V275L 4.26 ± 0.32 0.032 ± 0.001 7.5 0.9 
C281Y 1.02 ± 0.07 0.044 ± 0.001 43.5 5.1 
C281F 1.35 ± 0.10 0.042 ± 0.003 31.2 3.6 
N304A 1.09 ± 0.08 0.040 ± 0.002 36.5 4.2 
N304K 0.54 ± 0.03 0.038 ± 0.003 70.1 8.2 
N304L 1.65 ± 0.30 0.041 ± 0.001 24.8 2.9 
N304M 5.12 ± 0.52 0.054 ± 0.003 10.5 1.2 
N304R 0.26 ± 0.01 0.052 ± 0.001 197.1 22.9 
I305M 1.00 ± 0.08 0.104 ± 0.011 104.1 12.1 
R306L 1.01 ± 0.05 0.050 ± 0.002 49.2 5.7 
R307L 5.96 ± 1.48 0.050 ± 0.003 8.4 1.0 
N304AR306L 0.20 ± 0.10 0.034 ± 0.008 170.8 19.9 
N304KR306L 0.12 ± 0.03 0.033 ± 0.005 285.1 33.2 
N304LR306L 0.40 ± 0.09 0.029 ± 0.001 71.1 8.3 
N304MR306L 0.36 ± 0.06 0.026 ± 0.001 72.3 8.4 
N304RR306L 0.19 ± 0.03 0.030 ± 0.005 160.1 18.6 
V275IN304A 0.68 ± 0.10 0.042 ± 0.002 61.7 7.2 
C281YN304A 0.38 ± 0.03 0.052 ± 0.003 137.0 15.9 
V275IN304K 0.38 ± 0.07 0.040 ± 0.002 107.8 12.5 
C281YN304K 0.13 ± 0.003 0.046 ± 0.004 361.9 42.1 
V275IN304L 1.04 ± 0.13 0.043 ± 0.002 41.0 4.8 
C281YN304L 0.34 ± 0.03 0.043 ± 0.001 125.4 14.6 
V275IN304M 3.60 ± 0.40 0.048 ± 0.002 13.5 1.6 
C281YN304M 0.80 ± 0.03 0.047 ± 0.001 59.3 6.9 
V275IN304R 0.11 ± 0.03 0.039 ± 0.001 366.9 42.7 
C281YN304R 0.05 ± 0.01 0.043 ± 0.002 865.2 100.6 
V275II305M 0.70 ± 0.06 0.105 ± 0.003 151.3 17.6 
C281YI305M 0.21 ± 0.09 0.122 ± 0.010 569.9 66.3 
V275IR306L 0.51 ± 0.15 0.037 ± 0.004 72.3 8.4 
C281YR306L 0.15 ± 0.01 0.037 ± 0.001 254.3 29.6 
V275IR307L 4.27 ± 0.31 0.049 ± 0.003 11.4 1.3 
C281YR307L 1.20 ± 0.07 0.046 ± 0.002 38.3 4.5 





Figure 6.2. Schematic diagrams of predicted residues interacting with ampicillin 
substrate in scDAOCS (PDB accession number: 1UNB) using SwissPdb Viewer (left 
column) and LIGPLOT program (right column). (A) The predicted substrate-
interacting residues in wild-type scDAOCS did not include residue I305. After in 
silico mutation using SwissPdb Viewer, the mode of interaction was assessed by 





Figure 6.3. Spatial orientation of residues V275 and C281 (orange) in scDAOCS 
(PDB accession number: 1UNB). Top panel: close-up view of residues V275 and 
C281. Residues V275 and C281 are located at a small sub-domain away from the 
active site. Residue V275 is located on β13 strand and surrounded by F273, V285 and 
L287 residues. Residue C281 is located along the polypeptide chain extending 
between α9 helix and β14 strand.  Bottom panel: in silico mutations of (A) V275I, (B) 
V275L, (C) C281Y and (D) C281F mutations using SwissPdb Viewer (dotted green 
line: hydrogen bond). 
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6.4.  The importance of the small sub-domain where V275 and C281 reside 
Earlier studies by Wei and co-workers (2003) have identified V275I and 
C281Y single mutations to be beneficial in improving the conversion activity of 
scDAOCS for penicillin G. However, it was not clear how these two mutations led to 
higher conversion activities in scDAOCS.  
The replacement of valine at amino acid position 275 to a more hydrophobic 
isoleucine probably improved its interaction with surrounding residues F273, V285 
and L287. In this project, V275L mutation also yielded slight improvement in the 
ring-expansion activity of penicillin G and carbenicillin, and comparable ring-
expansion activity of ampicillin and phenethicillin as the wild-type enzyme. These 
two conserved mutations likely further stabilised the sub-domain itself and indirectly 
affect the catalytic activity of scDAOCS (Figure 6.4). Hence, the improvements 
obtained by these two mutations were not as great as that obtained for C281Y 
mutation.  
An earlier postulation for C281Y mutation was that upon mutating residue 
C281 to a tyrosine, a hydrogen bond could be formed with the backbone of V238, 
which leads to β11 where residue H243 resides (Figure 6.4). This could possibly help 
to stabilise the polypeptide chain, which forms part of the co-factor binding motif 
critical for iron (II) coordination. In this study, a mutation to phenylalanine showed 
that the plausible hydrogen bonding is not the leading factor in enhancing the 
conversion activity of scDAOCS; the aromatic ring in the side chain of the amino acid 
residue is sufficient to enhance the ring-expansion activity of scDAOCS. 
Interestingly, another mutation L277Q was also reported to elevate the activity of 
scDAOCS in penicillin G conversion (Table 6.5) (Wei et al., 2005). This residue 
resides near the polypeptide chain that leads to β11 (Figure 6.4), which probably has a 
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similar effect as C281Y and C281F mutations. Furthermore, based on the kinetic 
studies of V275I, L277Q and C281Y mutants, only L277Q and C281Y mutants 
demonstrated higher catalytic efficiency than the wild-type enzyme for both penicillin 
N and penicillin G conversions. This suggests that there is a certain amount of 
flexibility in this sub-domain, which is further stabilised by interacting with the main 
domain upon either L277Q or C281Y mutation. This stabilisation could indirectly 
influence the catalytic center and lead to a higher catalytic activity. Therefore, it is 





Table 6.5. Kinetic studies of wild-type and mutant scDAOCSs in penicillin N and 
penicillin G conversions (Wei et al., 2005, 2003).  
 
 Penicillin N Penicillin G 
Enzyme Km (mM) kcat (s-1) kcat/Km (M-1s-1) Km (mM) kcat (s-1) kcat/Km (M-1s-1) 
Wild-type 0.014  0.307  22,000 2.58  0.0453  18 
V275I 0.012  0.252  20,000 1.68  0.0502  30 
L277Q 0.011 0.297 27,000 1.02 0.1036 102 






Figure 6.4. Spatial location of small sub-domain where residues V275 and C281 






Chapter 7: Relevant double mutations of scDAOCS 
result in higher binding specificities which improve 
penicillin bioconversion 
	  
7.1. Double mutation analyses of scDAOCS  
Multiple mutations are often necessary to obtain a desired property or function 
in a protein. As reviewed by Wells (1990) and Mildvan and co-workers (1992), the 
effect of introducing a second mutation into a mutant enzyme could be synergistic, 
additive, partially additive, antagonistic or could have no additional effect, and 
therefore, the interactions between two or more mutations warrant experimental 
elucidation. 
The effects of selected single mutations on the activity of scDAOCS have 
been demonstrated in various studies, with two observations made. The C-terminal 
residues (i.e., N304, I305, R306, and R307) are close to the penicillin substrate. Thus, 
mutations at these sites would have a direct effect on enzyme catalysis through 
interactions with the substrate. In contrast, mutations at the V275 and C281 residues, 
which are not located at the catalytic site, would have indirect consequences. Since 
N304 of scDAOCS has been thoroughly studied for beneficial amino acid 
substitutions, it is a good candidate for investigating the effects of combining such 
mutations on the catalytic activity of the enzyme and the molecular effects of the 
mutations on each other. Therefore, two types of mutation combinations were tested; 
N304X mutations (where X is alanine, leucine, methionine, lysine, or arginine) were 
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combined with distal site mutations (V275I and C281Y), as well as a mutation at a 
site close to position 304 (R306L). 
 
7.1.1.  Comparative analyses of V275IN304X, C281YN304X, and N304XR306L 
double mutants 
A comparative analysis of the V275IN304X and C281YN304X double 
mutants with the corresponding single mutants revealed that the specific activities of 
the double mutants were higher than those of the corresponding single mutants for all 
the substrates tested (Table 6.2). The C281N304X double mutants were consistently 
more active than the V275IN304X double mutants. The trend observed was that the 
greatest increase in the conversion activities resulting from double mutations involved 
the single mutation that resulted in the greatest improvement (i.e., combination of 
C281Y with N304R or N304K). This suggests that combining relevant improved 
single mutants can have additive or synergistic effects on the resulting enzymatic 
capability. 
In contrast, some of the N304XR306L double mutants differed from the 
improved V275IN304X and C281YN304X double mutants (Table 6.2). For example, 
for ampicillin conversion, the relative activities of the N304KR306L (245%) and 
N304RR306L (256%) double mutants were lower than those of the corresponding 
single mutants, the N304K (270%) and N304R (346%) mutants. Only slight increases 
in the specific activity were observed for the N304AR306L (214%) and 
N304MR306L (194%) double mutants compared to the corresponding single mutants, 
the N304A (192%), N304M (120%), and R306L (186%) single mutants. For 
phenethicillin conversion, the N304AR306L, N304KR306L, and N304MR306L 
double mutants had higher relative activities than the corresponding single mutants. 
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As for carbenicillin conversion, the N304AR306L, N304KR306L, and N304RR306L 
double mutants had higher relative activities than the corresponding single mutants. 
These results suggest that the N304LR306L double mutation was not an ideal 
combination as the activity of the N304LR306L double mutant for any of the three 
conversions was lower than that of the corresponding single mutants. Intriguingly, all 
N304XR306L double mutations were counter effective for penicillin G conversion, 
and the relative activities were similar to or lower than that of the wild-type enzyme. 
These results suggest the possibility that one mutation affects the environment of 
another mutation in close proximity, leading to undesirable effects. 
 
7.1.2.  Effects of V275I or C281Y with other C-terminal mutations 
Since improvement was obtained by combining the V275I or C281Y mutation 
with N304X mutations, it can be extrapolated that when V275I and C281Y are 
combined with other C terminal mutations (namely, I305M, R306L, and R307L), 
similar outcomes should be obtained. As expected, V275I-C terminus double mutants 
exhibited further improvement compared to the corresponding single mutants (Table 
6.2). Although the trend for most C281Y-C terminus double mutants was similar to 
the trend for the V275I-C terminus double mutants, the C281YR306L double mutant 
did not show further improvement in the relative penicillin G conversion activity 
(191%) compared to the C281Y single mutant (251%). Nevertheless, these results 
supported the conclusion that the V275I and C281Y mutations increased the 





7.1.3.  Determination of specific activities of wild-type and mutant scDAOCSs by 
HPLC  
HPLC was also used to confirm the results obtained from bioassays for 
ampicillin conversion. These results were comparable to those obtained with 
bioassays (Table 6.3). 
 
7.1.4.  Kinetic parameters of wild-type and mutant scDAOCSs for ampicillin 
conversion  
The Km values of all mutant enzymes were lower than that of the wild-type 
scDAOCS (6.94 mM) for ampicillin conversion, indicating that the substrate binding 
affinities were higher (Table 6.4). In the single mutants, the N304R (0.26 mM), 
N304K (0.54 mM), and I305M (1.00 mM) mutations increased the substrate binding 
affinity of the enzyme most effectively. This property was further enhanced when 
these mutations were combined with the V275I, C281Y, or R306L mutations. 
Interestingly, the I305M mutation doubled the turnover rate of the enzyme 
(0.104 s-1) compared to that of the wild-type scDAOCS (0.059 s-1). This is the only 
mutation that significantly increased the turnover rate of scDAOCS’s ring-expansion 
activity. Similar kcat values were obtained regardless of the type of mutation with 
which I305M was combined; the kcat for V275II305M was 0.105 s-1, and the kcat for 
C281YI305M was 0.122 s-1. However, the other mutations affected the turnover rate 
of scDAOCS to various degrees. It was observed that the double mutants containing 
the R306L mutation had the lowest kcat values (0.026 s-1 for the N304MR306L double 
mutant and 0.037 s-1 for both the V275IR306L and C281YR306L double mutants). In 
contrast, the R306L single mutation (0.050 s-1) did not affect the turnover rate of the 
ring-expansion activity as much as the double mutations.  
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In general, the kcat/Km values of all double-mutant scDAOCSs were higher 
than that of the wild-type enzyme for ampicillin conversion. Four double mutants, 
C281YN304R, C281YI305M, V275IN304R, and C281YN304K, showed the greatest 
improvement in the enzyme’s catalytic efficiency (101-, 68-, 42-, and 42-fold 
increments, respectively). These kinetic data supported the hypothesis that the ring-
expansion activity of these double mutants is superior. 
 
7.2. Combinatory mutagenesis as an approach in understanding the substrate 
binding mechanism of scDAOCS  
More than one mutation in an enzyme is generally required to alter its 
properties in a desirable way. When two mutations are combined in a single protein, 
there can be various effects (Mildvan et al., 1992; Wells, 1990). The effects can be 
cumulative if the mutations are at distal sites (Skinner and Terwilliger, 1996; Lo et al., 
1995). For example, in crystallographic studies of double mutations in the gene V 
protein of bacteriophage f1, it was found that the coordinate shifts were greatest near 
the site of mutation and decreased with increasing distance (Skinner and Terwilliger, 
1996). Very few changes were observed more than 10Å from each mutation site. 
Thus, the influence of each mutation on the structural changes in an enzyme seems to 
be distance dependent. When two mutation sites are sufficiently distal, the effects of 
the mutations are independent of each other. However, the precise effect of combining 
two mutations that are close together is still not well understood. Hence, the effect of 
one mutation on another was investigated in this study using combinatory 
mutagenesis.  
The bioassay results showed that N304XR306L double mutant, which had two 
mutations that were one amino acid apart (approximately 7.1Å), exhibited similar or 
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higher specific activities compared to the corresponding single mutants for ampicillin, 
phenethicillin, and carbenicillin conversions. Surprisingly, the penicillin G conversion 
activity of N304XR306L double mutants was similar to or lower than that of the wild-
type enzyme. Since the side chains of residues N304 and R306 of scDAOCS are in 
opposite directions, it is very likely that they have an opposing effect on each other. 
The presence of a functional group in the side chain of ampicillin (amino group), 
carbenicillin (carboxyl group) and phenethicillin (methyl group) probably stabilised 
or enhanced the interaction of the penicillin substrate with the amino acid residue at 
position 304 and opposed the effect at position 306 after N304XR306L double 
mutations.  
When N304X mutations were combined with V275I and C281Y mutations, 
which are 28 and 22 amino acids from position 304, respectively, further 
improvements compared to the corresponding single mutants were observed. The 
bioassay results showed that approximately 10-fold increment in the carbenicillin 
conversion activity of scDAOCS was observed when the C281Y mutation was 
combined with the N304K and N304R mutations. Increases were also observed when 
the C281Y mutation was combined with other C-terminal single mutations (I305M, 
R306L, and R307L). These results showed that the effects of the mutations are 
independent of each other and the overall effect could be additive or synergistic. 
Therefore, this distance-dependent effect should be considered for rational 
engineering of DAOCS with desired properties. The results further supported the 
notion that the C281Y, N304K, N304R, and I305M mutations are strategic sites for 
engineering scDAOCS with improved substrate specificity and catalytic activity.  
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Chapter 8: Characterisation of scDACS 
	  
Native DACS from S. clavuligerus ATCC 27064 (synonymous to strain DSM 
738 and NRRL 3585) has been purified and shown to be active as a monomer. It 
requires α-ketoglutarate, ferrous iron and molecular oxygen for its hydroxylation 
activity. It is stimulated by DTT or reduced glutathione, and ATP. However, a large 
volume of culture is required to purify the native enzyme for characterisation. 
Therefore, high level heterologous expression would be beneficial. This has been 
attempted by another group where the cefF gene has been cloned and expressed in E. 
coli but the highly-expressed DACS occurred as inclusion bodies (Kovacevic and 
Miller, 1991). 
Recombinant DNA technology has offered the opportunity to express the 
desired protein with a fusion partner to improve its expression and solubility. GST as 
a fusion partner has successfully overcome many cases where the protein-of-interest 
was insolubly expressed. Furthermore, it allows purification of the protein-of-interest 
using affinity chromatography via GST tag. Since recombinant GST-scDAOCS has 
been shown to be active, a similar strategy was adopted for the study of scDACS. 
This also allows a direct comparison of the functional activities of scDAOCS and 
scDACS. Hence, cefF gene of S. clavuligerus NRRL 3585 strain was cloned into the 
same expression vector pGK and expressed as recombinant GST-scDACS in E. coli 
BL21 (DE3) strain. Subsequently, expression and solubility of recombinant GST-
scDACS was determined using SDS-PAGE analysis. Upon obtaining solubly-




8.1. Cloning of scDACS 
Both forward (OL963) and reverse (OL964) cloning primers were designed 
based on the sequence deposited in GenBank, with an accession number M63809. The 
forward and reverse cloning primers were designed with the inclusion of BamHI and 
EcoRI restriction endonuclease recognition sequences at their 5’-ends, respectively. 
This was to facilitate cloning of cefF gene into pGK expression vector. Upon PCR 
amplification of cefF from genomic DNA of S. clavuligerus NRRL 3858, an 
approximately 1 kbp PCR product was obtained and detected using agarose gel 
electrophoresis (Figure 8.1). This product was excised and purified from the agarose 
gel using QIAquick® Gel Extraction kit (Qiagen). The purified product was 
subsequently ligated into pCR®-Blunt II TOPO® vector using Zero Blunt® TOPO® 
PCR Cloning kit (Invitrogen). The nucleotide sequence of the ligated PCR product 
was then validated by DNA sequencing. Upon validating the identity of the ligated 
product to be cefF gene, it was sub-cloned into pGK expression vector and fully 
sequenced again to ensure authenticity.  
Interestingly, the nucleotide sequence of the cloned cefF gene possessed a 
nucleotide different from the deposited one. This cloned sequence has a transversion 
mutation at nucleotide position 126. This T126G transversion mutation resulted in a 
conserved amino acid mutation of an aspartic acid to a glutamic acid at amino acid 
position 42 (Figure 8.2). Repeated PCR amplification using another genomic DNA 
extract of S. clavuligerus and DNA sequencing showed the same sequence, hence, 
suggesting a sequence variant of scDACS from the earlier report (Kovacevic and 
Miller, 1991). This recombinant plasmid is designated as pGK-scDACS.  
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Figure 8.1. Agarose gel electrophoresis of PCR-amplified product of cefF gene from 
S. clavuligerus genomic DNA. Lane M: GeneRuler™ 1kb DNA ladder (Fermentas); 
Lane 1: PCR amplification of cefF; Lane 2: negative control (without S. clavuligerus 




Forward sequencing Reverse sequencingA
DACS_F         GGGGAGAAGGACCACCGGCTGGCCACGGACACGGCGATGGACTTCTTCGCGAACGGCACC 157
M63809         GGGGATAAGGACCACCGGCTGGCCACGGACACGGCGATGGACTTCTTCGCGAACGGCACC 180
***** ******************************************************
DACS1F         MADTPVPIFNLAALREGADQEKFRECVTGMGVFYLTGYGAGEKDHRLATDTAMDFFANGT 60






Figure 8.2. Verification of PCR-amplified cefF gene of S. clavuligerus NRRL 3858. 
A. Electropherograms of forward and reverse DNA sequencing of PCR amplified cefF 
gene. B. Top panel shows the partial nucleotide sequence alignment of PCR amplified 
(DACS_F) and GenBank M63809 cefF genes, illustrating the nucleotide difference at 
position 126. Bottom panel shows the partial protein sequence alignment of translated 
amino acid sequence of PCR-amplified (DACS1F) and GenBank M63809 cefF genes, 
illustrating the amino acid difference at position 42.  
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8.2. Heterologous expression of recombinant scDACS 
After verifying the nucleotide sequence of scDACS, the E. coli BL21 (DE3) 
clone harbouring pGK-scDACS was cultured and induced using the same conditions 
for scDAOCS to express the recombinant protein for purification and functional 
analysis. SDS-PAGE analysis of the cell-free extract showed that recombinant GST-
scDACS was highly expressed in E. coli BL21 (DE3) at 25ºC. The recombinant GST-
scDACS fusion protein was purified using Glutathione Sepharose 4B chromatography 
column. Cleavage by PreScission™ protease released the scDACS with an estimated 
molecular mass of approximately 35 kDa. A representative SDS-PAGE analysis of 
the cell free extract and purified fraction of the E. coli clone harbouring pGK-




Figure 8.3. SDS-PAGE analysis of cell-free extracts and purified fractions of E. coli 
BL21 (DE3) clone expressing recombinant GST-scDACS. Lane M: Precision Protein 
Standards™ Bio-Rad 161-0318; Lane 1: cell-free extract; Lane 2: insoluble fraction; 
Lane 3: purified fraction; Lane 4: PreScission™ Protease-cleaved scDACS; Lane 5: 
eluted fraction after protease cleavage; Lane 6: cell-free extract of E. coli BL21 (DE3) 
harbouring pGK; Lane 7: insoluble fraction of E. coli BL21 (DE3) harbouring pGK; 
Lane 8: purified GST; Lane 9: purified GST-scDAOCS.  
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8.3. Functional and mutational studies of recombinant scDACS 
8.3.1. Identification of functional amino acid residues of scDACS 
The amino acid sequences of all annotated DACSs deposited in GenBank 
were retrieved and aligned with all annotated DAOCSs and AchDAOC/DACS using 
ClustalW multiple sequence alignment program (Figure 8.4). The conserved 
HXDXnH co-factor binding motif and RXS co-substrate binding motif are highlighted 
in green and turquoise colours, respectively. The substrate binding residues of 
scDAOCS reported by Hsu et al. (2004) are highlighted in grey colour. These residues 
are highly conserved among DAOCSs, DACSs and AchDAOC/DACS, except amino 
acid position 73 (scDAOCS amino acid numbering) where it could be methionine, 
isoleucine, valine, alanine or threonine. Although position 158 is mainly leucine in 
DAOCSs and it is a valine in all annotated DACSs, it was reported to be a valine in S. 
chartreusis DAOCS. Since leucine and valine are aliphatic non-polar amino acids, 
they are probably not involved in substrate selectivity, i.e., they do not play a role in 
differentiating the substrate, leading to ring-expansion or hydroxylation activity. 
Hence, the amino acid residues involved in differentiating the substrates have to be 
other amino acid residues in the β-barrel that defines the substrate binding pocket of 
the enzyme.  
In silico analysis of scDACS structure revealed 57% and 73% sequence 
identity and similarity to scDAOCS (Table 8.1). Structural modelling of scDACS 
using Swiss-Model revealed highly homologous tertiary structure with scDAOCS 
(Figure 8.5). Since scDACS bears the same catalytic platform and is likely to possess 
the same tertiary structure as scDAOCS, structural and biochemical information of 
scDAOCS could be useful in identifying the amino acid residues involved in 
differentiating substrate recognition. The C-terminus of scDAOCS has been reported 
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to be important for substrate recognition. Similarly, the C-terminal residues of 
AchDAOC/DACS have been reported to be important for ring-expansion and 
hydroxylation activities (Wu et al., 2005; Lloyd et al., 2004). Hence, it is likely that 
the C-terminal residues of scDACS are crucial. Interestingly, residues N304 and R306 
of scDAOCS are conserved among the DAOCSs and AchDAOC/DACS (Figure 8.4). 
The corresponding residues in DACSs are also conserved but are instead threonine 
and histidine, respectively (Figure 8.4). Since the resolved crystal structure of 
scDAOCS showed that residue N304 is oriented close to penicillin, it is likely that the 
corresponding residue T308 in scDACS will interact with the cephalosporin substrate 
for hydroxylation (Figure 8.6). Similarly, residue T310 of scDACS, which is the 
corresponding residue of R306 of scDAOCS, is likely to play a role in substrate 






Figure 8.4. Multiple sequence alignment of annotated DAOCSs and DACSs of 
various microorganisms depicted with the secondary structure of scDAOCS. The 
secondary structure of scDAOCS was resolved from its crystal structure (Valegard et 
al., 1998). The cylinders refer to α-helices, the block arrows refer to β-sheets and the 
black lines refer to random coils of the tertiary structure of scDAOCS. The iron and 
co-substrate binding motifs of scDAOCS and scDACS are highlighted in green and 
turquoise colours, respectively. The substrate binding residues of scDAOCS reported 
by Hsu and co-workers (2004) and the corresponding residues in scDACS are 
highlighted in grey colour. Position 42 of scDACS and the corresponding positions in 
other DACS homologues are highlighted in a red box. Positions 304 and 306 of 
scDAOCS and the corresponding positions in other DAOCSs and DACSs are 
highlighted in blue boxes. (Scl: S. clavuligerus NRRL3585; Sch: S. chartreusis 
102SH3; Sam: S. ambofaciens 29SA4; Sju: S. jumonjinensis NRRL5741; Nla: N. 
lactamdurans; Lla: L. lactamgenus YK90; Ach: A. chrysogenum; S65PH1: 
Streptomyces sp. isolate 65PH1) (GenBank accession numbers: Scl_DAOCS – 
P18548, Sch_DAOCS – AY318743, Sam_DAOCS – AY318742, Sju_DAOCS – 
AF317908, Nla_DAOCS – Z13974, Lla_DAOCS – CAA39984, Ach_DAOC/DACS 
– P11935, Scl_DACS – P42220, S65PH1_DACS – AY318744, Nla_DACS – 
P42219, Lla_DACS – CAA39985) (* indicates a fully conserved position; : indicates 
a highly conserved position; . indicates a weakly conserved position) 
 
 
Table 8.1. Sequence homologies between various annotated DAOCSs and DACSs.  
 





















Sch DAOCS  79.7 77.2 66.9 54.2 76.5 54.1 54.4 60.3 58 52.9 
Sam DAOCS 88.7  85.9 70.4 54.5 81.4 54.1 56.3 60.3 58.3 52.2 
Sju DAOCS 87.1 91.3  68.2 53.3 81.7 52.9 57.2 60.3 57.4 51.6 
Nla DAOCS 78.7 84.1 82.2  56.6 70.1 57.3 57.7 61.5 60.8 54.1 
Lla DAOCS 70.8 71.2 70.5 72.4  56.1 52 53.7 52.8 53.9 53 
Scl DAOCS 86.8 92.3 91 83.4 72.4  53.8 57.2 60.3 60.3 52.7 
Ach DAOC/DACSb 68.7 67.5 67.5 70.8 69 67.8  51.8 51.4 52 48.6 
Scl DACS 70.1 72.3 72 71.7 69.3 73.3 66  75.8 76.1 50.9 
S65PH1 DACS 75 76.6 76.6 74.2 69 76.9 67.2 86.8  76.6 53.7 
Nla DACS 73 74 74 72.6 67.4 75.2 65.4 84.3 85.3  53 
Lla DACS 69.6 69.6 69.6 70.4 72.4 69 62.3 65.1 68.1 68.1  
aSequence homology values were determined using MatGAT programme (Campanella et al., 2003). (GenBank accession 
numbers: Scl_DAOCS – P18548, Sch_DAOCS – AY318743, Sam_DAOCS – AY318742, Sju_DAOCS – AF317908, 
Nla_DAOCS – Z13974, Lla_DAOCS – CAA39984, Ach_DAOC/DACS – P11935, Scl_DACS – P42220, S65PH1_DACS – 
AY318744, Nla_DACS – P42219, Lla_DACS – CAA39985) 
bA bifunctional enzyme that possesses both deacetoxycephalosporin C synthase and deacetylcephalosporin C synthase activities.  
(Scl: S. clavuligerus NRRL3585; Sch: S. chartreusis 102SH3; Sam: S. ambofaciens 29SA4; Sju: S. jumonjinensis NRRL5741; 




Figure 8.5. Crystal structure of scDAOCS (1UOB) and homology model of scDACS. 
Homology model of scDACS is generated using Swiss-Model programme. The 
structures were viewed and manipulated using SwissPdb Viewer. The green-coloured 
regions in scDACS model are the constructed regions of the corresponding disordered 
regions in the crystal structure of scDAOCS. The loop coloured red carries the three 





Figure 8.6. C-termini of scDAOCS crystal structure (1UOB) and scDACS in silico 
model. scDAOCS C-terminal residues N304, I305 and R306 have been shown to be 
important sites for manipulation to upgrade the enzyme’s capabilities. The 
corresponding residues in scDACS are residues T308, M309 and H310, respectively. 
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8.3.2. Hydroxylation activity of scDACS 
As the reaction mechanism of DACS is very similar to that of DAOCS, except 
for the difference in their substrate preferences, the ring-expansion assay conditions 
were often adopted, with the penicillin substrate replaced by DAOC (Lloyd et al. 
2004; Baker et al. 1991). Therefore, in this study, the optimised reaction mixture 
reported by Sim and Sim (2001) for the detection of the ring-expansion activity of 
GST-scDAOCS was adopted. Since the native hydroxylation substrate DAOC is not 
easily available, an analogue of DAOC, cephalexin, was used as a replacement. Under 
the reverse-phase HPLC conditions reported by Lloyd and co-workers (2004), the 
retention time of DAC (7.5 min) was lower than that of DAOC (13 min). This is 
expected since the addition of a hydroxyl group to DAOC will decrease its 
hydrophobicity and result in a lower retention time than the unhydroxylated substrate. 
Hence, the HPLC analysis described in Chapter 3.2.6.2 was used to detect for the 
hydroxylated product formed in the hydroxylation assay.  
The hydroxylation assay was done using purified GST-scDACS recombinant 
protein. The reaction was stopped by adding equal volume of absolute methanol to the 
reaction mixture. Subsequently, the test samples were analysed using reverse-phase 
HPLC. The HPLC chromatograms of scDACS before and after the reaction were 
compared. The presence of a new peak will indicate the formation of the hydroxylated 
product of cephalexin. However, there was no sign of a new peak in the HPLC 
chromatograms of scDACS after both 30 min and 1 hour reactions.  
Earlier studies on AchDAOC/DACS suggested its substrate specificity to be 
very narrow. It has been reported to show very low or negligible hydroxylation of 
DAOC G, which is the ring-expanded product of penicillin G, and cephalexin (Lloyd 
et al., 2004). Hence, it is likely that cephalexin is not a suitable substrate for scDACS. 
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Although this recombinant scDACS is a D42E variant of the reported scDACS, it is 
unlikely that the failure to detect hydroxylation activity was due to this sequence 
variation since the corresponding position in other DACS homologues was reported to 
be either glutamic acid or serine residues (Figure 8.4). Since scDACS is structurally 
homologous to scDAOCs, it can be postulated that scDACS could be engineered to 
possess ring-expansion activity. This will indirectly suggest that the mutated residues 
are important for substrate differentiation.   
 
8.3.3. Ring-expansion activity of scDACS 
Earlier studies on scDACS have reported approximately 3% of ring-expansion 
activity compared to scDAOCS using the native substrate of DAOCS, penicillin N 
(Baker et al. 1991). This suggests that scDACS is highly specific in its substrate 
recognition and hence, defines its enzymatic activity as hydroxylation. The standard 
ring-expansion assay reported by Sim and Sim (2001) was used on recombinant GST-
scDACS. The penicillin substrates used were penicillin G and ampicillin, since 
penicillin N is not easily available. The bioassays revealed no zone of growth 
inhibition of test bacterium E. coli Ess for both substrates. These results suggest that 
scDACS does not possess ring-expansion activity using penicillin G and ampicillin as 
substrates, despite having high structural homology with scDAOCS.  
 
8.3.4. C-terminal mutational studies of scDACS 
Since the corresponding residues of N304 and R306 of scDAOCS are T308 
and H310 in scDACS, respectively, these two residues were selected for mutational 
studies. To engineer scDACS with ring-expansion activity, T308 and H310 were 
mutated to asparagine and arginine, respectively, to mimic the C-terminus of wild-
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type scDAOCS. Since N304R and R306L single mutants of scDAOCS showed 
improved ring-expansion activity using penicillin G as a substrate (Chin et al., 2004; 
Chin and Sim, 2002), T308 and H310 of scDACS were also replaced with arginine 
and leucine, respectively, to determine possible enhancement in ring-expansion 
activity.  
A similar mutagenesis strategy described for generating scDAOCS mutants 
was used to generate these scDACS mutants. The SDM template used was pGK-
scDACS and the respective mutagenic oligonucleotides used are listed in Table 3.4. 
SDS-PAGE analysis of the mutant cell lysates revealed similar profile as that of the 
wild-type enzyme (Figure 8.3). This suggests that the various mutations did not affect 
the soluble expression of the mutant sequences in the expression host E. coli BL21 
(DE3).  
The scDACS mutants were subsequently tested for ring-expansion activity. 
Table 8.2 shows the results of the hole-plate bioassays. T308N mutant did not show 
any detectable ring-expansion activity, whereas H310R mutant showed approximately 
2% of wild-type scDAOCS’s ring-expansion activity. Interestingly, T308R and 
H310L single mutants, which are mimics of scDAOCS N304R and R306L single 
mutants with improved activities, showed 2% and 18% ring-expansion activity, 
respectively. This supports the possibility of conferring ring-expansion activity by 
mutating critical residues in the putative substrate binding pocket of scDACS. To 
further validate this notion, T308NH310R and T308RH310R double mutants, which 
are closer mimics of wild-type and N304R mutant of scDAOCS, respectively, were 
generated and evaluated (Table 8.2). T308NH310R and T308RH310R double mutants 
showed 3% and 8% ring-expansion activities, respectively. These are higher than the 
respective single mutants of scDACS. Together, these results suggest that the C-
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terminal residues T308 and H310 of scDACS, which are the corresponding residues 
of the C-terminal residues N304 and R306 of scDAOCS, are important in influencing 




Table 8.2. Specific and relative activities of scDAOCS, wild-type and mutant 
scDACSs in penicillin G conversion determined using a hole-plate bioassay.  
 
Enzyme Specific activity (U/mg) a Relative activity (%)b 
Wild-type scDAOCS 6.58 ± 0.243 100 
Wild-type scDACS NDc - 
T308N  ND - 
T308R 0.11 ± 0.003 2 
H310R 0.11 ± 0.002 2 
H310L 1.21 ± 0.006 18 
T308NH310R 0.23 ± 0.034 3 
T308RH310R 0.53 ± 0.034 8 
aOne unit of enzyme activity is the amount of enzyme required to form the equivalent of 1 µg of 
cephalosporin C per minute at 30°C. The specific activities are shown as the mean ± standard deviation 
of two independent experiments with duplicates. 
bRelative activity of each enzyme is expressed as the percentage of the specific activity of the enzyme 
relative to that of scDAOCS at 100%. 






8.4. Proposed differential substrate recognition of scDAOCS and scDACS 
It has long been recognised that scDACS resembles scDAOCS in various 
aspects. Although both enzymes use the same catalytic platform and reactants for 
enzymatic reaction, they recognise different substrates for respective enzymatic 
reactions. Since the catalytic reaction is essentially the same, i.e., oxidation, the 
difference lies in the substrate selectivity. Hence, structural differences in the 
substrate binding pocket should account for this reactivity difference. However, the 
challenge in this study is that the native substrates of DAOCS and DACS, i.e., 
penicillin N and DAOC, respectively, are not easily available. Providentially, other 
penicillins could be used as the substrate for probing the functionality of scDAOCS, 
albeit at a lower enzymatic activity (Chin and Sim, 2002; Cho et al., 1998). This has 
permitted various mutational studies of scDAOCS to be done, resulting in a better 
understanding of its structure-function relationship.  
Intriguingly, A. chrysogenum has a bifunctional enzyme that possesses both 
ring-expansion and hydroxylation activity, i.e., AchDAOC/DACS. In silico structural 
modelling of AchDAOC/DACS yielded similar structural folds as scDAOCS except 
for the additional 20 amino acid residues at its C-terminus, which could not be 
modelled (Chin et al., 2003). Truncation of this additional tail resulted in 50% loss of 
hydroxylation activity using DAOC as a substrate and doubled the ring-expansion 
activity using penicillin G as a substrate (Lloyd et al., 2004). This shows that the 
additional C-terminal tail has a role in the hydroxylation activity of 
AchDAOC/DACS. Importantly, M306I mutation of AchDAOC/DACS demonstrated 
the absolute importance of this residue at this position for hydroxylation activity 
(Table 8.3) (Lloyd et al., 2004). This accounts for the low or negligible hydroxylation 
activity of scDAOCS, which has an isoleucine at the corresponding position 305. 
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However, this does not account for the inability of scDACS to ring-expand penicillin 
G since it also possesses a methionine at the corresponding position 309. 
Retrospectively, scDACS does not have the additional amino acid residues as 
AchDAOC/DACS. Hence, the determinants for specific reactivity in the 
monofunctional scDAOC and scDACS have yet to be fully comprehended. Since 
scDACS could not hydroxylate cephalexin, a reverse engineering approach was 
adopted in this study to obtain more clues to this functional specificity.  
Although scDAOCS has negligible hydroxylation activity on DAOC, a crystal 
structure of scDAOCS bound with DAOC has been resolved (1UOG). The spatial 
orientation of DAOC in this structure was very similar to that of penicillin G (1UOB) 
and ampicillin (1UNB) in scDAOCS (Figure 8.7). Assuming that scDACS was to 
bind DAOC in a similar manner for hydroxylation, it would be very likely that 
scDAOCS will be able to hydroxylate DAOC. However, this position adopted by 
DAOC in the crystal structure of scDAOCS is not productive for hydroxylation 
(Valegard et al., 2004). One possible reason is that hydroxylation of DAOC occurs at 
the methyl group in the C3 position of the dihydrothiazine ring of DAOC. This 
position is too distant from the catalytic centre for hydroxylation to occur (Figure 
8.8). It is likely that DAOC has to be re-oriented to position the C3 methyl group to 
the iron centre.  
Another important clue lies in the C-termini of DAOCSs, DACSs and 
DAOC/DACS. Multiple sequence alignment of all annotated sequences revealed 
conservation at the corresponding position 304 of scDAOCS, i.e., asparagine in all 
DAOCSs and AchDAOC/DACS, and threonine in all DACSs. Since the side chain of 
penicillin N and DAOC is aminoadipate, which is zwitterionic, and residue N304 of 
scDAOCS is likely to interact with the side chain of the penicillin substrate during 
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ring-expansion, the distinct conservedness of the amino acid residue at this 
corresponding position in all annotated DAOCSs and DACSs suggests that asparagine 
is required for ring-expansion and threonine is required for hydroxylation. It is very 
likely that the type of amino acid residue at this position will guide the substrate in the 
correct orientation for reaction. This will also explain the inability of scDACS to 
hydroxylate cephalexin since the side chain of cephalexin is hydrophobic and not 
zwitterionic. As for AchDAOC/DACS, the presence of the additional amino acid 
residues at its C-terminus probably compensates for the inability of residue N305 to 
interact with DAOC for hydroxylation.  
In this study, scDACS was shown not to exhibit any ring-expansion and 
hydroxylation activity using penicillin G and ampicillin as respective substrates. Upon 
T308R mutation, 2% relative ring-expansion activity of wild-type scDAOCS was 
obtained. This indicates that amino acid position 308 of scDACS is indeed the 
corresponding position of 304 of scDAOCS and is important for substrate recognition.  
However, the undetectable ring-expansion activity of T308N mutant scDACS, which 
is a mimic of wild-type scDAOCS, and the low ring-expansion activity of T308R 
mutant also suggests that there are other residues involved in substrate recognition. 
Mutation of residue H310 of scDACS, which is the corresponding residue of R306 of 
scDAOCS, to either arginine or leucine validated this notion. By combining both 
mutations at T308 and H310, i.e., T308NH310R and T308RH310R double mutants, 
further enhancement in the ring-expansion activity of scDACS was achieved, 
indicating the importance of the type of amino acid residues in these two positions. 
However, combining T308N and T308R mutations with H310R mutation were not 
sufficient to confer a level of ring-expansion activity similar to that of scDAOCS. 
Since H310L mutation resulted in a much higher ring-expansion activity than H310R 
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mutation, i.e., 18% vs 2% relative ring-expansion activity, respectively, it will be 
worthwhile to investigate the outcomes of combining this mutation with T308N and 
T308R mutations. Since residue W82 of AchDAOC/DACS has been reported to be 
important for substrate selectivity, it is very likely that the corresponding residue A83 
in scDACS is also involved in substrate selectivity. This is further supported by 
distinct serine and alanine conservedness in the annotated DAOCSs and DACSs, 
respectively (Lloyd et al., 2004). However, residues E81-N90 were highly disordered 
and could not be resolved in the crystal structure of scDAOCS (Valegard et al., 2004). 
Hence, the involvement of residue S82, which is the corresponding residue of W82 in 
AchDAOC/DACS and that of A83 in scDACS, in the ring-expansion of scDAOCS 
could not be postulated.  
 
Table 8.3. Relative ring-expansion and hydroxylation activities of wild-type and 
mutant AchDAOC/DACSs using penicillin G and DAOC as respective substrates 




activity (%)  
Relative hydroxylation 
activity (%) 
Wild-type  100 100 
W82A 5.5 71 
W82S 44 18 
N305L 107 85 
M306I 59 <2 
∆310 203 50 
∆328	   64 45 
∆310/M306I	   185 3 







Figure 8.7. Superimposition of three crystal structures of scDAOCS complexed with 
ampicillin (brown) (1UNB), penicillin G (orange) (1UOB) and DAOC (gold) 




Figure 8.8. Spatial orientation of the methyl group (circled) at the C7 position of 





Chapter 9: Bioactivities of expanded cephalosporin 
products 
	  
In this project, various scDAOCS mutants were demonstrated to convert 
penicillin G, ampicillin, carbenicillin and phenethicillin to penicillinase-resistant 
cephalosporin products. They were also demonstrated to produce higher yields of the 
respective cephalosporin products than the wild-type enzyme. This allows further 
assessment of these cephalosporins for their bioactivities against a wider range of 
bacteria and for other potential uses. The maximum concentration of cephalosporin 
products formed by selected C281YI305M double mutant scDAOCS in the enzyme 
reaction was determined using HPLC. Since the dihydrothiazine ring of 
cephalosporins absorbed maximally at 260 nm of ultra-violet light (Dubus et al., 
2001; Baldwin and Crabbe, 1987), quantification of the cephalosporin products was 
based on the detection of their dihydrothiazine rings. The appearance of a new peak in 
the HPLC chromatogram of an assay sample compared to a control sample indicated 
the presence of the cephalosporin product (Figure 5.1). The area under the peak was 
used to determine the concentration of the cephalosporin product. A standard curve 
was generated using a range of concentration of cephalexin. The concentrations of 
cephalosporin products yielded from the enzymatic conversions of penicillin G, 
ampicillin, carbenicillin and phenethicillin were calculated using this standard curve. 
The maximum concentrations of cephalosporin products produced in the ring-
expansion assays containing penicillin G, ampicillin, carbenicillin and phenethicillin 




9.1. Antimicrobial spectra of expanded cephalosporin products 
The hole-plate bioassay used for the determination of the enzyme activity of 
DAOCS was employed to evaluate the inhibition profile of the cephalosporin 
products from the DAOCS ring-expansion assays. However, a modification was made 
where the test microorganisms were streaked onto the agar plate instead of seeding 
into it (Figure 3.1). This allows a higher number of test microorganisms to be 
evaluated per plate. Since DIFCO™ Penase was added to the bioassay plates to 
specifically degrade residual penicillin substrates, the zone of growth inhibition will 
reflect the bioactivity of the cephalosporin products. In order to compare the 
efficacies of the penicillins and their respective expanded cephalosporin products, 
equimolar concentrations of the respective penicillin substrates were also tested but 
DIFCO™ Penase was omitted in those bioassay plates. Since cephalexin is the 
cephalosporin moiety of ampicillin, the commercial cephalexin was used as a control. 
The test microorganisms used in the bioassay were Micrococcus luteus ATCC 381, 
Staphylococcus aureus ATCC 9144, Enterococcus faecalis ATCC 29212, Escherichia 
coli Ess strain, E. coli K12, Enterobacter aerogenes and Salmonella cholerasius 
ATCC 51741.  
Figure 9.1 shows the average zone of growth inhibition against the test 
microorganisms for ampicillin, its cephalosporin product and cephalexin. The 
inhibition profile of the cephalosporin product upon ampicillin conversion was 
identical to that of commercial cephalexin. However, both were not as bioactive as 
ampicillin against M. luteus ATCC 381, E. coli Ess strain, S. aureus ATCC 9144, E. 
coli K12 and S. cholerasius ATCC 51741, i.e., they showed smaller zones of 
inhibition than ampicillin. Conversely, both were able to inhibit E. aerogenes but 
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ampicillin was not able to. Interestingly, only ampicillin was able to inhibit E. faecalis 
ATCC 29212.  
The inhibitory profile of penicillin G included M. luteus ATCC 381, E. coli 
Ess strain, S. aureus ATCC 9144, E. coli K12, S. cholerasius ATCC 51741 and E. 
faecalis ATCC 29212. In contrast, its cephalosporin product was only able to inhibit 
M. luteus ATCC 381, E. coli Ess strain and S. aureus ATCC 9144, and at a lower 
level than penicillin G. This was similarly observed for carbenicillin, phenethicillin 
and their respective cephalosporin products. The inhibitory profile of carbenicillin 
included five bacteria, namely M. luteus ATCC 381, E. coli Ess strain, S. aureus 
ATCC 9144, E. coli K12 and S. cholerasius ATCC 51741, while that of its 
cephalosporin product only included the first three bacterial species. The inhibitory 
profile of phenethicillin was the narrowest among the penicillins, i.e., it included only 
M. luteus ATCC 381, E. coli Ess strain, S. aureus ATCC 9144, and E. faecalis ATCC 
29212. The inhibitory profile of its cephalosporin product was similar to that of 
penicillin G- and carbenicillin-converted cephalosporin products, which included only 
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Figure 9.1. Antimicrobial spectra of (A) ampicillin and cephalexin, (B) penicillin G, 
(C) carbenicillin, (D) phenethicillin and their respective ring-expanded cephalosporin 
products. These compounds were tested against Micrococcus luteus ATCC 381, 
Staphylococcus aureus ATCC 9144, Enterococcus faecalis ATCC 29212, Escherichia 
coli Ess strain, E. coli K12, Enterobacter aerogenes and Salmonella cholerasius 




9.2. Efficacies of penicillin substrates and their respective expanded 
cephalosporin moieties  
The hole-plate bioassay results suggest that the antimicrobial spectra of the 
cephalosporin products are similar or slightly smaller than those of their respective 
penicillin substrates. However, cephalosporins are generally penicillinase-resistant 
and more efficacious than the penicillins. The results obtained from the hole-plate 
bioassays might be due to the relatively small range of microorganisms tested and the 
unstandardised inoculum size of each test microorganism. In order to illustrate the 
efficacies of the cephalosporin products against a penicillin-resistant bacterium, a 
colony-forming unit (CFU) assay, which employs a standardised inoculum size, was 
used to assess the efficacies of the penicillins and their respective cephalosporin 
products in inhibiting a penicillinase-producing E. coli.  
The pGEX-6P-1 plasmid contains an ampicillin-resistance factor, which is 
constitutively expressed. This ampicillin-resistance factor encodes a TEM-1 β-
lactamase, which has been demonstrated to be a penicillinase (Bush et al., 1995). The 
pGEX-6P-1 plasmid was transformed into E. coli BL21 (DE3) to mimic the gain of 
penicillin-resistant phenotype. The transformed ampicillin-resistant E. coli BL21 
(DE3) strain (E. coli BL21-AmpR) was cultivated using LB broth containing 100 
µg/mL ampicillin for 24 hours. Thereafter, enumeration of the bacterial culture was 
done to estimate the viable bacterial count using dilution plating method before the 
CFU assay was performed. The bacterial culture was stored at 4°C prior to CFU assay 
to retard further proliferation. Upon obtaining the viable bacterial count of the 
transformed and untransformed E. coli BL21 (DE3) cultures, CFU assay was done 
according to the procedure described in Chapter 3.2.8.2, where the bacterial cultures 
were diluted in sterile Mueller-Hinton (II) broth to obtain approximately 100 CFU per 
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assay condition. The efficacies of the antibiotics were compared based on the reaction 
mixture before and after conversion by scDAOCS mutant enzyme. To ensure that the 
reagents for ring-expansion assay do not contribute to the results of the CFU assay, 
they were included as a control without the addition of any antibiotics. Thereafter, the 
viable bacterial count of this control was used to determine the percentage of survival 
upon exposure to respective β-lactam antibiotics.  
Figure 9.2A shows the CFU assay results of penicillin G, ampicillin, 
carbenicillin, phenenthicillin and their respective cephalosporin products against 
untransformed E. coli BL21 (DE3) cells. These results were comparable to those 
obtained for E. coli K12 in hole-plate bioassays, i.e., penicillin G, ampicillin and 
carbenicillin were able to inhibit the growth of E. coli K12 to various extents but not 
phenethicillin. This is expected since E. coli BL21 (DE3) strain is phylogenetically 
related to E. coli K12 (Jeong et al., 2009; Studier et al., 2009). Similarly, the results 
also showed that the cephalosporin products of penicillin G, ampicillin and 
carbenicillin were able to inhibit the growth of E. coli BL21 (DE3) cells but not that 
of phenethicillin in the CFU assays.  
Figure 9.2B shows the CFU assay results of penicillin G, ampicillin, 
carbenicillin, phenethicillin and their respective cephalosporin products against E. coli 
BL21-AmpR cells. The results showed that the cephalosporin products of ampicillin 
and carbenicillin were able to inhibit the growth of E. coli BL21-AmpR cells but not 
their respective penicillin moieties. Interestingly, penicillin G was able to inhibit 
approximately 80% of the E. coli BL21-AmpR population, while its cephalosporin 
product showed 99.9% inhibition. Similarly, phenethicillin and its cephalosporin 




Figure 9.2. Efficacies of penicillin G, ampicillin, carbenicillin, phenethicillin and their 
respective ring-expanded cephalosporin products against (A) untransformed E. coli 
BL21 (DE3) and (B) transformed E. coli BL21 (DE3) expressing ampicillin-
resistance gene. The number of CFUs for each antibiotic sample was compared to the 
negative control, which contained the test organism and the DAOCS ring-expansion 




9.3. Assessing additional properties conferred on expanded cephalosporin 
products: inhibition of elastase 
Calbiochem® InnoZyme™ Human Neutrophil Elastase Immunocapture 
activity assay kit was used to assess the potential inhibitory activity of the 
cephalosporin products. The plausible elastase inhibitory effect of the cephalosporin 
products were compared based on the reaction mixture before and after conversion by 
scDAOCS mutant enzyme, assuming that the amount of cephalosporin product 
formed is sufficiently potent to demonstrate some level of elastase inhibition. Due to 
the nature of the assay set-up, there was a 10X dilution to the DAOCS assay samples. 
Hence, the final concentration of the penicillins in the elastase assay was 
approximately 1 mM. The final concentrations of the cephalosporin products of 
penicillin G, ampicillin, carbenicillin and phenethicillin in the elastase assays were 
100 µM, 100 µM, 40 µM and 80 µM, respectively. 
Figure 9.3 shows the results of the elastase inhibitory assay of PMSF, DAOCS 
ring-expansion assay reagents, penicillin G, ampicillin, carbenicillin, phenethicillin 
and their respective cephalosporin products. The uninhibited elastase activity was 
determined to be 98.3 nM/min. As expected, PMSF almost inhibited the activity of 
elastase at 5 mM concentration. However, none of the penicillins and their respective 





Figure 9.3. Elastase inhibitory assay of penicillins and their respective expanded 





9.4. Potential applications of expanded cephalosporin products 
A plethora of semi-synthetic penicillins and cephalosporins has been 
generated over the last six decades. Studies on these penicillins have validated the 
efficacies of the aminopenicillins, e.g. ampicillin and amoxicillin, as antibacterials. 
This is, in part, due to the presence of the amino group in the side chain of the 
aminopenicillins. This importance was conserved in the structure of many latter semi-
synthetic cephalosporins, e.g. cephalexin, cefadroxil, cefuroxime, cefotaxime and 
ceftazidime, which have been classified into generations instead of the earlier 
structural classification of penicillin (Marshall and Blair, 1999; Wright, 1999; Hansch 
et al., 1990). Interestingly, the cephalosporin moieties of other penicillins, e.g. the 
carboxypenicillins (carbenicillin and ticarcillin), were not generated or reported. 
Hence, it is vital to validate the bioactivities of these cephalosporins as they could be 
potential chemotherapeutics.   
Although the wild-type scDAOCS is able to accept a range of penicillins as 
substrates (Chin and Sim, 2002; Cho et al., 1998), its limitation is the low activity in 
the ring-expansion of hydrophobic penicillin substrates, resulting in a low amount of 
product formed. This restricted further analysis of these products for their 
antimicrobial spectra. Although earlier studies on the structure-function relationship 
of β-lactam antibiotics have illustrated the importance of the amino group in the α-
position of the side chain of either a penicillin or a cephalosporin in broadening its 
antimicrobial spectrum (Wright, 1999; Hansch et al., 1990), other functional groups, 
e.g., a carboxyl group, have been shown to be effective against other bacteria 
(Rolinson, 1998; Tan and File, 1995). Furthermore, there are various factors affecting 
the efficacy of an antibiotic. For example, in a bacterium, there are many different 
types of PBPs and β-lactamases, which have different affinities for the same antibiotic 
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(Sauvage et al., 2008). Hence, it is difficult, if not impossible, to predict the efficacy 
of an antibiotic. It is still inevitable that the antimicrobial spectra of these 
cephalosporin products need to be determined empirically.  
In this project, several mutations have significantly improved the ring-
expansion activity of scDAOCS in converting penicillin G, ampicillin, carbenicillin 
and phenethicillin to their respective cephalosporin products. HPLC analysis of 
ampicillin conversions has also verified the production of cephalexin, which is the 
generic name of the cephalosporin moiety of ampicillin, and suggested that no further 
modification was done to the product even when the enzyme has been modified. 
Although the cephalosporin moieties of penicillin G, carbenicillin and phenethicillin 
were not available for authenticating the in vitro ring-expanded products of these 
three penicillin substrates, the same retention time of the products formed by the 
mutant and wild-type enzymes suggested the same conclusion. Therefore, only 
C281YI305M double mutant scDAOCS was selected to produce the cephalosporin 
products of penicillin G, ampicillin, carbenicillin and phenethicillin. Since cephalexin 
is available commercially, the results of the enzyme-converted cephalexin were used 
to compare with that of the standard cephalexin to assess the precision of HPLC in 
cephalosporin product quantification and the hole-plate bioassay method for screening 
of antimicrobial spectrum. As reflected by the hole-plate bioassay results, the 
antimicrobial spectra of both cephalosporins were the same, which supports the 
reliability of the antimicrobial screening results of other cephalosporin products.  
The antimicrobial spectra of the cephalosporin moieties of penicillin G, 
carbenicillin and phenethicillin were narrower than that of cephalexin. They were also 
smaller than that of the respective penicillins. This is expected since a cephalosporin 
is apparently not as active as its penicillin moiety against the same organism probably 
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due to its bulkier dihydrothiazine ring, which affects its binding with the PBPs 
(Hansch et al., 1990). For example, it has been reported that although cephalexin was 
inhibitory to E. coli, the affinities of various E. coli PBPs for cephalexin were also 
lower than ampicillin, resulting in higher MIC (Table 9.1) (Curtis et al., 1979). Other 
modification has to be done to cephalosporin to render it more efficacious to 
overcome the limitation of its dihydrothiazine ring. Hence, it is likely that the 
cephalosporin moieties of penicillin G, carbenicillin and phenethicillin are not ideal 
antibiotics and need further structural modification in order to be efficacious against a 
wide range of bacterial pathogens.  
Nevertheless, a cephalosporin is generally considered more efficacious than 
penicillin because of its natural resistance to penicillinase. Hence, it is often preferred 
over penicillin as a candidate for synthesising newer and more efficacious β-lactam 
antibiotic to overcome the emergence of resistant pathogens. In order to verify that the 
cephalosporin products are indeed penicillinase-resistant, a CFU assay using 
penicillin-susceptible and penicillin-resistant E. coli was employed. The results 
showed that while both the penicillins and their respective cephalosporin products 
were effective against susceptible E. coli, the cephalosporin products were able to 
inhibit the bacterium, but not the penicillins, when the organism expressed a 
penicillinase. This supports the notion that the cephalosporins are more efficacious 
than the penicillin moieties. 
For the past 60 years, the applications of β-lactams are mainly as 
chemotherapeutics or for research purposes. However, in the recent decades, new 
applications for β-lactams were discovered (Eisenstein, 2005; Rothstein et al., 2005). 
For example, in the recent effort of screening for an inducer of glutamate transporter 
expression in mice, a number of semi-synthetic β-lactams was found to induce the 
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expression of this transporter and prevent neurotoxicity (Rothstein et al., 2005). 
However, the molecular mechanism involved in inducing the expression of glutamate 
transporter is still not clear.  
Since β-lactams are acylating inhibitors of bacterial PBPs, which are classified 
as serine proteases, it has been suggested that they could also inhibit mammalian 
serine proteases (Veinberg et al., 2003; Davies et al., 1991; Doherty et al., 1986). By 
modifying the C7α position of the cephalosporin nucleus, a cephalosporin could be 
made potent to inhibit human leukocyte elastase (Alpegiani et al., 1994; Knight et al., 
1992; Doherty et al., 1986). Since the cephalosporin moieties of penicillin G, 
ampicillin, carbenicillin and phenethicillin are C7β isomers, which have been reported 
to be weak inhibitors or inactive (Knight et al., 1992; Doherty et al., 1986), it is 
expected that the elastase inhibition assays showed no potency in any of the 
cephalosporin products tested. Nevertheless, these cephalosporins may have 
applications other than as antibacterials, which remain to be uncovered.  
 
Table 9.1. Affinities of various penicillins and cephalosporins for the PBPs of E. coli 
DC0 (Curtis et al., 1979). 
 
 I50 binding concentration (µg/mL) for: MIC (µg/mL) 
β-Lactams PBP1a PBP1b PBP2 PBP3 PBP4 PBP5 PBP6 DC0 DC2* 
Penicillin G 0.5 3.0 0.8 0.9 1.0 24 19 16 1.6 
Penicillin V 1.4 9.5 7.7 10.5 14 50 17 50 12.5 
Carbenicillin 2.1 5.0 4.0 2.1 3.5 130 120 2 1 
Amoxicillin 0.7 2.2 0.9 4.1 2.5 110 9 3.2 1.6 
Ampicillin  1.4 3.9 0.7 0.9 2.0 140 9 3.2 0.5 
Cephalexin 4 240 >250 8 30 >250 >250 8 4 
Cefotaxime 0.05 0.7 5 <0.05 30 >50 >50 0.08 0.01 
Cephalothin <0.25 16 37 1 60 125 130 1.6 0.8 
Cephaloridine 0.25 2.5 50 8 17 >250 >250 2 2 
*Strain DC2 is a permeability mutant of E. coli DC0. 





Chapter 10: Concluding remarks and future 
directions  
  
The C-terminal residues of scDAOCS have been repeatedly demonstrated to 
be amenable to modification in order to improve the ring-expansion activity of 
scDAOCS. This study has provided a further understanding of the mechanisms behind 
these improvements. Interestingly, the effect of combining the single mutations at the 
C-terminus is less predictable when the two mutation sites are too close to each other. 
N304XR306L double mutants of scDAOCS did not show additive or synergistic 
effect when compared to the respective single mutants for ampicillin, carbenicillin 
and phenethicillin conversions. For penicillin G conversion, the enzymatic activities 
of the double mutants were even lower than that of the wild-type enzyme. It is very 
likely that this is due to the opposing effect of the residues at these two positions, i.e., 
the interaction forces at position 304 are towards the substrate binding site, while 
those at position 306 are away from the substrate binding site. Since residue I305 is 
also interacting with the penicillin substrate, by combining I305M single mutation 
with any of the N304X single mutations, further enhancement in the conversion 
activity of scDAOCS could be attained.  
scDAOCS has been modified and achieved approximately 4- to 10-fold 
increments in the specific activity of various penicillin conversions and almost 100-
fold improvement in its catalytic efficiency in ampicillin conversion. However, it is 
still at least a magnitude lower than the conversion of the native substrate penicillin N 
(Table 10.1). Since the effect of a mutation is independent of another when they are at 
least 10Å apart, by combining those improved mutations that conferred at least 2-fold 
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improvement in the catalytic efficiency of the enzyme, it is likely that the catalytic 
efficiency of scDAOCS can be further improved. In addition, since L277Q and 
C281Y single mutations in the small sub-domain could enhance the catalytic 
efficiency of the enzyme, it could be postulated that by combining L277Q and C281Y 
mutations, a synergistic effect could be achieved. Eventually, the ring-expansion 
activity of scDAOCS for industrially preferred penicillin substrates could be 
significantly enhanced by strategic combination of all the C-terminal and sub-domain 
mutations using a rational approach.  
Although the mechanism of substrate recognition of scDAOCS for 
hydrophobic penicillin substrates has been illuminated, studies on scDACS have 
elicited more questions with respect to the differences in their substrate selectivity, 
leading to different enzymatic reactions. Upon obtaining the crystal structures of the 
enzyme-substrate complexes of the various scDAOCS and scDACS mutants 
generated in this study, the exact mechanism could be elucidated. By understanding 
the mechanism of substrate selectivity of DAOCS, DACS and DAOC/DACS, the 
maximum potential or limitation of these enzymes could be realised, which is 
important for industrial application.   
In this study, some of the mutant scDAOCSs are more inclined to accept 
ampicillin than penicillin G, and thus, they could be exploited for efficient and 
cheaper industrial production of cephalexin. Since amoxicillin is an analogue of 
ampicillin, it is also appealing to investigate the potential of these mutant scDAOCSs 




Table 10.1. Kinetic parameters of wild-type and mutant scDAOCSs in penicillin N, 
penicillin G and ampicillin conversions. 
 



























2.58 0.0453 18 Wei et al., 2005; Hsu et al., 2004 












6.94 0.059 8.6 
This study  C281YN304R 0.05 0.043 865.2 
C281YI305M 0.21 0.122 569.9 
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2. Detailed map of pGEX-6P-1 plasmid vector (GE Healthcare) 
 
 




Appendix II  
Reagents used for SDS-PAGE analysis (Laemmli, 1970) 
1. 10% SDS-polyacrylamide resolving gel mix 
The gel mix was prepared as follows: 
30% acrylamide mix (BioRad) 33.3mL 
1.5M Tris-base (pH 8.8) 20.0mL 
10% (w/v) SDS 0.8mL 
Deionised water 25.6mL 
10% (w/v) APS (freshly prepared) 0.4mL 
TEMED 0.04mL 
 
2. 4% SDS-polyacrylamide stacking gel mix 
The gel mix was prepared as follows: 
30% acrylamide mix (BioRad) 5.34mL 
1M Tris-base (pH 6.8) 10.0mL 
10% (w/v) SDS 0.4mL 
Deionised water 24.0mL 
10% (w/v) APS (freshly prepared) 0.2mL 
TEMED 0.02mL 
 
3. Staining solution 
Methanol 50% (v/v) 
Acetic acid 10% (v/v) 
Coomasie blue (R250) 0.1% (w/v) 
 
4. Destaining solution 
Methanol 10% (v/v) 





Appendix III  
A 
 
Alignment of predicted secondary structures of scDAOCS R306 mutants with that of 
the wild-type enzyme. The mutants with improved ring-expansion activity were 
highlighted in yellow. R306A, R306F, R306Y and R306W mutants were predicted to 
have the same secondary structure as R306M mutant. R306L and R306I mutants were 





Alignment of predicted secondary structures of scDAOCS single and double mutants 
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